Custom Search
Sunday, January 31, 2010
PENN-PORT PROGRAM
PENN- Postdoctoral Opportunities in Research and Teaching (PENN-PORT) ,is a NIH sponsored, Institutional Research and Academic Career Development Award (IRACDA) postdoctoral fellowship, supported by the NIH division of Minority Opportunities in Research (MORE) at NIGMS awarded August 2007.
The NIH sponsored PENN-PORT program combines a traditional mentored postdoctoral research experience at the University of Pennsylvania with a mentored teaching experience at a partnering institution. The Program is designed to provide an opportunity for postdoctoral appointees to develop their teaching skills. An integral part of the program is formal instruction in pedagogical methods from the Graduate School of Education at the University of Pennsylvania. Postdocs will also be able to take advantage of the many research and career success skills training programs provided by Biomedical Postdoctoral Programs (BPP).
The partnering institutions are Delaware County Community College, Lincoln University and Rutgers University Camden Campus. All institutions are minority serving institutions in the Philadelphia locality. The PENN-PORT program is intended to enhance research-oriented teaching at partner institutions, foster collaboration in research and teaching between the faculty at the University of Pennsylvania and that of partner minority-serving institutions, and encourage undergraduates to enter a career in biomedical research. Since we wish to provide role models for the undergraduates at our partner institutions, candidates from underrepresented groups are encouraged to apply.
Eligible postdocs must provide proof of a doctoral degree and must be U.S. Citizens or Permanent Residents. We provide health benefits , stipend, support for research and teaching supplies, course development, and travel to attend two professional meetings, one being the IRACDA annual conference. The tenure for each fellowship is three years.
PENN-PORT Program Eligibility:
All postdocs must provide proof of a doctoral degree having a qualified Ph.D., M.D. or equivalent, and must be a U.S. Citizen or Permanent Resident. Preference is given to final year Ph.D. candidates and recent Ph.D. graduates with no previous postdoc experience.
Benefits and Stipend:
Fellowship stipends will be competitive with federal guidelines as set by the National Institute of Health (NIH), with annual increases as allowed by these guidelines. All medical benefits provided by the following insurance policies for all postdoctoral fellows http://www.garnett-powers.com/upenn/
Finding a Mentor:
Applicants do not need a mentor at the time of completing the PENN-PORT application. PENN-PORT applicants can identfiy potential research labs based on their graduate training, research interests and specific career goals, as traditional postdocs do. However, all applicants should include three faculty of interest on their application. To find research faculty and review their research interests please visit: http://www.med.upenn.edu/bgs/
All application documents can be submitted electronically to:
Dr. Yvonne Paterson, Director, PENN-PORT Program
yvonne@mail.med.upenn.edu
A complete PENN-PORT application packet includes:
- PENN-PORT IRACDA application form (including three faculty of interest)
- A copy of your curriculum vitae
- A personal statement (describing career goals and experiences,highlighting your interest in a career in academia, and working with undereprsented minorities)
- Three letters of reference (most circumstances one letter should be from your Ph.D. mentor)
We are currently accepting applications for Fall 2010.
Click the link below to retreive the application:
All letters of reference should be addressed to:
Yvonne Paterson, Ph.D.
Director,PENN-PORT Program
Department of Microbiology
323A Johnson Pavilion, 3610 Hamilton Walk
Philadelphia, PA 19104-6076
PENN-PORT Interview Process:
Upon the receipt of all documents, individuals of interest will be contacted to arrange an interview. During your interview you will meet with faculty of interest, current postdocs, and our program director. In addition, you will be asked to give a short seminar on your current research.
For more information please contact the PENN-PORT office directly at 215-573-4332
Monday, January 25, 2010
Zebrafish Swim into Drug Development
1/22/2010 -By combining the tools of medicinal chemistry and zebrafish biology, a team of Vanderbilt investigators has identified compounds that may offer therapeutic leads for bone-related diseases and cancer.
The findings, reported in ACS Chemical Biology, support using zebrafish as a novel platform for drug development.
In 2007, Charles Hong, M.D., Ph.D., and colleagues described using fish embryos to screen for compounds that interfere with signaling pathways involved in early development — pathways known to play roles in a variety of disease processes.
They discovered the compound “dorsomorphin” and demonstrated that it blocked BMP (bone morphogenetic protein) signaling, which has been implicated in anemia, inflammatory responses and bone-related disorders.
But in examining dorsomorphin further, the investigators found that it had other “off-target” effects — it also blocked the VEGF (vascular endothelial growth factor) receptor and disrupted zebrafish blood vessel development, a process called angiogenesis.
“Off-target effects contribute to side effects and limit the therapeutic potential of small molecule signaling inhibitors,” said Hong, assistant professor of Medicine and Pharmacology.
To find compounds that were more selective BMP inhibitors (didn't have the off-target effects), Hong and colleagues opted to use their zebrafish drug discovery screen as a drug development/optimization tool.
Craig Lindsley, Ph.D., director of Medicinal Chemistry for the Vanderbilt Program in Drug Discovery, Corey Hopkins, Ph.D., associate director, and their colleagues used the dorsomorphin “backbone” as a starting point to synthesize many different analogs — subtly different dorsomorphin-like compounds.
Then Hong and his team tested these compounds for their effects on zebrafish embryonic development.
“We quickly discovered that the two effects of dorsomorphin could be separated — some analogs only affected patterning and some only affected angiogenesis,” Hong said. The investigators biochemically characterized compounds of both types and found very selective and potent BMP inhibitors and selective VEGF inhibitors.
The zebrafish embryo, Hong said, is very good at assessing a compound's selectivity for a certain signaling pathway.
Mixed signals from compounds that are not selective (they hit multiple targets) are toxic to the embryo — it “shuts down development.”
The team identified a VEGF inhibitor, for example, that outperformed an existing VEGF inhibitor that was being developed for cancer therapy (blocking angiogenesis cuts off the “supply lines” for a growing tumor) but was pulled from development during a Phase III trial.
“If they (the pharmaceutical company) had tested that compound in zebrafish, they would have quickly learned that it wasn't potent or selective,” Hong said.
“Using zebrafish is a novel way to do a structure-activity relationship study” — a study that examines a series of analog compounds to determine which is the most selective and most potent, he added.
Traditionally, pharmaceutical companies perform these types of studies in vitro, with isolated proteins or cells. But Hong points out that in vitro studies assess only “one dimension” of the biology. Compounds that have great activity in vitro often fail later because they have poor selectivity or because they do not have chemical properties that make them good drugs (they are not “bioavailable”).
“The zebrafish assesses selectivity and bioavailability all at the same time,” Hong says. “What the traditional approach takes months to do, the zebrafish does in a day.”
Because BMP and VEGF inhibitors have therapeutic potential for a variety of diseases, the investigators will begin to test the drug candidates in mouse models.
Hong praised Vanderbilt leaders for putting into place the drug discovery infrastructure that made the work possible.
“Having medicinal chemists and zebrafish biologists together in the same building really fostered our collaboration,” he said. “This kind of collaboration would not be likely at the majority of medical institutions.”
The research was supported by the Veterans Administration, the Center for Research in Fibrodysplasia Ossificans Progressiva and Related Disorders, the National Institutes of Health and the GSK Cardiovascular Research and Education Foundation.
BY: LEIGH MACMILLAN from VANDERBILT MEDICAL CENTER
Thursday, January 21, 2010
Postdoctoral Positions Available in ELSI Research
The Center for Genomics and Society (CGS) at the University of North Carolina at Chapel Hill invites applications for postdoctoral appointments in ethical, legal, and social issues (ELSI) related to large-scale genetic/genomic research. Appointees will work closely with an interdisciplinary group of CGS investigators to conduct social science, philosophical, policy, or legal research on ELSI issues, help design ELSI teaching modules to be used in undergraduate classes; and co-author publications. Post-doctoral fellows will participate in individually tailored, mentored research and professional development activities, and will be supported in establishing independent lines of ELSI research. Our website has information about CGS aims, research activities, and faculty: www.genomics.unc.edu/genomicsandsociety/
This position is available immediately for duration of one year, with a possible additional year pending funding and acceptable progress. Candidates should be recent PhDs with interests in ELSI research, and training in the social sciences, genetics, medicine, nursing, public health, law, humanities or bioethics. Individuals from underrepresented groups are encouraged to apply. Stipends are established at the NIH rate, beginning at $39,009 for a recent PhD. Health benefits are included as well as sick and vacation time.
Applications should consist of a 1) curriculum vitae including previous research experience; 2) a personal statement describing interests in ELSI; and 3) names and contact information of three referees.
Applications will be accepted until April 15, 2009, or until positions are filled. Applicants should
address all materials and questions to:
Debra Skinner
Associate Director
Center for Genomics and Society
FPG Child Development Institute
CB#8180
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599-8180
Tel: (919) 966-4571
Email: skinner@mail.fpg.unc.edu
This position is available immediately for duration of one year, with a possible additional year pending funding and acceptable progress. Candidates should be recent PhDs with interests in ELSI research, and training in the social sciences, genetics, medicine, nursing, public health, law, humanities or bioethics. Individuals from underrepresented groups are encouraged to apply. Stipends are established at the NIH rate, beginning at $39,009 for a recent PhD. Health benefits are included as well as sick and vacation time.
Applications should consist of a 1) curriculum vitae including previous research experience; 2) a personal statement describing interests in ELSI; and 3) names and contact information of three referees.
Applications will be accepted until April 15, 2009, or until positions are filled. Applicants should
address all materials and questions to:
Debra Skinner
Associate Director
Center for Genomics and Society
FPG Child Development Institute
CB#8180
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599-8180
Tel: (919) 966-4571
Email: skinner@mail.fpg.unc.edu
Fellowship in Global Mental Health Research
Introduction
The Fogarty International Clinical Research Scholars Support Center at the Vanderbilt University Institute for Global Health (VIGH) is pleased to announce a new one-year clinical research training program for persons in post-residency clinical fellowships, in other health-related post-doctoral programs, and/or within three years of their last major degree training (e.g., registrar, residency, fellowship, doctoral program). Persons in residency programs are also eligible with the permission of their residency director. The program is designed for persons from low, lower middle, and upper middle income countries (as listed by the World Bank at http://go.worldbank.org/K2CKM78CC0) or for citizens or permanent residents of the U.S. This new program is sponsored by the Fogarty International Center (FIC) and several collaborating institutes and centers at the National Institutes of Health (NIH) and managed by VIGH.
The ICRF Program supports one year of mentored clinical research only in a developing country setting. High income nations as per the World Bank list are not eligible as training sites, nor are applicants from those countries, with the exception of the U.S. Applicants for the fellowship must develop a collaborative research proposal with an eligible institution overseas.
Sites were pre-approved as suitable for ICRF in a site competition completed in 2008, and several new sites have been added in 2009. These can be found on at http://www.fogartyscholars.org/fellows/sites. f one of these sites is selected for collaboration, no site component of this application is needed other than a letter of support.
The National Institute of Mental Health partners with the FIC to fund this opportunity through VIGH. Funding is available from VIGH from July 2010 to June 2011 for one year of proposed clinical research overseas related to basic, clinical, and translational research to advance understanding of the diagnosis, causes, treatment, and prevention of mental disorders.
* Two fellowships will be awarded for 2010-2011
* This fellowship is an opportunity to immerse medical and health scientists in training related to global health and international collaboration. Persons in health-related disciplines (human or animal) such as medicine, nursing, public health, dentistry, optometry, and others who are currently engaged in post-doctorate programs and qualified to do clinical research are welcome to apply.
Purpose of the Fellowship
The purpose of this program is to support a one-year, mentored research fellowship for clinical investigators studying diseases and conditions in developing countries and to build international health research capacity.
The ICRF is a post-doctoral program and is complementary, but not overlapping with the International Clinical Research Scholars (ICRS) Program for health science students (pre-doctoral). Information on the scholars program for health science students (rather than the post-doctoral or clinical fellow focus of ICRF described here) can be found on the Support Center webpage: www.fogartyscholars.org/scholars
Eligibility to Apply
* Citizens of the United States or its territories or possessions, or persons lawfully admitted to the United States for permanent residence. Resident aliens must include their green card number in their application.
OR
* Citizens of any nation exclusive of high income countries as defined on the World Bank web site http://go.worldbank.org/K2CKM78CC0) may apply for this award.
* Persons from developing countries who are neither U.S. citizens nor permanent residents MUST apply in partnership with one of our 48 approved fellows sites (http://www.fogartyscholars.org/fellows/sites) to be eligible for this fellowship.
Site Eligibility
* U.S. citizens and permanent residents can propose alternate sites other than approved sites under the specific conditions below. ICRF-eligible sites must be a recipient of U.S. government research or evaluation support and must have a standing Institutional Review Board (IRB) and Federal Wide Assurance (FWA) as documented in good standing as of February 1, 2010 at the Department of Health and Human Services Office for Human Research Protections (OHRP) web site: http://ohrp.cit.nih.gov/search/. There will be no exceptions to these two requirements for site eligibility, i.e., the site is in receipt of U.S. government health-related funding in research or evaluation and the site has an active IRB and FWA. All of the 48 pre-approved ICRF sites are eligible and we encourage prospective applicants to consider them as research venues.
Selection
Applications are received by the Institute for Global Health at Vanderbilt University as described in the SFA section – Submitting an Application. Vanderbilt University conducts a scientific peer review of all proposals and makes awards. The Vanderbilt-organized review considers issues of potential conflicts of interests of reviewers and other key issues following guidelines of the Center for Scientific Review of the NIH. The Principal Investigator at the Support Center at VIGH serves as the administrator for these reviews, but does not vote on any proposal.
Orientation
All fellows will be brought to Bethesda, Maryland for an approximately two-week intensive orientation session on the NIH campus from July 8-20, 2010. Economy-class air travel (or suitable ground transportation for persons near to Washington, D.C.) and lodging will be provided, as well as up to $200 for visa costs and added administrative facilitation for non-U.S. ICRF trainees from overseas.
Stipends
For U.S. Citizens & Permanent Residents – The standard stipend for a U.S. fellow regardless of site is $45,000. U.S. fellows will receive stipend payments directly from VIGH, or via subcontracts with their home U.S. institution.
For Non-U.S. Citizens or Permanent Residents – There is no standard stipend for non-U.S. fellows. Applicants must indicate a stipend level that is fair and equitable with salary ranges at their institution commensurate with the experience and qualifications of the applicant. Applicants will be asked for documentation demonstrating the basis for your proposed stipend. Under no circumstances will this stipend exceed $45,000 per annum (full-time), no matter what the circumstances are at the host institution. Non-U.S. fellows will receive their stipends via subcontract to their host institution.
Health & Evacuation Insurance – Fellows who are not citizens of the country in which they are working will receive health and evacuation insurance. Fellows can choose to retain their current health insurance of the institution where they are residents, clinical fellows or post-doctoral research fellows, and can opt for a reimbursement up to $4,000 for their expenses. Overseas fellows who are doing ICRF in their own nations are expected to have pre-existing health insurance from their home institutions that should be continued unabated through the ICRF year; if this is not feasible, the Support Center at Vanderbilt should be notified at least three months before the commencement of the ICRF so that the NIH can be informed and the ICRF award can be reconsidered. Fellows who are citizens where they will be working and whose institutions provide no health insurance coverage should contact the Support Center at Vanderbilt as soon as they receive their award notice. Fellows should consult with their home and host institutions to determine the best way to obtain the needed health insurance coverage. Non-U.S. fellows will receive health insurance coverage for their two-week stay in Bethesda, Maryland, arranged by the FICRS Support Center.
Pre-Departure Support for U.S. citizens, permanent residents, or international fellows who reside in the U.S.
The ICRF Program’s support to your partnering U.S. institution (if any) is:
* $4,000 administrative support payable to the U.S. institution (this amount is only applicable toward one fellow. If more than one fellow is administered out of the same U.S. institution, the institution will receive an additional $1,500 per fellow).
* Up to $1,200 for suitable travel and pre-travel medical consultation and services (anti-malarial and anti-diarrheal drugs, and indicated vaccinations), upon presentation of receipts as required by the subcontracted institution.
* Up to $300 toward visa and passport fees for each U.S. fellow, upon presentation of receipts as required.
* Up to $5,000 for roundtrip airfare to overseas sites for each U.S. fellow, upon presentation of receipts as required.
* Up to $200 miscellaneous transportation/arrival costs at overseas site such as taxi, upon presentation of receipts as required.
If your partnership is directly with an overseas institution, i.e., there is no U.S. academic partner, the Support Center at Vanderbilt will provide these services directly. Vanderbilt University requires receipts prior to any and all reimbursements.
Research Training Costs for all Fellows
The following financial support will be sent via subcontract to your U.S. institution, which will provide support to your overseas site as applicable. If you do not have a partnering U.S. institution, these amounts will be handled via cost-reimbursement by the Support Center at Vanderbilt or subcontracted directly to your overseas site or partnering US institution.
* $8,000 infrastructure and administrative support for the overseas site.
* Up to $15,000 discretionary and research-project-related funds for scholar-related expenses per fellow, such as support for supplies, analysis, equipment, meetings, supplies, language courses, computer, software, etc. We expect your partner institutions to have most of the necessary equipment and supplies in place for a fellow’s project. These funds are supplementary and must be justified in the application.
Program Timeline
I. February 12, 2010: Applications are due by 3PM Eastern Standard Time.
II. Early March 2010: All finalists will be interviewed by telephone, after which final awardees will be selected by the VIGH-organized selection committee.
III. Late March 2010: Awards will be announced.
IV. July 2010: Fellows will participate in a two-week experience on the NIH campus. All fellows are required to attend and participate fully.
V. On or around August 1, 2010: ICRF awardees will begin their overseas work on-site and will be on-site for at least 10 months.
VI. After completion of the research training year: Selected ICRF fellows will return to Bethesda, MD, to present their findings at a Fogarty Trainee Conference in March 2011, depending upon the availability of funds provided by the Support Center at Vanderbilt. In addition, the completion of a brief questionnaire (anticipated to be approximately four questions) about their current career decisions plus a copy of their current curriculum vitae (including basic contact information, training and research experiences, awards, publications, and employment history) will be required every two years for the next 20 years. This is part of the NIH-mandated long-term career tracking function of the Support Center at Vanderbilt in order to assess the impact of the training.
Eligible Sites
A total of 48 sites have been competitively selected as pre-approved ICRF Fellowship sites. Information on these sites can be found at http://www.fogartyscholars.org/fellows/sites.
Non-U.S. applicants in particular are required to apply to conduct their research training at one of these sites.
Applicants affiliated with one of these sites are not required to submit a Site Application along with the rest their application; however, US citizen/permanent resident applicants are able to choose sites other than those that have been approved. U.S. applicants not partnering with approved sites must partner with an eligible developing country site willing to host and mentor the candidate during their research. The eligible site must further be willing to select a local national to also become an ICRF for the same year. To be eligible to host a fellow, a site must demonstrate U.S. federal government supported research and/or evaluation (e.g., PEPFAR*) funding, e.g., from the National Institutes of Health, the Centers for Disease Control and Prevention, the National Science Foundation, the Department of Defense, or the United States Agency for International Development. This funding support must be extant during the year that a fellow is on-site (i.e., for the 2009-2010 ICRF, U.S. federal funding must extend through June 2010). IRB and FWA requirements are given earlier in this RFA.
(*President’s Emergency Plan for AIDS Relief: www.pepfar.gov)
Submitting an Application
Applications are due electronically to Catherine Lem, MPH, Program Manager, (c.lem@vanderbilt.edu) by 3 pm EST on February 12, 2010. It is expected that all candidates will submit electronically. However, if a candidate is unable to submit the application electronically, please contact Cat Lem by February 1, 2010 to make alternative mailing arrangements. Please anticipate these deadlines and avoid a last minute submission as there will be no applications accepted after this deadline even due to circumstances beyond the applicants’ control.
Application forms and instructions are found at:
Submitting an Application (www.fogartyscholars.org/fellows/submitting-an-application)
Where to Direct Inquiries
All general-interest queries will be posted to the web site and answered therein. Please read “Frequently Asked Questions for the ICRF Program” on the following web site: http://www.fogartyscholars.org/fellows/faq to see if a given query has already been addressed.
Queries by telephone to the VIGH will be abstracted such that questions and answers are summarized and added to our web site. You may contact the following resource persons for this solicitation:
Catherine Lem, MPH, Senior Program Manager
Tel: (615) 343-3555
Email: catherine.lem@vanderbilt.edu
Sten H. Vermund, MD, PhD, Principal Investigator of the Fogarty International Clinical Research Scholars/Fellows Support Center at Vanderbilt and an additional resource person
Tel: (615) 322-9374
Email: sten.vermund@vanderbilt.edu
The Fogarty International Clinical Research Scholars Support Center at the Vanderbilt University Institute for Global Health (VIGH) is pleased to announce a new one-year clinical research training program for persons in post-residency clinical fellowships, in other health-related post-doctoral programs, and/or within three years of their last major degree training (e.g., registrar, residency, fellowship, doctoral program). Persons in residency programs are also eligible with the permission of their residency director. The program is designed for persons from low, lower middle, and upper middle income countries (as listed by the World Bank at http://go.worldbank.org/K2CKM78CC0) or for citizens or permanent residents of the U.S. This new program is sponsored by the Fogarty International Center (FIC) and several collaborating institutes and centers at the National Institutes of Health (NIH) and managed by VIGH.
The ICRF Program supports one year of mentored clinical research only in a developing country setting. High income nations as per the World Bank list are not eligible as training sites, nor are applicants from those countries, with the exception of the U.S. Applicants for the fellowship must develop a collaborative research proposal with an eligible institution overseas.
Sites were pre-approved as suitable for ICRF in a site competition completed in 2008, and several new sites have been added in 2009. These can be found on at http://www.fogartyscholars.org/fellows/sites. f one of these sites is selected for collaboration, no site component of this application is needed other than a letter of support.
The National Institute of Mental Health partners with the FIC to fund this opportunity through VIGH. Funding is available from VIGH from July 2010 to June 2011 for one year of proposed clinical research overseas related to basic, clinical, and translational research to advance understanding of the diagnosis, causes, treatment, and prevention of mental disorders.
* Two fellowships will be awarded for 2010-2011
* This fellowship is an opportunity to immerse medical and health scientists in training related to global health and international collaboration. Persons in health-related disciplines (human or animal) such as medicine, nursing, public health, dentistry, optometry, and others who are currently engaged in post-doctorate programs and qualified to do clinical research are welcome to apply.
Purpose of the Fellowship
The purpose of this program is to support a one-year, mentored research fellowship for clinical investigators studying diseases and conditions in developing countries and to build international health research capacity.
The ICRF is a post-doctoral program and is complementary, but not overlapping with the International Clinical Research Scholars (ICRS) Program for health science students (pre-doctoral). Information on the scholars program for health science students (rather than the post-doctoral or clinical fellow focus of ICRF described here) can be found on the Support Center webpage: www.fogartyscholars.org/scholars
Eligibility to Apply
* Citizens of the United States or its territories or possessions, or persons lawfully admitted to the United States for permanent residence. Resident aliens must include their green card number in their application.
OR
* Citizens of any nation exclusive of high income countries as defined on the World Bank web site http://go.worldbank.org/K2CKM78CC0) may apply for this award.
* Persons from developing countries who are neither U.S. citizens nor permanent residents MUST apply in partnership with one of our 48 approved fellows sites (http://www.fogartyscholars.org/fellows/sites) to be eligible for this fellowship.
Site Eligibility
* U.S. citizens and permanent residents can propose alternate sites other than approved sites under the specific conditions below. ICRF-eligible sites must be a recipient of U.S. government research or evaluation support and must have a standing Institutional Review Board (IRB) and Federal Wide Assurance (FWA) as documented in good standing as of February 1, 2010 at the Department of Health and Human Services Office for Human Research Protections (OHRP) web site: http://ohrp.cit.nih.gov/search/. There will be no exceptions to these two requirements for site eligibility, i.e., the site is in receipt of U.S. government health-related funding in research or evaluation and the site has an active IRB and FWA. All of the 48 pre-approved ICRF sites are eligible and we encourage prospective applicants to consider them as research venues.
Selection
Applications are received by the Institute for Global Health at Vanderbilt University as described in the SFA section – Submitting an Application. Vanderbilt University conducts a scientific peer review of all proposals and makes awards. The Vanderbilt-organized review considers issues of potential conflicts of interests of reviewers and other key issues following guidelines of the Center for Scientific Review of the NIH. The Principal Investigator at the Support Center at VIGH serves as the administrator for these reviews, but does not vote on any proposal.
Orientation
All fellows will be brought to Bethesda, Maryland for an approximately two-week intensive orientation session on the NIH campus from July 8-20, 2010. Economy-class air travel (or suitable ground transportation for persons near to Washington, D.C.) and lodging will be provided, as well as up to $200 for visa costs and added administrative facilitation for non-U.S. ICRF trainees from overseas.
Stipends
For U.S. Citizens & Permanent Residents – The standard stipend for a U.S. fellow regardless of site is $45,000. U.S. fellows will receive stipend payments directly from VIGH, or via subcontracts with their home U.S. institution.
For Non-U.S. Citizens or Permanent Residents – There is no standard stipend for non-U.S. fellows. Applicants must indicate a stipend level that is fair and equitable with salary ranges at their institution commensurate with the experience and qualifications of the applicant. Applicants will be asked for documentation demonstrating the basis for your proposed stipend. Under no circumstances will this stipend exceed $45,000 per annum (full-time), no matter what the circumstances are at the host institution. Non-U.S. fellows will receive their stipends via subcontract to their host institution.
Health & Evacuation Insurance – Fellows who are not citizens of the country in which they are working will receive health and evacuation insurance. Fellows can choose to retain their current health insurance of the institution where they are residents, clinical fellows or post-doctoral research fellows, and can opt for a reimbursement up to $4,000 for their expenses. Overseas fellows who are doing ICRF in their own nations are expected to have pre-existing health insurance from their home institutions that should be continued unabated through the ICRF year; if this is not feasible, the Support Center at Vanderbilt should be notified at least three months before the commencement of the ICRF so that the NIH can be informed and the ICRF award can be reconsidered. Fellows who are citizens where they will be working and whose institutions provide no health insurance coverage should contact the Support Center at Vanderbilt as soon as they receive their award notice. Fellows should consult with their home and host institutions to determine the best way to obtain the needed health insurance coverage. Non-U.S. fellows will receive health insurance coverage for their two-week stay in Bethesda, Maryland, arranged by the FICRS Support Center.
Pre-Departure Support for U.S. citizens, permanent residents, or international fellows who reside in the U.S.
The ICRF Program’s support to your partnering U.S. institution (if any) is:
* $4,000 administrative support payable to the U.S. institution (this amount is only applicable toward one fellow. If more than one fellow is administered out of the same U.S. institution, the institution will receive an additional $1,500 per fellow).
* Up to $1,200 for suitable travel and pre-travel medical consultation and services (anti-malarial and anti-diarrheal drugs, and indicated vaccinations), upon presentation of receipts as required by the subcontracted institution.
* Up to $300 toward visa and passport fees for each U.S. fellow, upon presentation of receipts as required.
* Up to $5,000 for roundtrip airfare to overseas sites for each U.S. fellow, upon presentation of receipts as required.
* Up to $200 miscellaneous transportation/arrival costs at overseas site such as taxi, upon presentation of receipts as required.
If your partnership is directly with an overseas institution, i.e., there is no U.S. academic partner, the Support Center at Vanderbilt will provide these services directly. Vanderbilt University requires receipts prior to any and all reimbursements.
Research Training Costs for all Fellows
The following financial support will be sent via subcontract to your U.S. institution, which will provide support to your overseas site as applicable. If you do not have a partnering U.S. institution, these amounts will be handled via cost-reimbursement by the Support Center at Vanderbilt or subcontracted directly to your overseas site or partnering US institution.
* $8,000 infrastructure and administrative support for the overseas site.
* Up to $15,000 discretionary and research-project-related funds for scholar-related expenses per fellow, such as support for supplies, analysis, equipment, meetings, supplies, language courses, computer, software, etc. We expect your partner institutions to have most of the necessary equipment and supplies in place for a fellow’s project. These funds are supplementary and must be justified in the application.
Program Timeline
I. February 12, 2010: Applications are due by 3PM Eastern Standard Time.
II. Early March 2010: All finalists will be interviewed by telephone, after which final awardees will be selected by the VIGH-organized selection committee.
III. Late March 2010: Awards will be announced.
IV. July 2010: Fellows will participate in a two-week experience on the NIH campus. All fellows are required to attend and participate fully.
V. On or around August 1, 2010: ICRF awardees will begin their overseas work on-site and will be on-site for at least 10 months.
VI. After completion of the research training year: Selected ICRF fellows will return to Bethesda, MD, to present their findings at a Fogarty Trainee Conference in March 2011, depending upon the availability of funds provided by the Support Center at Vanderbilt. In addition, the completion of a brief questionnaire (anticipated to be approximately four questions) about their current career decisions plus a copy of their current curriculum vitae (including basic contact information, training and research experiences, awards, publications, and employment history) will be required every two years for the next 20 years. This is part of the NIH-mandated long-term career tracking function of the Support Center at Vanderbilt in order to assess the impact of the training.
Eligible Sites
A total of 48 sites have been competitively selected as pre-approved ICRF Fellowship sites. Information on these sites can be found at http://www.fogartyscholars.org/fellows/sites.
Non-U.S. applicants in particular are required to apply to conduct their research training at one of these sites.
Applicants affiliated with one of these sites are not required to submit a Site Application along with the rest their application; however, US citizen/permanent resident applicants are able to choose sites other than those that have been approved. U.S. applicants not partnering with approved sites must partner with an eligible developing country site willing to host and mentor the candidate during their research. The eligible site must further be willing to select a local national to also become an ICRF for the same year. To be eligible to host a fellow, a site must demonstrate U.S. federal government supported research and/or evaluation (e.g., PEPFAR*) funding, e.g., from the National Institutes of Health, the Centers for Disease Control and Prevention, the National Science Foundation, the Department of Defense, or the United States Agency for International Development. This funding support must be extant during the year that a fellow is on-site (i.e., for the 2009-2010 ICRF, U.S. federal funding must extend through June 2010). IRB and FWA requirements are given earlier in this RFA.
(*President’s Emergency Plan for AIDS Relief: www.pepfar.gov)
Submitting an Application
Applications are due electronically to Catherine Lem, MPH, Program Manager, (c.lem@vanderbilt.edu) by 3 pm EST on February 12, 2010. It is expected that all candidates will submit electronically. However, if a candidate is unable to submit the application electronically, please contact Cat Lem by February 1, 2010 to make alternative mailing arrangements. Please anticipate these deadlines and avoid a last minute submission as there will be no applications accepted after this deadline even due to circumstances beyond the applicants’ control.
Application forms and instructions are found at:
Submitting an Application (www.fogartyscholars.org/fellows/submitting-an-application)
Where to Direct Inquiries
All general-interest queries will be posted to the web site and answered therein. Please read “Frequently Asked Questions for the ICRF Program” on the following web site: http://www.fogartyscholars.org/fellows/faq to see if a given query has already been addressed.
Queries by telephone to the VIGH will be abstracted such that questions and answers are summarized and added to our web site. You may contact the following resource persons for this solicitation:
Catherine Lem, MPH, Senior Program Manager
Tel: (615) 343-3555
Email: catherine.lem@vanderbilt.edu
Sten H. Vermund, MD, PhD, Principal Investigator of the Fogarty International Clinical Research Scholars/Fellows Support Center at Vanderbilt and an additional resource person
Tel: (615) 322-9374
Email: sten.vermund@vanderbilt.edu
Thursday, January 14, 2010
Foundation for Womens Wellness - Barbara G. & Jack M. Krulewitz Women’s Health Fellowship Award (for Medical Graduate Student)
The Foundation for Women’s Wellness (FWW) accepts applications for the Barbara G. & Jack M. Krulewitz Women’s Health Fellowship Award. Created in loving memory of Barbara G. & Jack M. Krulewitz, this award will go to a selected medical graduate student working on a study deemed important to women’s health. This award is non-recurring for $2,500.
FWW is currently accepting applications
Deadline: March 31, 2010 (by 12:00pm EST).
Requirements:
Applicants should be medical students, fellows, residents or the like at an accredited U.S. medical school/institution.
Application:
Please submit the following 3 items via e-mail to sharoncravitz@thefww.org:
- A brief letter (no more than 2 pages) explaining the study or research you are currently pursuing (either as an assistant to a larger research study or as part of an academic pursuit) and its relevance to women’s health. You should also explain your interest and any professional pursuits related to women’s health.
- Resume
- Letter of recommendation from current supervisor
Wednesday, January 13, 2010
Incoming Science Webinar Series
Moving Stem Cell Research Forward: The Need for Standardization
Thursday, January 28, 2010
11 a.m. Eastern, 8 a.m. Pacific, 4 p.m. GMT
Stem cell research has the potential to significantly impact a broad range of life science endeavors, ranging from improved drug discovery processes to revolutionary new therapeutics. The ability to control differentiation of stem cells into specialized cell types with high yield and precision is a key success factor that will determine the ultimate utility of such research. However, researchers are facing significant challenges in these efforts because stem cells are difficult to handle and there are very few automated or standardized tools available in this relatively new field. In this hour, we will hear from three panelists on the need for, and progress toward, a new level of standardization and automation in the management and handling of stem cell cultures and their differentiated progeny.
Webinar viewers will:
- learn about common hurdles to be overcome when culturing stem cells
- obtain guidance on best practices for handling and manipulating stem cells
- hear about the latest technologies for standardizing and automating stem cell culture
- have the chance to put their questions to the panelists live!
Participants:
- Ronald D.G. McKay, Ph.D. National Institutes of Health, Bethesda, MD
- Amy Wagers, Ph.D. Harvard University, Boston, MA
- Mark D. Noble, Ph.D. University of Rochester Medical Center, Rochester, NY
Denmark: Better, Faster, Stronger - Leading the Way in Translational Medicine
Wednesday, February 10, 2010 - 5 p.m. CET, 4 p.m. GMT, 11 a.m. U.S. Eastern, 8 a.m. U.S. Pacific
Translational medicine is a field that continues to grow rapidly. Encouraging, supporting, and developing both basic translational research and its therapeutic application is essential to building a strong foundation in science. This webinar will focus on what Denmark is doing in the area of translational medicine to advance research, strengthen ties between academia and industry, and provide a fertile environment for innovation and the practical application of new discoveries. Discussion will cover government initiatives (Danish and the European Union) to support translational medicine, as well as the infrastructure that has been put in place within Denmark to support and nurture domestic and foreign investment in this research.
During this webinar our panelists will:
- discuss the importance of translational research and its impact on scientific discovery and drug development within Denmark
- outline government and other programs that encourage partnerships between academic institutions and industry
- talk about the potential advantages for companies of relocation to Denmark to carry out translational research–related work
- answer your questions live!
Participants:
- Prof. Lars Arendt-Nielsen Aalborg University, Aalborg, Denmark
- Prof. Liselotte Højgaard Rigshospitalet, Copenhagen, Denmark
- Dr. Niels Porksen Eli Lilly & Company, Indianapolis, IN, USA
- Dr. Peter Høngaard Andersen H. Lundbeck A/S, Copenhagen, Denmark
Monday, January 11, 2010
New Therapy Grants Program From The Epilepsy Research Foundation
The New Therapy Grants Program seeks to advance the development of specific new therapies including new medicines and therapeutic devices. Consistent with the theme of translational research, all grant proposals must demonstrate a clear path from the lab to the patient. Other areas of consideration include but are not limited to:
* Seed funding for preliminary and targeted work deemed necessary to explore novel therapeutic approaches
* Projects which if successful offer a clear path to downstream development
* Proposals that support the commercialization of exceptional academic research projects
* Research to bring new approaches and therapy to children
Key issues for reviewers are whether the program could lead to a new therapy that is approvable by FDA or meet other criteria for reimbursement: major roadblocks to getting new therapies to patients.
Areas of Interest:
* Meaningful grants to senior level scientific and clinical investigators on the brink of new discoveries, working at the nation’s leading academic and research institutions, and in private industry.
* Seed funding for preliminary work necessary to explore novel approaches
* Building innovative platform technologies. Investigation of innovative tests to streamline the development of new therapies and the development of a genomics database for epilepsy.
* Research to bring new approaches and therapy to children
* Innovative cutting edge projects that could lead to breakthrough discoveries.
* Support for applying work in other areas which shows the potential for promise in epilepsy.
* Research programs that might not otherwise be funded through traditional sources.
* Projects that encourage collaboration among scientists and industry.
* Proposals dealing with commercializing academic research projects.
Disciplinary Category:
Medical - Translational.
Applicant Type:
Investigators must hold a relevant advanced degree (M.D.and/or Ph.D.), and have completed all research training. This call for proposals is open to investigators at corporations as well as the academic/university arena. All applications will be judged on a competitive basis, without regard to the academic rank or title of the investigator. Applicants whose research will involve patient care or direct involvement with patients must be licensed to practice their profession at their institution and must obtain Institutional Review Board (IRB) approval of their research. IRB approval must be included with the original application.
Award Amount:
Awards will range between $100,000 to $200,000 per year. Multi-year awards will be considered.
Numerical value: $200,000
Application Process:
Application instructions and forms can be obtained at the foundation website.
Funding Agency Contact:
Epilepsy Foundation
Cassandra Richard, Research Coordinator
4351 Garden City Drive
Landover MD 20785-7223
Phone: 301/918-3724
Email: crichard@efa.org
Deadlines:
Mar. 1, 2010 (REQUIRED letter of intent); Apr. 23, 2010 (invited application).
* Seed funding for preliminary and targeted work deemed necessary to explore novel therapeutic approaches
* Projects which if successful offer a clear path to downstream development
* Proposals that support the commercialization of exceptional academic research projects
* Research to bring new approaches and therapy to children
Key issues for reviewers are whether the program could lead to a new therapy that is approvable by FDA or meet other criteria for reimbursement: major roadblocks to getting new therapies to patients.
Areas of Interest:
* Meaningful grants to senior level scientific and clinical investigators on the brink of new discoveries, working at the nation’s leading academic and research institutions, and in private industry.
* Seed funding for preliminary work necessary to explore novel approaches
* Building innovative platform technologies. Investigation of innovative tests to streamline the development of new therapies and the development of a genomics database for epilepsy.
* Research to bring new approaches and therapy to children
* Innovative cutting edge projects that could lead to breakthrough discoveries.
* Support for applying work in other areas which shows the potential for promise in epilepsy.
* Research programs that might not otherwise be funded through traditional sources.
* Projects that encourage collaboration among scientists and industry.
* Proposals dealing with commercializing academic research projects.
Disciplinary Category:
Medical - Translational.
Applicant Type:
Investigators must hold a relevant advanced degree (M.D.and/or Ph.D.), and have completed all research training. This call for proposals is open to investigators at corporations as well as the academic/university arena. All applications will be judged on a competitive basis, without regard to the academic rank or title of the investigator. Applicants whose research will involve patient care or direct involvement with patients must be licensed to practice their profession at their institution and must obtain Institutional Review Board (IRB) approval of their research. IRB approval must be included with the original application.
Award Amount:
Awards will range between $100,000 to $200,000 per year. Multi-year awards will be considered.
Numerical value: $200,000
Application Process:
Application instructions and forms can be obtained at the foundation website.
Funding Agency Contact:
Epilepsy Foundation
Cassandra Richard, Research Coordinator
4351 Garden City Drive
Landover MD 20785-7223
Phone: 301/918-3724
Email: crichard@efa.org
Deadlines:
Mar. 1, 2010 (REQUIRED letter of intent); Apr. 23, 2010 (invited application).
Job Opening with the U.S. Environmental Protection Agency at RTP
The Environmental Protection Agency (EPA) is seeking qualified applicants for an exposure/risk analyst position to work in the Ambient Standards Group (ASG), Health and Environmental Impacts Division (HEID), Office of Air Quality Planning and Standards (OAQPS) in Research Triangle Park., NC that is within EPA's Office of Air and Radiation (OAR) - see http://www.epa.gov/oar/oaqps for more information on OAQPS.
ASG plays a vital role in EPA's work to protect against air pollution effects on public health and the environment by leading the assessments of scientific and technical information about common air pollutants for use in the development and review of the national ambient air quality standards (NAAQS). Major products of this work are the risk/exposure assessment and policy assessment documents that are prepared for the criteria air pollutants (e.g., ozone, particulate matter, nitrogen dioxide, sulfur dioxide, lead, and carbon monoxide). These documents are key components in EPA's review of the NAAQS and undergo extensive review by the Clean Air Scientific Advisory Committee (CASAC). These documents also serve as a resource for other air pollution work in EPA and State and local agencies, as well as international organizations. The NAAQS have exceedingly high impact in protecting public health and the environment, thus, the scientific soundness of the risk/exposure assessment and policy assessment is of crucial importance.
The employee will play a key role in planning and managing population risk/exposure analyses and developing technical documents and policy assessments for the NAAQS reviews. This work will include participating in public meetings of the CASAC in which draft documents are reviewed.
Excellent Benefits: The selected candidate will be eligible for a full benefits package, including health insurance, life insurance, retirement, and vacation and sick leave. U. S. citizenship required.
Salary Range: The salary range is $69,704 to $107,756 per year, commensurate with qualifications.
Qualifications: A bachelor's degree (or higher) is required, and desirable applicants will have a masters or doctoral degree (e.g. Ph.D.) in an academic field related to environmental health, biology, toxicology, health sciences or a related field.
How to Apply: Applicants should apply through USAJOBS at http://www.usajobs.opm.gov. Application materials must be submitted online by the closing date. You need to submit the additional documentation described in the full text vacancy. The announcements will close in mid-January 2010.
Contact: For further information, contact Zachary Pekar (Pekar.zachary@epa.gov; 919 541-3704) or Beth Hassett-Sipple (hassett-sipple.beth@epa.gov; 919 541-4605) for any technical questions or Glinda Bowden (Bowden.glinda@epa.gov) for any questions about the application process.
ASG plays a vital role in EPA's work to protect against air pollution effects on public health and the environment by leading the assessments of scientific and technical information about common air pollutants for use in the development and review of the national ambient air quality standards (NAAQS). Major products of this work are the risk/exposure assessment and policy assessment documents that are prepared for the criteria air pollutants (e.g., ozone, particulate matter, nitrogen dioxide, sulfur dioxide, lead, and carbon monoxide). These documents are key components in EPA's review of the NAAQS and undergo extensive review by the Clean Air Scientific Advisory Committee (CASAC). These documents also serve as a resource for other air pollution work in EPA and State and local agencies, as well as international organizations. The NAAQS have exceedingly high impact in protecting public health and the environment, thus, the scientific soundness of the risk/exposure assessment and policy assessment is of crucial importance.
The employee will play a key role in planning and managing population risk/exposure analyses and developing technical documents and policy assessments for the NAAQS reviews. This work will include participating in public meetings of the CASAC in which draft documents are reviewed.
Excellent Benefits: The selected candidate will be eligible for a full benefits package, including health insurance, life insurance, retirement, and vacation and sick leave. U. S. citizenship required.
Salary Range: The salary range is $69,704 to $107,756 per year, commensurate with qualifications.
Qualifications: A bachelor's degree (or higher) is required, and desirable applicants will have a masters or doctoral degree (e.g. Ph.D.) in an academic field related to environmental health, biology, toxicology, health sciences or a related field.
How to Apply: Applicants should apply through USAJOBS at http://www.usajobs.opm.gov. Application materials must be submitted online by the closing date. You need to submit the additional documentation described in the full text vacancy. The announcements will close in mid-January 2010.
Contact: For further information, contact Zachary Pekar (Pekar.zachary@epa.gov; 919 541-3704) or Beth Hassett-Sipple (hassett-sipple.beth@epa.gov; 919 541-4605) for any technical questions or Glinda Bowden (Bowden.glinda@epa.gov) for any questions about the application process.
Thursday, January 7, 2010
Director, iPS Core Laboratory Facility Duke University School of Medicine
The Duke University School of Medicine invites applications for the position of Director of a newly created iPS Core Laboratory Facility. This facility will play a key role in supporting Duke's efforts to advance the field of stem cell research through the development and application of reprogramming technologies using induced pluripotent stem (iPS) cells.
The iPS Core will provide Duke researchers with training and access to cutting edge capabilities to support their own research endeavors, with a focus on the derivation and storage of new iPS cell lines. The Core will serve as a repository for iPS cells produced by Duke investigators and a laboratory for the generation and characterization of new disease-specific lines. The Director will oversee the scientific output of the Core through the day-to-day management of operations, personnel and finances. The Director will ensure that exceptional support is provided to the Duke research community in a timely, economical, and regulatory compliant manner.
In addition, the iPS Core will contribute to the efforts of the broader research community through the large scale production and global distribution of iPS cell lines developed by Duke scientists.
The Director will report to Brigid Hogan, Ph.D., Professor and Chair, Department of Cell Biology. Dr. Hogan will lead a faculty governance board for the Core.
Responsibilities: This role will include the following specific responsibilities:
- Provide scientific and technical expertise necessary to assist researchers in designing the experimental framework for their investigations. Foster a collaborative process for the design of all iPS cell experiments via discussions between senior laboratory staff and the investigators utilizing the Core resources. Ensure that research staff have a clear understanding of the desired metrics of success for each experiment and that scientists are fully informed of laboratory procedures, requirements and costs.
- Oversee laboratory facilities including space, equipment and supplies. Facilitate the selection, procurement, and maintenance of equipment. Ensure adherence to environmental requirements. Develop and implement processes for scheduling and training of new users.
- Oversee laboratory operations including the development and maintenance of standard operating procedures for cell culture and other specialized laboratory techniques as well as quality control and assurance activities. Manage cell culture procedures through established protocols, and design and evaluate protocols for new technical services. Foster effective project and resource management needed for successful operations and service.
- Identify opportunities to leverage information technology to facilitate the efficient operation of the Core and made recommendations regarding the purchase of hardware and software, application development, etc.
- Develop and manage the Core's annual operating budget and cost recovery mechanism to ensure long-term financial sustainability.
- Identify strategies for improving and enhancing the Core?s services to the research community and make recommendations to leadership regarding opportunities to develop and implement new resources and capabilities.
- Maintain a strong awareness of other shared resources at Duke that may be of benefit to investigators involved in iPS cell research and facilitate connections as appropriate.
- Identify and implement opportunities to inform prospective Core users of the capabilities, expertise and services available.
Qualifications:
Candidates must hold a PhD in cell biology, or related field, with a focus on molecular biology or developmental and stem cell biology, as well as a strong record of postdoctoral research accomplishments and publications. The ideal candidate will have experience with ES and iPS cell culture (or alternatively mouse ES cell culture), culture of primary human cells, and the use of lentiviral vectors. At minimum, candidates must have demonstrated experience with mammalian tissue culture technology, cell transfection, and basic molecular biology. Excellent organizational, communication and interpersonal skills are required. Experience working in a collaborative research environment is strongly preferred. A faculty level (non-tenure track) appointment may be considered based on the candidate's credentials.
Interested individuals should send request for more information or a formal application with names of 3 references to Brigid Hogan, PhD, only at the e-mail address: stemcell@cellbio.duke.edu
Closing date for applications: Feb 28th 2010.
The iPS Core will provide Duke researchers with training and access to cutting edge capabilities to support their own research endeavors, with a focus on the derivation and storage of new iPS cell lines. The Core will serve as a repository for iPS cells produced by Duke investigators and a laboratory for the generation and characterization of new disease-specific lines. The Director will oversee the scientific output of the Core through the day-to-day management of operations, personnel and finances. The Director will ensure that exceptional support is provided to the Duke research community in a timely, economical, and regulatory compliant manner.
In addition, the iPS Core will contribute to the efforts of the broader research community through the large scale production and global distribution of iPS cell lines developed by Duke scientists.
The Director will report to Brigid Hogan, Ph.D., Professor and Chair, Department of Cell Biology. Dr. Hogan will lead a faculty governance board for the Core.
Responsibilities: This role will include the following specific responsibilities:
- Provide scientific and technical expertise necessary to assist researchers in designing the experimental framework for their investigations. Foster a collaborative process for the design of all iPS cell experiments via discussions between senior laboratory staff and the investigators utilizing the Core resources. Ensure that research staff have a clear understanding of the desired metrics of success for each experiment and that scientists are fully informed of laboratory procedures, requirements and costs.
- Oversee laboratory facilities including space, equipment and supplies. Facilitate the selection, procurement, and maintenance of equipment. Ensure adherence to environmental requirements. Develop and implement processes for scheduling and training of new users.
- Oversee laboratory operations including the development and maintenance of standard operating procedures for cell culture and other specialized laboratory techniques as well as quality control and assurance activities. Manage cell culture procedures through established protocols, and design and evaluate protocols for new technical services. Foster effective project and resource management needed for successful operations and service.
- Identify opportunities to leverage information technology to facilitate the efficient operation of the Core and made recommendations regarding the purchase of hardware and software, application development, etc.
- Develop and manage the Core's annual operating budget and cost recovery mechanism to ensure long-term financial sustainability.
- Identify strategies for improving and enhancing the Core?s services to the research community and make recommendations to leadership regarding opportunities to develop and implement new resources and capabilities.
- Maintain a strong awareness of other shared resources at Duke that may be of benefit to investigators involved in iPS cell research and facilitate connections as appropriate.
- Identify and implement opportunities to inform prospective Core users of the capabilities, expertise and services available.
Qualifications:
Candidates must hold a PhD in cell biology, or related field, with a focus on molecular biology or developmental and stem cell biology, as well as a strong record of postdoctoral research accomplishments and publications. The ideal candidate will have experience with ES and iPS cell culture (or alternatively mouse ES cell culture), culture of primary human cells, and the use of lentiviral vectors. At minimum, candidates must have demonstrated experience with mammalian tissue culture technology, cell transfection, and basic molecular biology. Excellent organizational, communication and interpersonal skills are required. Experience working in a collaborative research environment is strongly preferred. A faculty level (non-tenure track) appointment may be considered based on the candidate's credentials.
Interested individuals should send request for more information or a formal application with names of 3 references to Brigid Hogan, PhD, only at the e-mail address: stemcell@cellbio.duke.edu
Closing date for applications: Feb 28th 2010.
Wednesday, January 6, 2010
FDA Commissioner's Fellowship Program
The FDA offers a two-year Fellowship Program, which provides an opportunity for health professionals and scientists to receive training and experience at the FDA. Fellows will train at FDA's new state-of-the-art White Oak campus in Silver Spring, Maryland or at other FDA facilities. Salaries are extremely competitive, and travel funds are available to attend scientific meetings.
Preceptors and Coursework
The Fellowship Program combines rigorous didactic coursework with the development of a regulatory science research project. Under the guidance of an FDA senior scientist Preceptor committed to mentoring, Fellows will explore a specific aspect of FDA regulatory science. This experience can be in a biology, physics or engineering lab, in a clinical review team, in biostatistics, informatics, epidemiology, risk analysis or other aspects of FDA science.
To learn more about the proposed projects, please visit the Preceptor page.
The coursework is designed to provide an in-depth understanding of the science behind regulatory review, encompassing the activities of the FDA across foods, drugs, devices, biologics, and cosmetics. Coursework during the two years includes graduate level public policy, FDA law, epidemiology, clinical trials and design, and statistics.
Please visit our coursework page for more information.
Eligibility Criteria
Applicants must have a Doctoral level degree (M.D., D.O., D.V.M., D.D.S., D.P.M., Pharm.D., or Ph.D.) to be eligible. Applicants with a Bachelor's degree in an engineering discipline will also be considered. Applicants must be U.S. citizens, non-citizen nationals of the U.S., or have been admitted to the U.S. for permanent residence before the program start date. Applicants cannot be current FDA employees or FDA contractors (such as ORISE fellows).
Benefits of Working at the FDA
We offer an excellent benefits package including health insurance, retirement, and paid vacation leave.
Key Dates
January – March – Applications Accepted
June/July – Interviews
July – August - Applicants Notified of Their Standing
October – Program Start Date
This year, all applications are due on April 10th, 2010, at 11:59pm.
Questions? Contact:Kirk Prutzman, PhD
Food and Drug Administration Commissioner's Fellow
Kirk.Prutzman@fda.hhs.gov
(301) 402-2770
Monday, January 4, 2010
The Journal Impact Factors (IF factor)
People working in academia care about the importance and significance of their research, which can be evaluated based on the impact factors of their published papers. What to know more about the journal impact factors and how the impact factors are calculated? Please read the article "What about Journal Impact Factors?".
Below is the list of the recent released impact factors for most journals:
Below is the list of the recent released impact factors for most journals:
| CA-CANCER J CLIN | 63.342 |
| NEW ENGL J MED | 51.296 |
| ANNU REV IMMUNOL | 47.237 |
| ANNU REV BIOCHEM | 36.525 |
| REV MOD PHYS | 33.508 |
| NAT REV CANCER | 31.583 |
| PHYSIOL REV | 31.441 |
| NAT REV MOL CELL BIO | 31.354 |
| SCIENCE | 30.028 |
| CELL | 29.194 |
| NAT REV IMMUNOL | 28.697 |
| NAT MED | 28.588 |
| ANNU REV NEUROSCI | 28.533 |
| NAT IMMUNOL | 27.596 |
| NATURE | 26.681 |
| ANNU REV CELL DEV BI | 26.576 |
| CHEM REV | 26.054 |
| LANCET | 25.8 |
| BRIEF BIOINFORM | 24.37 |
| NAT GENET | 24.176 |
| CANCER CELL | 24.077 |
| ENDOCR REV | 23.901 |
| JAMA-J AM MED ASSOC | 23.175 |
| NAT REV NEUROSCI | 23.054 |
| NAT REV GENET | 22.947 |
| ANNU REV PHARMACOL | 22.808 |
| NAT BIOTECHNOL | 22.672 |
| NAT REV DRUG DISCOV | 20.97 |
| ANNU REV PLANT BIOL | 19.837 |
| NAT MATER | 19.194 |
| ANNU REV GENET | 19.098 |
| NAT CELL BIOL | 18.485 |
| IMMUNITY | 18.306 |
| MAT SCI ENG R | 17.731 |
| ACCOUNTS CHEM RES | 17.113 |
| ANNU REV BIOPH BIOM | 16.921 |
| ANNU REV ASTRON ASTR | 16.914 |
| PHARMACOL REV | 16.854 |
| CELL METAB | 16.71 |
| MICROBIOL MOL BIOL R | 15.864 |
| NAT REV MICROBIOL | 15.845 |
| J CLIN INVEST | 15.754 |
| ANNU REV PHYSIOL | 15.356 |
| J NATL CANCER I | 15.271 |
| GENE DEV | 15.05 |
| BEHAV BRAIN SCI | 14.964 |
| NAT METHODS | 14.959 |
| PROG POLYM SCI | 14.818 |
| NAT NEUROSCI | 14.805 |
| ANN INTERN MED | 14.78 |
| ANNU REV MICROBIOL | 14.553 |
| J EXP MED | 14.484 |
| CURR OPIN CELL BIOL | 14.299 |
| TRENDS ECOL EVOL | 14.125 |
| PLOS BIOL | 14.101 |
| MOL CELL | 14.033 |
| ARCH GEN PSYCHIAT | 13.936 |
| NEURON | 13.894 |
| TRENDS BIOCHEM SCI | 13.863 |
| PLOS MED | 13.75 |
| CHEM SOC REV | 13.69 |
| ASTRON ASTROPHYS REV | 13.667 |
| J CLIN ONCOL | 13.598 |
| DEV CELL | 13.523 |
| TRENDS NEUROSCI | 13.494 |
| ANNU REV MED | 13.237 |
| PSYCHOL BULL | 12.725 |
| CLIN MICROBIOL REV | 12.643 |
| AM J HUM GENET | 12.629 |
| ANNU REV FLUID MECH | 12.469 |
| GASTROENTEROLOGY | 12.457 |
| TRENDS CELL BIOL | 12.429 |
| NAT CHEM BIOL | 12.409 |
| PROG LIPID RES | 12.235 |
| NAT PHYS | 12.04 |
| LANCET INFECT DIS | 11.808 |
| MOL PSYCHIATR | 11.804 |
| ANNU REV PSYCHOL | 11.706 |
| CYTOKINE GROWTH F R | 11.549 |
| FRONT NEUROENDOCRIN | 11.526 |
| NAT STRUCT MOL BIOL | 11.502 |
| PROG NEUROBIOL | 11.304 |
| ADV CATAL | 11.25 |
| ANNU REV PHYS CHEM | 11.25 |
| CURR OPIN STRUC BIOL | 11.215 |
| CURR BIOL | 10.988 |
| MASS SPECTROM REV | 10.947 |
| CIRCULATION | 10.94 |
| ANNU REV GENOM HUM G | 10.771 |
| IMMUNOL REV | 10.758 |
| ALDRICHIM ACTA | 10.692 |
| ADV CANCER RES | 10.682 |
| ANNU REV BIOMED ENG | 10.533 |
| ANNU REV NUTR | 10.449 |
| HEPATOLOGY | 10.446 |
| PHYS REP | 10.438 |
| ANNU REV MATER RES | 10.4 |
| TRENDS PHARMACOL SCI | 10.4 |
| GENOME RES | 10.256 |
| ANGEW CHEM INT EDIT | 10.232 |
| PROG MATER SCI | 10.229 |
| TRENDS IMMUNOL | 10.213 |
| CURR OPIN PLANT BIOL | 10.182 |
| J CELL BIOL | 10.152 |
| LANCET ONCOL | 10.119 |
| EMBO J | 10.086 |
| CURR OPIN GENET DEV | 10.006 |
| SEMIN IMMUNOL | 10 |
| NANO LETT | 9.96 |
| TRENDS GENET | 9.95 |
| PLANT CELL | 9.868 |
| CIRC RES | 9.854 |
| ANNU REV ECOL EVOL S | 9.784 |
| J AM COLL CARDIOL | 9.701 |
| P NATL ACAD SCI USA | 9.643 |
| MOL CELL PROTEOMICS | 9.62 |
| REP PROG PHYS | 9.549 |
| SOLID STATE PHYS | 9.5 |
| LANCET NEUROL | 9.479 |
| CURR OPIN IMMUNOL | 9.422 |
| CRIT REV BIOCHEM MOL | 9.393 |
| ADV PHYS | 9.389 |
| TRENDS COGN SCI | 9.374 |
| SURF SCI REP | 9.304 |
| CURR OPIN NEUROBIOL | 9.286 |
| RECENT PROG HORM RES | 9.263 |
| BRIT MED J | 9.245 |
| CATAL REV | 9.222 |
| BBA-REV CANCER | 9.156 |
| AM J RESP CRIT CARE | 9.091 |
| PROG RETIN EYE RES | 9.039 |
| GUT | 9.002 |
| ANNU REV PHYTOPATHOL | 9 |
| NAT PROD REP | 8.889 |
| J ALLERGY CLIN IMMUN | 8.829 |
| PSYCHOL REV | 8.825 |
| COORDIN CHEM REV | 8.815 |
| ANNU REV ENTOMOL | 8.714 |
| FEMS MICROBIOL REV | 8.691 |
| SEMIN CELL DEV BIOL | 8.672 |
| PHARMACOL THERAPEUT | 8.657 |
| ASTROPHYS J SUPPL S | 8.627 |
| REV GEOPHYS | 8.375 |
| REJUV RES | 8.353 |
| TRENDS MICROBIOL | 8.335 |
| CURR OPIN CHEM BIOL | 8.32 |
| EPIDEMIOL REV | 8.3 |
| NEUROSCI BIOBEHAV R | 8.293 |
| AM J PSYCHIAT | 8.25 |
| EMBO REP | 8.175 |
| HUM MOL GENET | 8.099 |
| CLIN PHARMACOL THER | 8.066 |
| ANN NEUROL | 8.051 |
| TRENDS PLANT SCI | 8 |
| ADV DRUG DELIVER REV | 7.977 |
| DIABETES | 7.955 |
| MOL SYST BIOL | 7.941 |
| STEM CELLS | 7.924 |
| ARCH INTERN MED | 7.92 |
| DIABETES CARE | 7.912 |
| ADV MATER | 7.896 |
| TRENDS BIOTECHNOL | 7.843 |
| ADV MICROB PHYSIOL | 7.818 |
| DEVELOPMENT | 7.764 |
| ARTH RHEUM/AR C RES | 7.751 |
| SYSTEMATIC BIOL | 7.748 |
| J AM CHEM SOC | 7.696 |
| ANNU REV EARTH PL SC | 7.683 |
| ANN SURG | 7.678 |
| PLOS GENET | 7.671 |
| CANCER RES | 7.656 |
| BRAIN | 7.617 |
| ECOL LETT | 7.609 |
| MUTAT RES-REV MUTAT | 7.579 |
| CELL DEATH DIFFER | 7.463 |
| J NEUROSCI | 7.453 |
| GLYCOCONJUGATE J | 7.446 |
| CURR OPIN MICROBIOL | 7.445 |
| SEMIN CANCER BIOL | 7.378 |
| J AM SOC NEPHROL | 7.371 |
| J PHOTOCH PHOTOBIO C | 7.32 |
| EUR HEART J | 7.286 |
| PHARMACOGENETICS | 7.221 |
| MED RES REV | 7.218 |
| GENOME BIOL | 7.172 |
| BIOL PSYCHIAT | 7.154 |
| DRUG DISCOV TODAY | 7.152 |
| ECOL MONOGR | 7.102 |
| PHYS REV LETT | 7.072 |
| TRENDS ENDOCRIN MET | 7.066 |
| PROG HISTOCHEM CYTO | 7 |
| CURR OPIN BIOTECH | 6.949 |
| CURR OPIN PHARMACOL | 6.916 |
| BBA-MOL CELL RES | 6.9 |
| ARTERIOSCL THROM VAS | 6.883 |
| CAN MED ASSOC J | 6.862 |
| ANNU REV PUBL HEALTH | 6.854 |
| ADV ORGANOMET CHEM | 6.85 |
| AM J TRANSPLANT | 6.843 |
| MILBANK Q | 6.794 |
| HUM REPROD UPDATE | 6.793 |
| ADV FUNCT MATER | 6.779 |
| MOL CELL BIOL | 6.773 |
| MOL BIOL EVOL | 6.726 |
| FASEB J | 6.721 |
| AUTOPHAGY | 6.708 |
| CHEM BIOL | 6.677 |
| J BONE MINER RES | 6.635 |
| TRAFFIC | 6.612 |
| CRIT CARE MED | 6.599 |
| ONCOGENE | 6.582 |
| PLANT J | 6.565 |
| AM J CLIN NUTR | 6.562 |
| MOL BIOL CELL | 6.562 |
| J CELL MOL MED | 6.555 |
| HUM MUTAT | 6.473 |
| J CELL SCI | 6.427 |
| PROG NUCL MAG RES SP | 6.417 |
| CEREB CORTEX | 6.368 |
| REV MED VIROL | 6.347 |
| NUCLEIC ACIDS RES | 6.317 |
| J IMMUNOL | 6.293 |
| AGING CELL | 6.276 |
| PHYSIOLOGY | 6.268 |
| ANNU REV NUCL PART S | 6.214 |
| CLIN INFECT DIS | 6.186 |
| CLIN CANCER RES | 6.177 |
| J COSMOL ASTROPART P | 6.175 |
| LEUKEMIA | 6.146 |
| CRIT REV CL LAB SCI | 6.138 |
| PLANT PHYSIOL | 6.125 |
| ASTROPHYS J | 6.119 |
| CANCER METAST REV | 6.115 |
| INT J COMPUT VISION | 6.085 |
| J HEPATOL | 6.073 |
| THORAX | 6.064 |
| PLOS PATHOG | 6.056 |
| CEPHALALGIA | 6.049 |
| INT REV PHYS CHEM | 6.036 |
| GOLD BULL | 6.029 |
| SMALL | 6.024 |
| HYPERTENSION | 6.007 |
| CRIT REV ORAL BIOL M | 6 |
| INT REV CYTOL | 5.988 |
| PROG SURF SCI | 5.968 |
| BIOESSAYS | 5.965 |
| Q REV BIOL | 5.944 |
| AM J PATHOL | 5.917 |
| NEUROPSYCHOPHARMACOL | 5.889 |
| SEMIN RADIAT ONCOL | 5.889 |
| ATHEROSCLEROSIS SUPP | 5.875 |
| DNA REPAIR | 5.868 |
| TRENDS MOL MED | 5.864 |
| ENVIRON HEALTH PERSP | 5.861 |
| MOL THER | 5.841 |
| PHYS TODAY | 5.839 |
| CARDIOVASC RES | 5.826 |
| LAB CHIP | 5.821 |
| J BIOL CHEM | 5.808 |
| J CLIN ENDOCR METAB | 5.799 |
| ANN RHEUM DIS | 5.767 |
| CURR DRUG METAB | 5.762 |
| J PATHOL | 5.759 |
| BLOOD REV | 5.756 |
| DRUG METAB REV | 5.754 |
| STRUCTURE | 5.738 |
| PROTEOMICS | 5.735 |
| NEUROSCIENTIST | 5.71 |
| NEUROLOGY | 5.69 |
| CURR OPIN LIPIDOL | 5.689 |
| ADV PROTEIN CHEM | 5.685 |
| PROG BIOPHYS MOL BIO | 5.684 |
| CURR CANCER DRUG TAR | 5.677 |
| MRS BULL | 5.671 |
| ANAL CHEM | 5.646 |
| MOL MICROBIOL | 5.634 |
| AIDS | 5.632 |
| REV PHYSIOL BIOCH P | 5.625 |
| AM J GASTROENTEROL | 5.608 |
| NEUROBIOL AGING | 5.599 |
| BRAIN RES REV | 5.595 |
| MOL INTERV | 5.595 |
| BIOL REV | 5.565 |
| NEUROIMAGE | 5.559 |
| J CLIN PSYCHIAT | 5.533 |
| PROG NUCLEIC ACID RE | 5.529 |
| CLIN CHEM | 5.454 |
| FREE RADICAL BIO MED | 5.44 |
| BRIT J PSYCHIAT | 5.436 |
| BIOSCIENCE | 5.424 |
| BIOSCIENCE | 5.424 |
| J HIGH ENERGY PHYS | 5.393 |
| PHARMACOGENET GENOM | 5.391 |
| STROKE | 5.391 |
| INT MATER REV | 5.382 |
| CARCINOGENESIS | 5.366 |
| NAT CLIN PRACT ONCOL | 5.364 |
| J INFECT DIS | 5.363 |
| J VIROL | 5.341 |
| ALLERGY | 5.334 |
| SEMIN LIVER DIS | 5.302 |
| HEALTH TECHNOL ASSES | 5.29 |
| BRAIN PATHOL | 5.274 |
| CURR PHARM DESIGN | 5.27 |
| DRUG RESIST UPDATE | 5.268 |
| RADIOLOGY | 5.251 |
| DIABETOLOGIA | 5.247 |
| AM J EPIDEMIOL | 5.241 |
| NEWS PHYSIOL SCI | 5.241 |
| ENDOCRINOLOGY | 5.236 |
| CURR OPIN NEUROL | 5.229 |
| GENET EPIDEMIOL | 5.226 |
| CURR MED CHEM | 5.207 |
| ONCOLOGIST | 5.206 |
| ARCH NEUROL-CHICAGO | 5.204 |
| CURR OPIN HEMATOL | 5.202 |
| NUCL PHYS B | 5.199 |
| J COGNITIVE NEUROSCI | 5.197 |
| BIOMATERIALS | 5.196 |
| INT J NEUROPSYCHOPH | 5.184 |
| ANN ONCOL | 5.179 |
| MEDICINE | 5.167 |
| J MOL MED-JMM | 5.157 |
| J PROTEOME RES | 5.151 |
| J THROMB HAEMOST | 5.138 |
| MOL CANCER THER | 5.137 |
| SLEEP | 5.126 |
| J MED CHEM | 5.115 |
| RNA | 5.111 |
| CHEM MATER | 5.104 |
| LEARN MEMORY | 5.099 |
| EMERG INFECT DIS | 5.094 |
| J MED GENET | 5.087 |
| SLEEP MED REV | 5.083 |
| EUR RESPIR J | 5.076 |
| CELL MICROBIOL | 5.07 |
| TRAC-TREND ANAL CHEM | 5.068 |
| ACM T INFORM SYST | 5.059 |
| MON NOT R ASTRON SOC | 5.057 |
| PHYS LETT B | 5.043 |
| HAEMATOL-HEMATOL J | 5.032 |
| B WORLD HEALTH ORGAN | 5.029 |
| CHEM-EUR J | 5.015 |
| GLIA | 5.013 |
| PEDIATRICS | 5.012 |
| ADV APPL MECH | 5 |
| CRIT REV THER DRUG | 5 |
| J NUCL MED | 4.986 |
| ANTIVIR THER | 4.982 |
| MOL ENDOCRINOL | 4.967 |
| NEURO-ONCOLOGY | 4.939 |
| ADV IMMUNOL | 4.935 |
| PLOS COMPUT BIOL | 4.914 |
| NEOPLASIA | 4.913 |
| TRENDS PARASITOL | 4.907 |
| PHYS REV D | 4.896 |
| BIOINFORMATICS | 4.894 |
| DEV BIOL | 4.893 |
| J COMPUT CHEM | 4.893 |
| J MOL BIOL | 4.89 |
| HUM BRAIN MAPP | 4.888 |
| CELL SIGNAL | 4.887 |
| ESSAYS BIOCHEM | 4.885 |
| J MOL CELL CARDIOL | 4.859 |
| ASTRON J | 4.854 |
| CURR MOL MED | 4.85 |
| EUR UROL | 4.85 |
| PSYCHONEUROENDOCRINO | 4.85 |
| J CEREBR BLOOD F MET | 4.843 |
| FRONT ECOL ENVIRON | 4.842 |
| PAIN | 4.836 |
| ADV PARASIT | 4.826 |
| GASTROINTEST ENDOSC | 4.825 |
| MOL ECOL | 4.825 |
| PFLUG ARCH EUR J PHY | 4.807 |
| CURR OPIN RHEUMATOL | 4.805 |
| INT J BIOCHEM CELL B | 4.804 |
| CURR OPIN INFECT DIS | 4.795 |
| TOP CURR CHEM | 4.789 |
| ECOLOGY | 4.782 |
| GENE THER | 4.782 |
| KIDNEY INT | 4.773 |
| EUR J IMMUNOL | 4.772 |
| MOL IMMUNOL | 4.768 |
| J AM ACAD CHILD PSY | 4.767 |
| ENDOCR-RELAT CANCER | 4.763 |
| ADV SYNTH CATAL | 4.762 |
| MOL CANCER RES | 4.759 |
| BIOPHYS J | 4.757 |
| BIOPHYS J | 4.757 |
| SPRINGER SEMIN IMMUN | 4.754 |
| ARCH DIS CHILD-FETAL | 4.734 |
| FARADAY DISCUSS | 4.731 |
| MIS QUART | 4.731 |
| J INTERN MED | 4.73 |
| TRENDS CARDIOVAS MED | 4.724 |
| TOXICOL APPL PHARM | 4.722 |
| INT J CANCER | 4.693 |
| J GEN PHYSIOL | 4.685 |
| J SEX MED | 4.676 |
| BREAST CANCER RES TR | 4.671 |
| AM NAT | 4.66 |
| ORG LETT | 4.659 |
| CELL MOL LIFE SCI | 4.655 |
| J BIOL RHYTHM | 4.633 |
| CURR OPIN COLLOID IN | 4.63 |
| ENVIRON MICROBIOL | 4.63 |
| LIVER TRANSPLANT | 4.629 |
| MOL CELL NEUROSCI | 4.607 |
| CURR TOP MICROBIOL | 4.606 |
| ANN MED | 4.594 |
| AM J RESP CELL MOL | 4.593 |
| CANCER | 4.582 |
| PHILOS T R SOC B | 4.579 |
| J LEUKOCYTE BIOL | 4.572 |
| J CLIN PSYCHOPHARM | 4.561 |
| J INVEST DERMATOL | 4.535 |
| GENES IMMUN | 4.533 |
| J CATAL | 4.533 |
| J APPL ECOL | 4.527 |
| AGEING RES REV | 4.526 |
| CHEM COMMUN | 4.521 |
| AM J MED | 4.518 |
| INT J EPIDEMIOL | 4.517 |
| HUM GENE THER | 4.514 |
| J IMMUNOTHER | 4.508 |
| CRIT REV SOLID STATE | 4.5 |
| PROG QUANT ELECTRON | 4.5 |
| BRIT J HAEMATOL | 4.498 |
| CELL PROLIFERAT | 4.492 |
| ANTIOXID REDOX SIGN | 4.491 |
| CRIT REV ONCOL HEMAT | 4.49 |
| CURR ISSUES MOL BIOL | 4.481 |
| SEMIN NUCL MED | 4.473 |
| DRUGS | 4.472 |
| MOL PHARMACOL | 4.469 |
| AM J MED GENET B | 4.463 |
| INT J RADIAT ONCOL | 4.463 |
| BRIT J CANCER | 4.459 |
| BMC EVOL BIOL | 4.455 |
| LAB INVEST | 4.453 |
| J PHYSIOL-LONDON | 4.407 |
| INTENS CARE MED | 4.406 |
| SOFT MATTER | 4.391 |
| INT J NONLINEAR SCI | 4.386 |
| GENES BRAIN BEHAV | 4.385 |
| J NEUROPATH EXP NEUR | 4.371 |
| CANCER TREAT REV | 4.37 |
| ATMOS CHEM PHYS | 4.362 |
| J LIPID RES | 4.357 |
| SCHIZOPHRENIA BULL | 4.352 |
| CRYST GROWTH DES | 4.339 |
| EPIDEMIOLOGY | 4.339 |
| GLOBAL CHANGE BIOL | 4.339 |
| AM J PHYSIOL-CELL PH | 4.334 |
| PROG ENERG COMBUST | 4.333 |
| PSYCHOTHER PSYCHOSOM | 4.333 |
| CURR OPIN DRUG DISC | 4.319 |
| CANCER IMMUNOL IMMUN | 4.313 |
| IEEE T PATTERN ANAL | 4.306 |
| BIOL CELL | 4.303 |
| EVOLUTION | 4.292 |
| CANCER EPIDEM BIOMAR | 4.289 |
| J MATER CHEM | 4.287 |
| ADV POLYM SCI | 4.284 |
| MACROMOLECULES | 4.277 |
| CURR DRUG TARGETS | 4.274 |
| CLADISTICS | 4.27 |
| SCHIZOPHR RES | 4.264 |
| J NEUROCHEM | 4.26 |
| FISH FISH | 4.257 |
| AM J PHYSIOL-LUNG C | 4.25 |
| NEUROGENETICS | 4.25 |
| NEW PHYTOL | 4.245 |
| GENETICS | 4.242 |
| J ECOL | 4.239 |
| BBA-BIOENERGETICS | 4.237 |
| HIPPOCAMPUS | 4.232 |
| J PINEAL RES | 4.228 |
| SEMIN HEMATOL | 4.213 |
| CNS DRUGS | 4.21 |
| J NEUROBIOL | 4.209 |
| ANESTHESIOLOGY | 4.207 |
| AM J PHYSIOL-RENAL | 4.199 |
| GREEN CHEM | 4.192 |
| CANCER GENE THER | 4.187 |
| AM J MED GENET C | 4.169 |
| CURR TOP MED CHEM | 4.167 |
| EUR J CANCER | 4.167 |
| BREAST CANCER RES | 4.157 |
| EXP NEUROL | 4.156 |
| ANTIMICROB AGENTS CH | 4.153 |
| AM J SURG PATHOL | 4.144 |
| CURR OPIN NEPHROL HY | 4.137 |
| PLANT CELL ENVIRON | 4.135 |
| BIOSENS BIOELECTRON | 4.132 |
| BIOSENS BIOELECTRON | 4.132 |
| ACM COMPUT SURV | 4.13 |
| NEUROBIOL DIS | 4.128 |
| AM J PHYSIOL-ENDOC M | 4.123 |
| CELL CALCIUM | 4.118 |
| CLIN PHARMACOKINET | 4.115 |
| J PHYS CHEM B | 4.115 |
| INT J PLASTICITY | 4.113 |
| QUATERNARY SCI REV | 4.113 |
| MUTAT RES-FUND MOL M | 4.111 |
| ELECTROPHORESIS | 4.101 |
| BIOCHEM J | 4.1 |
| CHEMBIOCHEM | 4.1 |
| J PSYCHIATR NEUROSCI | 4.1 |
| BRIT J SURG | 4.092 |
| ADDICTION | 4.088 |
| ACM T GRAPHIC | 4.081 |
| AM J KIDNEY DIS | 4.072 |
| CHROMOSOMA | 4.065 |
| INT J OBESITY | 4.055 |
| RHEUMATOLOGY | 4.052 |
| EUR J NUCL MED MOL I | 4.041 |
| ENVIRON SCI TECHNOL | 4.04 |
| PUBL ASTRON SOC PAC | 4.035 |
| OPHTHALMOLOGY | 4.031 |
| BMC GENOMICS | 4.029 |
| CONTROL CLIN TRIALS | 4.025 |
| AIDS REV | 4.022 |
| MAYO CLIN PROC | 4.022 |
| J HYPERTENS | 4.021 |
| OSTEOARTHR CARTILAGE | 4.017 |
| INT IMMUNOL | 4.015 |
| J CONTROL RELEASE | 4.012 |
| J NUTR | 4.009 |
| OPT EXPRESS | 4.009 |
| INFECT IMMUN | 4.004 |
| COMMENT INORG CHEM | 4 |
| J BACTERIOL | 3.993 |
| J PEDIATR | 3.991 |
| EARTH-SCI REV | 3.989 |
| PROG PART NUCL PHYS | 3.989 |
| J AM MED INFORM ASSN | 3.979 |
| APPL PHYS LETT | 3.977 |
| CURR PROTEIN PEPT SC | 3.976 |
| TRANSPLANTATION | 3.972 |
| ASTRON ASTROPHYS | 3.971 |
| RADIOTHER ONCOL | 3.97 |
| LASER PART BEAMS | 3.958 |
| PHARMACOGENOMICS J | 3.957 |
| J PHARMACOL EXP THER | 3.956 |
| J UROLOGY | 3.956 |
| JAIDS-J ACQ IMM DEF | 3.946 |
| APPL CATAL B-ENVIRON | 3.942 |
| CRIT REV IMMUNOL | 3.938 |
| MOL PLANT MICROBE IN | 3.936 |
| GROWTH FACTORS | 3.925 |
| CHEST | 3.924 |
| CURR VASC PHARMACOL | 3.924 |
| NEUROPSYCHOLOGIA | 3.924 |
| J GENE MED | 3.916 |
| INFLAMM BOWEL DIS | 3.912 |
| INORG CHEM | 3.911 |
| LANGMUIR | 3.902 |
| GENE CHROMOSOME CANC | 3.9 |
| J ANTIMICROB CHEMOTH | 3.891 |
| EARTH PLANET SC LETT | 3.887 |
| CARBON | 3.884 |
| CANCER SCI | 3.869 |
| ASTROPART PHYS | 3.865 |
| NEUROPHARMACOLOGY | 3.86 |
| ACTA PSYCHIAT SCAND | 3.857 |
| CONTEMP PHYS | 3.857 |
| PSYCHOSOM MED | 3.857 |
| APPL SPECTROSC REV | 3.846 |
| MECH AGEING DEV | 3.846 |
| MECH DEVELOP | 3.836 |
| REV COMP CH | 3.833 |
| J COMP NEUROL | 3.831 |
| BONE | 3.829 |
| CRIT REV MICROBIOL | 3.829 |
| BRIT J PHARMACOL | 3.825 |
| BIOCONJUGATE CHEM | 3.823 |
| METHODS | 3.817 |
| PSYCHOL MED | 3.816 |
| OBSTET GYNECOL | 3.813 |
| ATHEROSCLEROSIS | 3.811 |
| CRIT REV FOOD SCI | 3.805 |
| ANN FAM MED | 3.803 |
| ARTHRITIS RES THER | 3.801 |
| J MAMMARY GLAND BIOL | 3.8 |
| BASIC RES CARDIOL | 3.798 |
| GLOBAL BIOGEOCHEM CY | 3.796 |
| EUR NEUROPSYCHOPHARM | 3.794 |
| J MOL RECOGNIT | 3.794 |
| ADV INORG CHEM | 3.792 |
| ADV COLLOID INTERFAC | 3.79 |
| J ORG CHEM | 3.79 |
| HORM BEHAV | 3.789 |
| PHYSIOL GENOMICS | 3.789 |
| SPACE SCI REV | 3.789 |
| EXP CELL RES | 3.777 |
| HEART RHYTHM | 3.777 |
| IEEE T EVOLUT COMPUT | 3.77 |
| HUM REPROD | 3.769 |
| INVEST OPHTH VIS SCI | 3.766 |
| CONSERV BIOL | 3.762 |
| MOL NEUROBIOL | 3.762 |
| AUTOIMMUN REV | 3.76 |
| BRAIN BEHAV IMMUN | 3.757 |
| IEEE T MED IMAGING | 3.757 |
| NEW J PHYS | 3.754 |
| J VISION | 3.753 |
| MODERN PATHOL | 3.753 |
| GEOCHIM COSMOCHIM AC | 3.751 |
| DIFFERENTIATION | 3.745 |
| MED CARE | 3.745 |
| PROTEINS | 3.73 |
| CRYSTENGCOMM | 3.729 |
| B AM METEOROL SOC | 3.728 |
| TISSUE ENG | 3.725 |
| AM J PHYSIOL-HEART C | 3.724 |
| CORTEX | 3.724 |
| PROSTATE | 3.724 |
| OBES SURG | 3.723 |
| OSTEOPOROSIS INT | 3.718 |
| EUR J NEUROSCI | 3.709 |
| HEART | 3.708 |
| CRIT REV TOXICOL | 3.707 |
| EUKARYOT CELL | 3.707 |
| J PSYCHIATR RES | 3.7 |
| AM J PUBLIC HEALTH | 3.698 |
| EUR J HUM GENET | 3.697 |
| HEALTH PSYCHOL | 3.693 |
| CURR HIV RES | 3.687 |
| P IEEE | 3.686 |
| AM J PHYSIOL-REG I | 3.685 |
| STRAHLENTHER ONKOL | 3.682 |
| AM J PHYSIOL-GASTR L | 3.681 |
| CURR GENE THER | 3.681 |
| HEALTH AFFAIR | 3.68 |
| MATRIX BIOL | 3.679 |
| CURR OPIN CLIN NUTR | 3.676 |
| IMMUNOLOGY | 3.674 |
| DRUG SAFETY | 3.673 |
| CLIN EXP ALLERGY | 3.668 |
| GLYCOBIOLOGY | 3.668 |
| BIOMACROMOLECULES | 3.664 |
| HUM GENET | 3.662 |
| COGNITIVE PSYCHOL | 3.659 |
| J NEUROPHYSIOL | 3.652 |
| DRUG METAB DISPOS | 3.638 |
| J CELL PHYSIOL | 3.638 |
| BIOCHEMISTRY-US | 3.633 |
| ORGANOMETALLICS | 3.632 |
| J ANAL ATOM SPECTROM | 3.63 |
| J EXP BOT | 3.63 |
| J NEUROL NEUROSUR PS | 3.63 |
| J CHEM THEORY COMPUT | 3.627 |
| NMR BIOMED | 3.626 |
| PSYCHOPHARMACOLOGY | 3.625 |
| BMC BIOINFORMATICS | 3.617 |
| P ROY SOC B-BIOL SCI | 3.612 |
| J MECH PHYS SOLIDS | 3.609 |
| CLIN IMMUNOL | 3.606 |
| ENDOSCOPY | 3.605 |
| PHARMACOGENOMICS | 3.603 |
| OPT LETT | 3.598 |
| TOXICOL SCI | 3.598 |
| NEUROBIOL LEARN MEM | 3.593 |
| BBA-BIOMEMBRANES | 3.587 |
| CHEM REC | 3.583 |
| BIOCHEM PHARMACOL | 3.581 |
| EUR J BIOCHEM | 3.579 |
| INT J DEV BIOL | 3.577 |
| PLANT MOL BIOL | 3.577 |
| ESA BULL-EUR SPACE | 3.575 |
| CURR OPIN ONCOL | 3.571 |
| MED PHYS | 3.571 |
| ARCH PEDIAT ADOL MED | 3.565 |
| J THORAC CARDIOV SUR | 3.56 |
| CELL PHYSIOL BIOCHEM | 3.558 |
| GENOMICS | 3.558 |
| J CHROMATOGR A | 3.554 |
| LUNG CANCER | 3.554 |
| ACTA MATER | 3.549 |
| NEUROINFORMATICS | 3.541 |
| APPL ENVIRON MICROB | 3.532 |
| MOL PHYLOGENET EVOL | 3.528 |
| EPILEPSIA | 3.526 |
| VIROLOGY | 3.525 |
| J POWER SOURCES | 3.521 |
| GENES CELLS | 3.517 |
| AM HEART J | 3.514 |
| BEST PRACT RES CL EN | 3.513 |
| BMC DEV BIOL | 3.512 |
| SPORTS MED | 3.504 |
| ADV CARBOHYD CHEM BI | 3.5 |
| BMC MOL BIOL | 3.5 |
| BIOL REPROD | 3.498 |
| AM J PREV MED | 3.497 |
| J STRUCT BIOL | 3.496 |
| OBES RES | 3.491 |
| ELECTROCHEM COMMUN | 3.484 |
| BIOCHEM CELL BIOL | 3.483 |
| CELL TRANSPLANT | 3.482 |
| ADV VIRUS RES | 3.48 |
| GEOLOGY | 3.477 |
| J NEUROSCI RES | 3.476 |
| J DENT RES | 3.475 |
| CNS DRUG REV | 3.474 |
| REV MINERAL GEOCHEM | 3.472 |
| ECOL APPL | 3.47 |
| PROTEIN SCI | 3.462 |
| BIOL BLOOD MARROW TR | 3.458 |
| J SLEEP RES | 3.458 |
| J NEUROTRAUM | 3.453 |
| SURV OPHTHALMOL | 3.451 |
| CHEMPHYSCHEM | 3.449 |
| J CLIN MICROBIOL | 3.445 |
| OCEANOGR MAR BIOL | 3.444 |
| J MEMBRANE SCI | 3.442 |
| DIVERS DISTRIB | 3.441 |
| SEMIN ARTHRITIS RHEU | 3.44 |
| VALUE HEALTH | 3.433 |
| GENET MED | 3.427 |
| MAGN RESON MED | 3.427 |
| NEUROSCIENCE | 3.427 |
| CELL RES | 3.426 |
| TUBERCULOSIS | 3.425 |
| J CHEM INF MODEL | 3.423 |
| APOPTOSIS | 3.421 |
| J CLIMATE | 3.419 |
| ORG ELECTRON | 3.418 |
| CURR PROB CARDIOLOGY | 3.417 |
| FUNCT ECOL | 3.417 |
| P NUTR SOC | 3.411 |
| J CELL BIOCHEM | 3.409 |
| EXP HEMATOL | 3.408 |
| J POLYM SCI POL CHEM | 3.405 |
| CRIT REV PLANT SCI | 3.4 |
| DEV COMP IMMUNOL | 3.399 |
| INVEST RADIOL | 3.398 |
| NEUROMOL MED | 3.396 |
| SEX TRANSM INFECT | 3.395 |
| J ANIM ECOL | 3.39 |
| OIKOS | 3.381 |
| AM J BIOETHICS | 3.379 |
| PLANT BIOTECHNOL J | 3.378 |
| FEBS LETT | 3.372 |
| CLIN ENDOCRINOL | 3.358 |
| CLIM DYNAM | 3.344 |
| CRIT REV EUKAR GENE | 3.342 |
| ECOGRAPHY | 3.34 |
| NEUROGASTROENT MOTIL | 3.338 |
| INT J PARASITOL | 3.337 |
| BRIT J DERMATOL | 3.334 |
| EUR J PAIN | 3.333 |
| OECOLOGIA | 3.333 |
| J AM GERIATR SOC | 3.331 |
| ANN SURG ONCOL | 3.329 |
| OBSTET GYNECOL SURV | 3.329 |
| PHYS REV C | 3.327 |
| BIOCHEM SOC SYMP | 3.324 |
| PLANT CELL PHYSIOL | 3.324 |
| MOVEMENT DISORD | 3.323 |
| REV NEUROSCI | 3.32 |
| SHOCK | 3.318 |
| GLOBAL ECOL BIOGEOGR | 3.314 |
| BBA-PROTEINS PROTEOM | 3.311 |
| J VASC SURG | 3.311 |
| J AM SOC MASS SPECTR | 3.307 |
| J BIOL INORG CHEM | 3.303 |
| BBA-MOL BASIS DIS | 3.298 |
| CYTOM PART A | 3.293 |
| EVOL DEV | 3.293 |
| J VIRAL HEPATITIS | 3.29 |
| VLDB J | 3.289 |
| ALIMENT PHARM THERAP | 3.287 |
| LIMNOL OCEANOGR | 3.287 |
| TRANSFUSION | 3.278 |
| CANCER LETT | 3.277 |
| FERTIL STERIL | 3.277 |
| Q REV BIOPHYS | 3.269 |
| J HUM EVOL | 3.267 |
| J CARDIOVASC ELECTR | 3.265 |
| CLIN SCI | 3.263 |
| PROTIST | 3.262 |
| MED IMAGE ANAL | 3.256 |
| J PSYCHOPHARMACOL | 3.255 |
| CLIN MICROBIOL INFEC | 3.254 |
| EUR PHYS J C | 3.251 |
| MOL MEMBR BIOL | 3.25 |
| CURR TOP DEV BIOL | 3.246 |
| J PETROL | 3.246 |
| EUR J HEART FAIL | 3.242 |
| BIOCHIMIE | 3.237 |
| CURR ORG CHEM | 3.232 |
| HISTOCHEM CELL BIOL | 3.22 |
| HISTOPATHOLOGY | 3.216 |
| PEDIATR INFECT DIS J | 3.215 |
| CELL CYCLE | 3.214 |
| DRUG ALCOHOL DEPEN | 3.213 |
| INT J IMMUNOPATH PH | 3.213 |
| ARCH OPHTHALMOL-CHIC | 3.206 |
| REPROD BIOMED ONLINE | 3.206 |
| ECOL SOC | 3.204 |
| STRESS | 3.2 |
| ANALYST | 3.198 |
| EUR J PHARM BIOPHARM | 3.185 |
| PIGM CELL RES | 3.18 |
| IMMUNOL ALLERGY CLIN | 3.178 |
| J APPL PHYSIOL | 3.178 |
| HYPERTENS RES | 3.177 |
| EUR UROL SUPPL | 3.174 |
| EXPERT OPIN INV DRUG | 3.174 |
| MENOPAUSE | 3.17 |
| DEV DYNAM | 3.169 |
| J CHEM PHYS | 3.166 |
| J BIOENERG BIOMEMBR | 3.164 |
| MACROMOL RAPID COMM | 3.164 |
| MINI-REV MED CHEM | 3.163 |
| CHEM RES TOXICOL | 3.162 |
| NEUROCHEM INT | 3.159 |
| PSYCHOPHYSIOLOGY | 3.159 |
| VACCINE | 3.159 |
| FEMS MICROBIOL ECOL | 3.157 |
| NEPHROL DIAL TRANSPL | 3.154 |
| J COMB CHEM | 3.153 |
| VET RES | 3.152 |
| ICARUS | 3.151 |
| EUR J ENDOCRINOL | 3.145 |
| ATOM DATA NUCL DATA | 3.143 |
| TECTONICS | 3.143 |
| CLIN GENET | 3.14 |
| MICROBIOL-SGM | 3.139 |
| J AFFECT DISORDERS | 3.138 |
| MICROBES INFECT | 3.127 |
| NEUROPSYCHOLOGY | 3.123 |
| FUNGAL GENET BIOL | 3.121 |
| ANN EMERG MED | 3.12 |
| J PAIN | 3.12 |
| BBA-MOL CELL BIOL L | 3.117 |
| AM J HYPERTENS | 3.116 |
| CRIT CARE | 3.116 |
| BEST PRACT RES CL HA | 3.111 |
| J GEN VIROL | 3.11 |
| PHYS REV B | 3.107 |
| CELL STRESS CHAPERON | 3.097 |
| SPECTROCHIM ACTA B | 3.092 |
| CELL MOTIL CYTOSKEL | 3.089 |
| J PHYS CHEM REF DATA | 3.083 |
| ANNU REV ENV RESOUR | 3.08 |
| INT CLIN PSYCHOPHARM | 3.08 |
| J ENDODONT | 3.077 |
| STEM CELLS DEV | 3.076 |
| HAEMOPHILIA | 3.073 |
| J ENDOCRINOL | 3.072 |
| DNA RES | 3.066 |
| REMOTE SENS ENVIRON | 3.064 |
| SEMIN ONCOL | 3.064 |
| CURR MED RES OPIN | 3.062 |
| BEHAV ECOL | 3.061 |
| ARCH SURG-CHICAGO | 3.058 |
| J ALZHEIMERS DIS | 3.058 |
| J CLIN PHARMACOL | 3.058 |
| CHROMOSOME RES | 3.057 |
| J PHYS CHEM A | 3.047 |
| PHYS REV A | 3.047 |
| CURR OPIN GASTROEN | 3.045 |
| BMC IMMUNOL | 3.043 |
| EUR ARCH PSY CLIN N | 3.042 |
| EUR J CELL BIOL | 3.039 |
| NANOTECHNOLOGY | 3.037 |
| AGE | 3.034 |
| FEBS J | 3.033 |
| THER DRUG MONIT | 3.032 |
| ANN PHYS-NEW YORK | 3.019 |
| PALEOCEANOGRAPHY | 3.018 |
| J PALEOLIMNOL | 3.016 |
| AM J CARDIOL | 3.015 |
| SEMIN NEPHROL | 3.014 |
| BIOSTATISTICS | 3.012 |
| BIOSTATISTICS | 3.012 |
| DALTON T | 3.012 |
| METAB ENG | 3.012 |
| ADV PHYS ORG CHEM | 3 |
| CURR ORG SYNTH | 3 |
| EXERC SPORT SCI REV | 3 |
| PLASMAS POLYM | 3 |
| PROTEIN ENG DES SEL | 3 |
| SEMIN REPROD MED | 3 |
| EXPERT REV PROTEOMIC | 2.991 |
| J MOL ENDOCRINOL | 2.988 |
| J NEUROL | 2.984 |
| CELL ONCOL | 2.979 |
| SURGERY | 2.977 |
| J PHYSIOL PHARMACOL | 2.974 |
| J EVOLUTION BIOL | 2.97 |
| AM J BOT | 2.969 |
| ARCH BIOCHEM BIOPHYS | 2.969 |
| PLACENTA | 2.969 |
| J MOL NEUROSCI | 2.965 |
| AQUAT TOXICOL | 2.964 |
| J GEN INTERN MED | 2.964 |
| MOL PLANT PATHOL | 2.963 |
| PLANTA | 2.963 |
| BIOCHEM SOC T | 2.962 |
| MOL IMAGING BIOL | 2.961 |
| J HUM HYPERTENS | 2.96 |
| REPRODUCTION | 2.958 |
| STUD MYCOL | 2.957 |
| ECOSYSTEMS | 2.955 |
| ELECTROCHIM ACTA | 2.955 |
| J AEROSOL SCI | 2.952 |
| PRECAMBRIAN RES | 2.949 |
| ANAL BIOCHEM | 2.948 |
| J MASS SPECTROM | 2.945 |
| J NUTR BIOCHEM | 2.945 |
| EXERC IMMUNOL REV | 2.941 |
| J RHEUMATOL | 2.94 |
| AM J CLIN PATHOL | 2.939 |
| J NEURAL TRANSM | 2.938 |
| NUTR REV | 2.937 |
| ALCOHOL CLIN EXP RES | 2.933 |
| J ENDOTOXIN RES | 2.933 |
| EXP GERONTOL | 2.93 |
| SLEEP MED | 2.926 |
| INT J DEV NEUROSCI | 2.924 |
| CANCER CAUSE CONTROL | 2.92 |
| BIOFOULING | 2.919 |
| MOL CELL ENDOCRINOL | 2.918 |
| J ACM | 2.917 |
| MED SCI SPORT EXER | 2.909 |
| BEHAV NEUROSCI | 2.907 |
| AEROSOL SCI TECH | 2.905 |
| PERSPECT PLANT ECOL | 2.905 |
| AGR FOREST METEOROL | 2.903 |
| SEMIN DIALYSIS | 2.902 |
| J MOL DIAGN | 2.901 |
| OCEAN MODEL | 2.897 |
| BMC MICROBIOL | 2.896 |
| AM J GERIAT PSYCHIAT | 2.894 |
| ANAL CHIM ACTA | 2.894 |
| CLIN THER | 2.893 |
| STRUCT BOND | 2.893 |
| PHYS CHEM CHEM PHYS | 2.892 |
| CRIT REV BIOTECHNOL | 2.889 |
| J MED INTERNET RES | 2.888 |
| J NEUROIMMUNOL | 2.88 |
| AM J NEPHROL | 2.879 |
| ANTIVIR RES | 2.878 |
| J BIOGEOGR | 2.878 |
| ORG BIOMOL CHEM | 2.874 |
| PHYS MED BIOL | 2.873 |
| HEREDITY | 2.872 |
| PROG BRAIN RES | 2.872 |
| J BIOMED OPT | 2.87 |
| SYNAPSE | 2.87 |
| Q J EXP PSYCHOL-B | 2.868 |
| RESTOR NEUROL NEUROS | 2.862 |
| DEV NEUROPSYCHOL | 2.861 |
| J GERONTOL A-BIOL | 2.861 |
| TRENDS FOOD SCI TECH | 2.861 |
| BRAIN COGNITION | 2.858 |
| BIOCHEM BIOPH RES CO | 2.855 |
| BIOL CONSERV | 2.854 |
| IMMUNOGENETICS | 2.852 |
| ARCH DERMATOL | 2.851 |
| PEDIATR ALLERGY IMMU | 2.849 |
| PHARMACOPSYCHIATRY | 2.849 |
| STEROIDS | 2.849 |
| PHARM RES | 2.848 |
| EUR J CLIN INVEST | 2.847 |
| ENDOCRIN METAB CLIN | 2.845 |
| EXP BIOL MED | 2.845 |
| IEEE J SEL TOP QUANT | 2.842 |
| NUCL FUSION | 2.839 |
| SYNLETT | 2.838 |
| J CRYPTOL | 2.833 |
| J HEART LUNG TRANSPL | 2.83 |
| HEART FAIL REV | 2.828 |
| J MEM LANG | 2.827 |
| J STEROID BIOCHEM | 2.825 |
| J LIGHTWAVE TECHNOL | 2.824 |
| GEOL SOC AM BULL | 2.82 |
| PLASMA PHYS CONTR F | 2.82 |
| CANCER BIOL THER | 2.818 |
| TETRAHEDRON | 2.817 |
| J AM COLL SURGEONS | 2.813 |
| HUM PATHOL | 2.81 |
| TALANTA | 2.81 |
| OLIGONUCLEOTIDES | 2.808 |
| AM J OBSTET GYNECOL | 2.805 |
| J EPIDEMIOL COMMUN H | 2.805 |
| THROMB HAEMOSTASIS | 2.803 |
| J GEOPHYS RES | 2.8 |
| PERIODONTOL 2000 | 2.8 |
| CURR OPIN CARDIOL | 2.797 |
| TOB CONTROL | 2.797 |
| MICROPOR MESOPOR MAT | 2.796 |
| TRANSFUS MED REV | 2.791 |
| NEUROPEPTIDES | 2.789 |
| J ORTHOP RES | 2.784 |
| TOXICOL LETT | 2.784 |
| VIRUS RES | 2.783 |
| J MED VIROL | 2.779 |
| N-S ARCH PHARMACOL | 2.779 |
| EXP EYE RES | 2.776 |
| BMC NEUROSCI | 2.775 |
| COGN BEHAV NEUROL | 2.774 |
| J NEUROENDOCRINOL | 2.774 |
| CLASSICAL QUANT GRAV | 2.773 |
| MULT SCLER | 2.773 |
| PHYS BIOL | 2.773 |
| POLYMER | 2.773 |
| IEEE T AUTOMAT CONTR | 2.772 |
| PSYCHO-ONCOL | 2.772 |
| FRONT BIOSCI | 2.771 |
| QJM-INT J MED | 2.77 |
| CRIT REV ENV SCI TEC | 2.769 |
| ENVIRON POLLUT | 2.769 |
| EUR J ORG CHEM | 2.769 |
| PULM PHARMACOL THER | 2.769 |
| BIODRUGS | 2.768 |
| J MOL EVOL | 2.767 |
| MET IONS BIOL SYST | 2.761 |
| INT J MED MICROBIOL | 2.76 |
| MOL HUM REPROD | 2.76 |
| J EXP ZOOL PART B | 2.756 |
| PSYCHIAT RES-NEUROIM | 2.755 |
| CONTRIB MINERAL PETR | 2.754 |
| CURR PHARM BIOTECHNO | 2.753 |
| BIOL CHEM | 2.752 |
| J BIOMOL SCREEN | 2.75 |
| J CLIN IMMUNOL | 2.748 |
| MALARIA J | 2.748 |
| CLIN EXP IMMUNOL | 2.747 |
| MOL CARCINOGEN | 2.743 |
| BMC BIOTECHNOL | 2.742 |
| BMC CELL BIOL | 2.742 |
| HEADACHE | 2.74 |
| J CARD FAIL | 2.737 |
| SEMIN THROMB HEMOST | 2.733 |
| ANN HUM GENET | 2.727 |
| FISH SHELLFISH IMMUN | 2.725 |
| NAT CLIN PRACT CARD | 2.723 |
| GENE | 2.721 |
| BRIT J CLIN PHARMACO | 2.718 |
| CLIN NEUROPHYSIOL | 2.718 |
| NEUROTOXICOLOGY | 2.718 |
| CHEM GEOL | 2.716 |
| IEEE ELECTR DEVICE L | 2.716 |
| IEEE T IMAGE PROCESS | 2.715 |
| THEOR APPL GENET | 2.715 |
| ANIM BEHAV | 2.711 |
| HEMATOL J | 2.711 |
| INSECT BIOCHEM MOLEC | 2.711 |
| J ADOLESCENT HEALTH | 2.71 |
| BRIT J NUTR | 2.708 |
| MOL MED | 2.708 |
| INT J EXP PATHOL | 2.707 |
| EXPERT OPIN BIOL TH | 2.705 |
| EUR J INORG CHEM | 2.704 |
| PEPTIDES | 2.701 |
| BIOL PSYCHOL | 2.698 |
| ACTA NEUROPATHOL | 2.694 |
| AM J SPORT MED | 2.694 |
| NEUROSURGERY | 2.692 |
| DEV NEUROSCI-BASEL | 2.691 |
| NEUROUROL URODYNAM | 2.688 |
| MOL NUTR FOOD RES | 2.687 |
| TOXICOLOGY | 2.685 |
| CURR OPIN UROL | 2.684 |
| J CHEM NEUROANAT | 2.682 |
| NEUROPATH APPL NEURO | 2.681 |
| NEUROENDOCRINOLOGY | 2.68 |
| RAPID COMMUN MASS SP | 2.68 |
| BRIT J ANAESTH | 2.679 |
| PHYS-USP+ | 2.675 |
| HIV MED | 2.674 |
| MENT RETARD DEV D R | 2.671 |
| SIAM REV | 2.667 |
| MAR CHEM | 2.663 |
| CURR OPIN SOLID ST M | 2.662 |
| EXPERT OPIN THER TAR | 2.662 |
| INT J SYST EVOL MICR | 2.662 |
| J MICROELECTROMECH S | 2.659 |
| IEEE SIGNAL PROC MAG | 2.655 |
| J INORG BIOCHEM | 2.654 |
| MACH LEARN | 2.654 |
| ENVIRON MOL MUTAGEN | 2.653 |
| BIORHEOLOGY | 2.651 |
| BIORHEOLOGY | 2.651 |
| ADV HETEROCYCL CHEM | 2.647 |
| J CHROMATOGR B | 2.647 |
| NEW J CHEM | 2.647 |
| MOL BIOCHEM PARASIT | 2.641 |
| INSECT MOL BIOL | 2.639 |
| J MAGN RESON IMAGING | 2.637 |
| J DERMATOL SCI | 2.636 |
| BEHAV GENET | 2.634 |
| J EXP BIOL | 2.631 |
| APPL CATAL A-GEN | 2.63 |
| ATMOS ENVIRON | 2.63 |
| J CLIN VIROL | 2.63 |
| ENVIRON INT | 2.626 |
| BIOORGAN MED CHEM | 2.624 |
| BIOORGAN MED CHEM | 2.624 |
| SOIL BIOL BIOCHEM | 2.623 |
| BONE MARROW TRANSPL | 2.621 |
| IEEE T NEURAL NETWOR | 2.62 |
| INT J LEGAL MED | 2.62 |
| PEDIATR RES | 2.619 |
| REV ENVIRON CONTAM T | 2.619 |
| GENESIS | 2.615 |
| MICROFLUID NANOFLUID | 2.615 |
| NEUROMUSCULAR DISORD | 2.615 |
| INT J HYDROGEN ENERG | 2.612 |
| J FLUORESC | 2.61 |
| INT J FOOD MICROBIOL | 2.608 |
| ACAD MED | 2.607 |
| HUM IMMUNOL | 2.605 |
| GEOPHYS RES LETT | 2.602 |
| RADIAT RES | 2.602 |
| J EXP PSYCHOL LEARN | 2.601 |
| ADV CHROMATOGR | 2.6 |
| GLOBAL ENVIRON CHANG | 2.6 |
| J BIOTECHNOL | 2.6 |
| NAT CLIN PRACT GASTR | 2.6 |
| TROP MED INT HEALTH | 2.595 |
| SYSTEMS BIOL | 2.593 |
| IEEE T NANOBIOSCI | 2.592 |
| ANAL BIOANAL CHEM | 2.591 |
| BEHAV BRAIN RES | 2.591 |
| NEUROPSYCHOL REV | 2.591 |
| EVOL HUM BEHAV | 2.586 |
| PROG NEURO-PSYCHOPH | 2.584 |
| MED J AUSTRALIA | 2.582 |
| CELL TISSUE RES | 2.58 |
| J PHYCOL | 2.58 |
| IEEE WIREL COMMUN | 2.577 |
| SEX TRANSM DIS | 2.577 |
| SYST ENTOMOL | 2.571 |
| BIOMOL ENG | 2.568 |
| BIOMOL ENG | 2.568 |
| COGNITIVE BRAIN RES | 2.568 |
| RHEUM DIS CLIN N AM | 2.568 |
| J AM DIET ASSOC | 2.564 |
| LANDSCAPE ECOL | 2.558 |
| ENVIRON RES | 2.556 |
| INT J ONCOL | 2.556 |
| EUR RADIOL | 2.554 |
| DIAGN MICR INFEC DIS | 2.553 |
| J AM ACAD DERMATOL | 2.553 |
| J AM MATH SOC | 2.552 |
| MOL GENET GENOMICS | 2.552 |
| BIOMED MICRODEVICES | 2.551 |
| DIABETES-METAB RES | 2.551 |
| COMB CHEM HIGH T SCR | 2.55 |
| IEEE T MOBILE COMPUT | 2.55 |
| DEPRESS ANXIETY | 2.549 |
| AM J TROP MED HYG | 2.546 |
| ASSAY DRUG DEV TECHN | 2.544 |
| TELLUS B | 2.543 |
| J BIOMECH | 2.542 |
| REPROD FERT DEVELOP | 2.541 |
| ANIM COGN | 2.54 |
| BIOORG MED CHEM LETT | 2.538 |
| BIOORG MED CHEM LETT | 2.538 |
| INVEST NEW DRUG | 2.538 |
| RADIOCARBON | 2.538 |
| ADV ENVIRON RES | 2.537 |
| BIOGEOCHEMISTRY | 2.536 |
| FREE RADICAL RES | 2.536 |
| J REPROD IMMUNOL | 2.536 |
| TURK J EARTH SCI | 2.536 |
| J SEP SCI | 2.535 |
| RADIOL CLIN N AM | 2.533 |
| BIOL INVASIONS | 2.531 |
| CAN J PSYCHIAT | 2.531 |
| BRIT J OPHTHALMOL | 2.524 |
| INT ARCH ALLERGY IMM | 2.524 |
| METEORIT PLANET SCI | 2.524 |
| EUR J PHARMACOL | 2.522 |
| JARO-J ASSOC RES OTO | 2.522 |
| MACROMOL BIOSCI | 2.521 |
| INT DAIRY J | 2.519 |
| TAXON | 2.519 |
| CHRONOBIOL INT | 2.517 |
| PROD OPER MANAG | 2.516 |
| AIDS RES HUM RETROV | 2.513 |
| DEMENT GERIATR COGN | 2.511 |
| J MOL CATAL A-CHEM | 2.511 |
| NITRIC OXIDE-BIOL CH | 2.509 |
| TETRAHEDRON LETT | 2.509 |
| TOXICON | 2.509 |
| J VASC RES | 2.505 |
| RES MICROBIOL | 2.504 |
| FRESHWATER BIOL | 2.502 |
| GEN HOSP PSYCHIAT | 2.5 |
| ORTHOP CLIN N AM | 2.5 |
| PROG SOLID STATE CH | 2.5 |
| CLIN ORAL IMPLAN RES | 2.497 |
| J BIOMED MATER RES A | 2.497 |
| METABOLISM | 2.497 |
| SEP PURIF TECHNOL | 2.497 |
| ADV BIOCHEM ENG BIOT | 2.495 |
| J APPL CRYSTALLOGR | 2.495 |
| CURR OPIN PULM MED | 2.494 |
| J EXPO SCI ENV EPID | 2.492 |
| PROG CARDIOVASC DIS | 2.492 |
| CLIN LYMPHOMA | 2.491 |
| THEOR POPUL BIOL | 2.491 |
| AM J INFECT CONTROL | 2.489 |
| DRUG NEWS PERSPECT | 2.489 |
| GEN COMP ENDOCR | 2.487 |
| J CHILD ADOL PSYCHOP | 2.486 |
| NUTR RES REV | 2.486 |
| DIABETIC MED | 2.484 |
| ADV ECOL RES | 2.483 |
| CALCIFIED TISSUE INT | 2.483 |
| LEUKEMIA RES | 2.483 |
| EUR J PHARM SCI | 2.482 |
| IMMUNOL CELL BIOL | 2.482 |
| BIOPOLYMERS | 2.48 |
| BIOPOLYMERS | 2.48 |
| HELICOBACTER | 2.477 |
| MICROVASC RES | 2.477 |
| CLIN NUTR | 2.474 |
| J AVIAN BIOL | 2.472 |
| J INTERF CYTOK RES | 2.472 |
| J PERIODONTAL RES | 2.472 |
| ASTROBIOLOGY | 2.471 |
| J CANCER RES CLIN | 2.469 |
| AM J OPHTHALMOL | 2.468 |
| TETRAHEDRON-ASYMMETR | 2.468 |
| MED EDUC | 2.467 |
| CHEM PHYS LETT | 2.462 |
| TISSUE ANTIGENS | 2.462 |
| HARMFUL ALGAE | 2.46 |
| CLIMATIC CHANGE | 2.459 |
| WATER RES | 2.459 |
| J ANAT | 2.458 |
| MUSCLE NERVE | 2.456 |
| ADV BIOPHYS | 2.455 |
| INT MICROBIOL | 2.455 |
| AM J SCI | 2.453 |
| J AM COLL NUTR | 2.452 |
| CHEMOMETR INTELL LAB | 2.45 |
| MOL BIOSYST | 2.45 |
| EXP DERMATOL | 2.449 |
| J HISTOCHEM CYTOCHEM | 2.449 |
| ANN BOT-LONDON | 2.448 |
| CLIN J PAIN | 2.448 |
| PAIN MED | 2.447 |
| CONTACT DERMATITIS | 2.446 |
| THEOR CHEM ACC | 2.446 |
| BIOL J LINN SOC | 2.445 |
| PHYSIOL BEHAV | 2.445 |
| CLIN LYMPHOMA MYELOM | 2.444 |
| ELECTROANAL | 2.444 |
| J BONE JOINT SURG AM | 2.444 |
| CHEMOSPHERE | 2.442 |
| DIS COLON RECTUM | 2.442 |
| J HOSP INFECT | 2.442 |
| J MICROBIOL METH | 2.442 |
| REGUL PEPTIDES | 2.442 |
| APPL MICROBIOL BIOT | 2.441 |
| ADV CLIN CHEM | 2.44 |
| J CLIN EPIDEMIOL | 2.44 |
| J NUCL CARDIOL | 2.44 |
| PHYS EARTH PLANET IN | 2.44 |
| INTEGR COMP BIOL | 2.439 |
| DIS MARKERS | 2.438 |
| EXPERT REV MOL DIAGN | 2.438 |
| PHYS REV E | 2.438 |
| EUR J NEUROL | 2.437 |
| J PAIN SYMPTOM MANAG | 2.437 |
| DIABETES OBES METAB | 2.434 |
| FOOD CHEM | 2.433 |
| CLONING STEM CELLS | 2.431 |
| COGN NEUROPSYCHOL | 2.43 |
| PSYCHIAT SERV | 2.43 |
| ANAESTHESIA | 2.427 |
| ANN MATH | 2.426 |
| PHARMACOL RES | 2.421 |
| ADV ANAT PATHOL | 2.42 |
| CURR NEUROVASC RES | 2.418 |
| J NAT PROD | 2.418 |
| J MACROMOL SCI-POL R | 2.417 |
| PHYTOCHEMISTRY | 2.417 |
| PHOTOCH PHOTOBIO SCI | 2.416 |
| IEEE INTELL SYST | 2.413 |
| ADV STUD BEHAV | 2.412 |
| J NEUROL SCI | 2.412 |
| CURR OPIN MOL THER | 2.411 |
| MAR BIOTECHNOL | 2.408 |
| TUMOR BIOL | 2.407 |
| MICROCIRCULATION | 2.405 |
| PALEOBIOLOGY | 2.405 |
| J CLIN GASTROENTEROL | 2.403 |
| NEUROREHAB NEURAL RE | 2.403 |
| ECONOMETRICA | 2.402 |
| J IMMUNOL METHODS | 2.402 |
| J VASC INTERV RADIOL | 2.398 |
| BEST PRACT RES CL GA | 2.396 |
| EJC SUPPL | 2.396 |
| FOOD CHEM TOXICOL | 2.393 |
| BASIC APPL ECOL | 2.392 |
| HUM-COMPUT INTERACT | 2.391 |
| PREV MED | 2.39 |
| LIFE SCI | 2.389 |
| BEHAV PHARMACOL | 2.388 |
| J ELECTROCHEM SOC | 2.387 |
| J HYDROMETEOROL | 2.387 |
| HUM PSYCHOPHARM CLIN | 2.386 |
| B AM MATH SOC | 2.385 |
| GEOCHEM GEOPHY GEOSY | 2.384 |
| J VEG SCI | 2.382 |
| QUAL SAF HEALTH CARE | 2.382 |
| DENT MATER | 2.381 |
| J CLIN PERIODONTOL | 2.38 |
| J SOC GYNECOL INVEST | 2.379 |
| MOL REPROD DEV | 2.379 |
| J SYNCHROTRON RADIAT | 2.377 |
| MOL VIS | 2.377 |
| EUR PHYS J E | 2.373 |
| PERITON DIALYSIS INT | 2.372 |
| CHEM PHYS LIPIDS | 2.371 |
| J MOL GRAPH MODEL | 2.371 |
| MOL GENET METAB | 2.371 |
| INFECTION | 2.368 |
| J INT NEUROPSYCH SOC | 2.367 |
| NEUROPSYCHOBIOLOGY | 2.367 |
| LUPUS | 2.366 |
| TECHNOL CANCER RES T | 2.366 |
| CANCER CHEMOTH PHARM | 2.363 |
| REPROD TOXICOL | 2.362 |
| BMC CANCER | 2.359 |
| SCI TOTAL ENVIRON | 2.359 |
| SEMIN PERINATOL | 2.358 |
| EUR J NUTR | 2.356 |
| CYTOKINE | 2.355 |
| J MATER RES | 2.354 |
| GEOPHYS J INT | 2.353 |
| IEEE PHOTONIC TECH L | 2.353 |
| INT J IMPOT RES | 2.353 |
| IMMUNOL LETT | 2.352 |
| NEUROEPIDEMIOLOGY | 2.352 |
| SPINE | 2.351 |
| EPISODES | 2.35 |
| J METAMORPH GEOL | 2.35 |
| J BIOMED INFORM | 2.346 |
| PLASMA SOURCES SCI T | 2.346 |
| ENDOTHELIUM-J ENDOTH | 2.344 |
| LIVER INT | 2.344 |
| RADIOGRAPHICS | 2.344 |
| ANN THORAC SURG | 2.342 |
| IMMUNOL RES | 2.342 |
| BRAIN RES | 2.341 |
| EXP PHYSIOL | 2.339 |
| J ELECTROANAL CHEM | 2.339 |
| ZOOL SCR | 2.338 |
| INT J MASS SPECTROM | 2.337 |
| CANCER INVEST | 2.335 |
| RESP RES | 2.335 |
| SYNTHESIS-STUTTGART | 2.333 |
| WILDLIFE MONOGR | 2.333 |
| INT J CLIMATOL | 2.332 |
| J ORGANOMET CHEM | 2.332 |
| MICROB ECOL | 2.332 |
| CLIN BIOCHEM | 2.331 |
| ORG GEOCHEM | 2.331 |
| SENSOR ACTUAT B-CHEM | 2.331 |
| EUR J CLIN MICROBIOL | 2.33 |
| CLIN CHIM ACTA | 2.328 |
| J COMPUT PHYS | 2.328 |
| CLIN NEUROPHARMACOL | 2.323 |
| J AGR FOOD CHEM | 2.322 |
| J PSYCHOSOM RES | 2.322 |
| LIMNOL OCEANOGR-METH | 2.322 |
| J MICROMECH MICROENG | 2.321 |
| SOL ENERG MAT SOL C | 2.321 |
| TOP CATAL | 2.321 |
| GYNECOL ONCOL | 2.319 |
| QUATERNARY RES | 2.319 |
| BRAIN LANG | 2.317 |
| BEHAV ECOL SOCIOBIOL | 2.316 |
| IUBMB LIFE | 2.316 |
| J APPL PHYS | 2.316 |
| J R STAT SOC B | 2.315 |
| RESUSCITATION | 2.314 |
| PSYCHIAT RES | 2.31 |
| DERMATOL SURG | 2.309 |
| PARKINSONISM RELAT D | 2.308 |
| CARIES RES | 2.304 |
| IEEE T BIO-MED ENG | 2.302 |
| NICOTINE TOB RES | 2.299 |
| PLASMA PROCESS POLYM | 2.298 |
| FUNGAL DIVERS | 2.297 |
| TRANSPL IMMUNOL | 2.297 |
| TREE PHYSIOL | 2.297 |
| EXP MOL MED | 2.296 |
| DATA MIN KNOWL DISC | 2.295 |
| BBA-GENE STRUCT EXPR | 2.293 |
| J CLIN NEUROPHYSIOL | 2.293 |
| NUTR CANCER | 2.289 |
| J EUKARYOT MICROBIOL | 2.288 |
| ULTRASOUND OBST GYN | 2.288 |
| J GEOL SOC LONDON | 2.287 |
| AAPS PHARMSCI | 2.286 |
| MAR ECOL-PROG SER | 2.286 |
| SEMIN NEUROL | 2.286 |
| J CATARACT REFR SURG | 2.285 |
| FOOD HYDROCOLLOID | 2.284 |
| J DAIRY SCI | 2.284 |
| IEEE ACM T COMPUT BI | 2.283 |
| PHILOS T R SOC A | 2.282 |
| FEMS IMMUNOL MED MIC | 2.281 |
| AM J NEURORADIOL | 2.279 |
| MAMM GENOME | 2.279 |
| J CLIN DENSITOM | 2.277 |
| ANN BIOMED ENG | 2.276 |
| FEMS YEAST RES | 2.274 |
| AUTOMATICA | 2.273 |
| SCAND J RHEUMATOL | 2.273 |
| FUNCT PLANT BIOL | 2.272 |
| J ENVIRON QUAL | 2.272 |
| ARTIF INTELL | 2.271 |
| J GASTROINTEST SURG | 2.265 |
| J TRACE ELEM MED BIO | 2.265 |
| J THEOR BIOL | 2.264 |
| PROG OCEANOGR | 2.264 |
| IEEE J QUANTUM ELECT | 2.262 |
| J EXP PSYCHOL HUMAN | 2.261 |
| PROSTAG LEUKOTR ESS | 2.261 |
| ANN PHARMACOTHER | 2.259 |
| MICROB PATHOGENESIS | 2.258 |
| PHYS PLASMAS | 2.258 |
| J MACH LEARN RES | 2.255 |
| OCCUP ENVIRON MED | 2.255 |
| ANN ALLERG ASTHMA IM | 2.254 |
| ANN HEMATOL | 2.254 |
| HEALTH SERV RES | 2.254 |
| ONCOLOGY-BASEL | 2.252 |
| VIRCHOWS ARCH | 2.251 |
| METAB BRAIN DIS | 2.25 |
| INT J PSYCHOPHYSIOL | 2.247 |
| ANTI-CANCER DRUG | 2.245 |
| ETHOLOGY | 2.245 |
| J CLIN PATHOL | 2.245 |
| TELLUS A | 2.245 |
| VECTOR-BORNE ZOONOT | 2.244 |
| J NEUROSCI METH | 2.243 |
| J NEUROSURG | 2.242 |
| J PHARMACOL SCI | 2.242 |
| PHARMACOECONOMICS | 2.242 |
| VITAM HORM | 2.24 |
| INFECT CONT HOSP EP | 2.236 |
| INT J CARDIOL | 2.234 |
| BRIT J SPORT MED | 2.233 |
| J COLLOID INTERF SCI | 2.233 |
| AUST J GRAPE WINE R | 2.231 |
| ACTA PHYSIOL SCAND | 2.23 |
| WOUND REPAIR REGEN | 2.23 |
| EUROPHYS LETT | 2.229 |
| NEURAL COMPUT | 2.229 |
| NUTRITION | 2.229 |
| J PHARM SCI-US | 2.228 |
| NEUROSIGNALS | 2.228 |
| INT J ANTIMICROB AG | 2.221 |
| CURR GENET | 2.22 |
| NEW ASTRON | 2.22 |
| CELL MOL NEUROBIOL | 2.219 |
| J N AM BENTHOL SOC | 2.219 |
| CLIN NUCL MED | 2.217 |
| ARCH CLIN NEUROPSYCH | 2.215 |
| DEEP-SEA RES PT I | 2.214 |
| INT J PHARM | 2.212 |
| ACTA TROP | 2.211 |
| IEEE NETWORK | 2.211 |
| ANN EPIDEMIOL | 2.21 |
| SEISMOL RES LETT | 2.21 |
| AQUAT MICROB ECOL | 2.209 |
| J APPL MICROBIOL | 2.206 |
| J HUM GENET | 2.205 |
| BIOMARKERS | 2.203 |
| CORAL REEFS | 2.203 |
| LITHOS | 2.203 |
| ENVIRON TOXICOL CHEM | 2.202 |
| DRUG AGING | 2.2 |
| PLANT PATHOL | 2.198 |
| BRAIN BEHAV EVOLUT | 2.195 |
| PHYTOPATHOLOGY | 2.195 |
| J NANOSCI NANOTECHNO | 2.194 |
| PHOTOSYNTH RES | 2.193 |
| J NEUROVIROL | 2.192 |
| J INVEST DERM SYMP P | 2.191 |
| MITOCHONDRION | 2.191 |
| SOLID STATE IONICS | 2.19 |
| CLIN EXP RHEUMATOL | 2.189 |
| EUR J MED CHEM | 2.187 |
| ANIM REPROD SCI | 2.186 |
| J STAT MECH-THEORY E | 2.185 |
| INT J GYNECOL PATHOL | 2.184 |
| GROWTH HORM IGF RES | 2.183 |
| INT J ANDROL | 2.183 |
| J SURG ONCOL | 2.183 |
| HISTOL HISTOPATHOL | 2.182 |
| COMPR PSYCHIAT | 2.181 |
| BIORESOURCE TECHNOL | 2.18 |
| BIORESOURCE TECHNOL | 2.18 |
| J MED MICROBIOL | 2.18 |
| REV ESP CARDIOL | 2.176 |
| POLYM DEGRAD STABIL | 2.174 |
| ACTA CRYSTALLOGR B | 2.172 |
| J AM STAT ASSOC | 2.171 |
| J DEV BEHAV PEDIATR | 2.17 |
| PHYSIOL PLANTARUM | 2.169 |
| DOMEST ANIM ENDOCRIN | 2.168 |
| J REHABIL MED | 2.168 |
| INHAL TOXICOL | 2.167 |
| VISION RES | 2.167 |
| CHIRALITY | 2.165 |
| CYTOTHERAPY | 2.165 |
| CLIMACTERIC | 2.163 |
| J ATMOS SCI | 2.163 |
| CRYOBIOLOGY | 2.162 |
| PEDIATR DIABETES | 2.162 |
| CLIN ORTHOP RELAT R | 2.161 |
| DEV GENES EVOL | 2.161 |
| SCRIPTA MATER | 2.161 |
| ADV MAR BIOL | 2.158 |
| CANCER CYTOPATHOL | 2.157 |
| INT IMMUNOPHARMACOL | 2.157 |
| EUR J VASC ENDOVASC | 2.156 |
| J NANOPART RES | 2.156 |
| NUCL PHYS A | 2.155 |
| PHARMACOEPIDEM DR S | 2.155 |
| J AUTOIMMUN | 2.154 |
| J ENVIRON SCI HEAL C | 2.154 |
| Q J EXP PSYCHOL-A | 2.154 |
| AICHE J | 2.153 |
| J EXP PSYCHOL ANIM B | 2.153 |
| J CLIN LASER MED SUR | 2.15 |
| J MOL CATAL B-ENZYM | 2.149 |
| CATAL TODAY | 2.148 |
| PANCREATOLOGY | 2.147 |
| TRANSPL INT | 2.146 |
| ACM T DATABASE SYST | 2.143 |
| CELL STRUCT FUNCT | 2.143 |
| NEUROTOXICOL TERATOL | 2.143 |
| STRUCT EQU MODELING | 2.143 |
| YEARB PHYS ANTHROPOL | 2.143 |
| PSYCHIAT GENET | 2.141 |
| NEUROCHEM RES | 2.139 |
| FOOD MICROBIOL | 2.137 |
| J ANDROL | 2.137 |
| NEUROREPORT | 2.137 |
| AM J PHYS ANTHROPOL | 2.136 |
| CIRC J | 2.135 |
| COMPUT BIOL CHEM | 2.135 |
| J ENDOVASC THER | 2.135 |
| MOL BREEDING | 2.135 |
| J RAMAN SPECTROSC | 2.133 |
| VIRAL IMMUNOL | 2.133 |
| ACTA BIOMATER | 2.132 |
| IEEE T SOFTWARE ENG | 2.132 |
| ANESTH ANALG | 2.131 |
| UROLOGY | 2.13 |
| BASIN RES | 2.129 |
| BIOGEOSCIENCES | 2.125 |
| BIOGERONTOLOGY | 2.125 |
| MUTAGENESIS | 2.125 |
| GEODERMA | 2.124 |
| CEREBELLUM | 2.123 |
| PUBLIC HEALTH NUTR | 2.123 |
| MUTAT RES-GEN TOX EN | 2.122 |
| NUCL MED BIOL | 2.121 |
| PANCREAS | 2.121 |
| INFORM MANAGE-AMSTER | 2.119 |
| PRESLIA | 2.119 |
| COMPR REV FOOD SCI F | 2.118 |
| J STRUCT GEOL | 2.118 |
| AM J ROENTGENOL | 2.117 |
| J HYDROL | 2.117 |
| EUR J CLIN NUTR | 2.116 |
| EUR POLYM J | 2.113 |
| J MEMBRANE BIOL | 2.112 |
| VOX SANG | 2.111 |
| MICROSC MICROANAL | 2.108 |
| J PLANT GROWTH REGUL | 2.107 |
| J SOLID STATE CHEM | 2.107 |
| EUR J CARDIO-THORAC | 2.106 |
| MAR ENVIRON RES | 2.106 |
| MECH MATER | 2.106 |
| PUBL ASTRON SOC JPN | 2.106 |
| QUANTUM INF COMPUT | 2.105 |
| AMINO ACIDS | 2.104 |
| ORAL ONCOL | 2.103 |
| ULTRASCHALL MED | 2.103 |
| AM J SURG | 2.101 |
| B AM MUS NAT HIST | 2.1 |
| J PHOTOCH PHOTOBIO A | 2.098 |
| J REFRACT SURG | 2.097 |
| J VIROL METHODS | 2.097 |
| MULTIVAR BEHAV RES | 2.095 |
| REV MEX ASTRON ASTR | 2.094 |
| WORLD J BIOL PSYCHIA | 2.094 |
| PHYSIOL RES | 2.093 |
| NEUROSCI LETT | 2.092 |
| PHARMACOL BIOCHEM BE | 2.092 |
| TOXICOL PATHOL | 2.092 |
| MED CARE RES REV | 2.091 |
| ARCH DIS CHILD | 2.09 |
| SCAND J IMMUNOL | 2.09 |
| HEALTH EXPECT | 2.089 |
| J COMPUT AID MOL DES | 2.089 |
| ORAL MICROBIOL IMMUN | 2.089 |
| UROL ONCOL-SEMIN ORI | 2.089 |
| EPILEPSY RES | 2.088 |
| RESP MED | 2.086 |
| SEED SCI RES | 2.085 |
| EYE | 2.084 |
| J RHEOL | 2.082 |
| AQUACULTURE | 2.081 |
| CURR NANOSCI | 2.08 |
| ADV RENAL REPLACE TH | 2.077 |
| COMMUN MATH PHYS | 2.077 |
| J PHYS D APPL PHYS | 2.077 |
| LASER SURG MED | 2.077 |
| J MAGN RESON | 2.076 |
| VET MICROBIOL | 2.073 |
| FEMS MICROBIOL LETT | 2.068 |
| J PEDIATR GASTR NUTR | 2.067 |
| ZOOL J LINN SOC-LOND | 2.066 |
| CYTOM PART B-CLIN CY | 2.065 |
| J PERIPHER NERV SYST | 2.065 |
| AM J MED GENET A | 2.063 |
| IEEE T KNOWL DATA EN | 2.063 |
| IEEE PERVAS COMPUT | 2.062 |
| INT J INFECT DIS | 2.062 |
| Q J NUCL MED MOL IM | 2.062 |
| ALCOHOL ALCOHOLISM | 2.061 |
| PHOTOCHEM PHOTOBIOL | 2.061 |
| AM J MANAG CARE | 2.06 |
| GLOBAL PLANET CHANGE | 2.06 |
| ADV AGRON | 2.059 |
| PLANT BIOLOGY | 2.059 |
| J MOL MICROB BIOTECH | 2.058 |
| THROMB RES | 2.058 |
| INDOOR AIR | 2.057 |
| AUK | 2.056 |
| OMICS | 2.056 |
| REGION ANESTH PAIN M | 2.056 |
| B VOLCANOL | 2.054 |
| BOUND-LAY METEOROL | 2.054 |
| MED CLIN N AM | 2.054 |
| IEEE T ELECTRON DEV | 2.052 |
| CLIN TRANSPLANT | 2.051 |
| CNS SPECTRUMS | 2.051 |
| HUM HERED | 2.051 |
| BIOORG CHEM | 2.049 |
| BIOORG CHEM | 2.049 |
| GEOSTAND GEOANAL RES | 2.049 |
| RESP PHYSIOL NEUROBI | 2.049 |
| B ENTOMOL RES | 2.046 |
| J CEREAL SCI | 2.046 |
| Q J ROY METEOR SOC | 2.045 |
| TOXICOL IN VITRO | 2.045 |
| CHAOS SOLITON FRACT | 2.042 |
| J OPER MANAG | 2.042 |
| MOL BIOTECHNOL | 2.041 |
| ACTA ASTRONOM | 2.039 |
| CMES-COMP MODEL ENG | 2.038 |
| J PHYS-CONDENS MAT | 2.038 |
| J SURG RES | 2.038 |
| J INFECTION | 2.037 |
| J MICROBIOL BIOTECHN | 2.037 |
| J SUPERCRIT FLUID | 2.037 |
| QUAL LIFE RES | 2.037 |
| SYST APPL MICROBIOL | 2.037 |
| INT J TUBERC LUNG D | 2.035 |
| J TRAUMA | 2.035 |
| ARTHROPOD STRUCT DEV | 2.033 |
| AUTOIMMUNITY | 2.033 |
| MED VET ENTOMOL | 2.033 |
| J PHARMACEUT BIOMED | 2.032 |
| COMMUN PUR APPL MATH | 2.031 |
| CONT SHELF RES | 2.03 |
| HEALTH ECON | 2.03 |
| T ROY SOC TROP MED H | 2.03 |
| EUR J CLIN PHARMACOL | 2.029 |
| LANDSCAPE URBAN PLAN | 2.029 |
| MAR GEOL | 2.029 |
| CANCER J | 2.028 |
| COMPOS SCI TECHNOL | 2.027 |
| IEEE T MICROW THEORY | 2.027 |
| EPILEPSY BEHAV | 2.026 |
| BBA-GEN SUBJECTS | 2.024 |
| J PHYS B-AT MOL OPT | 2.024 |
| APPL PHYS B-LASERS O | 2.023 |
| AM J CLIN DERMATOL | 2.022 |
| J FLUID MECH | 2.022 |
| MACROMOL CHEM PHYS | 2.021 |
| NATURWISSENSCHAFTEN | 2.021 |
| ALCOHOL | 2.02 |
| GASTROENTEROL CLIN N | 2.019 |
| J INSECT PHYSIOL | 2.019 |
| J HEALTH ECON | 2.017 |
| CURR ALLERGY ASTHM R | 2.016 |
| DIABETES EDUCATOR | 2.016 |
| MOL CELL PROBE | 2.016 |
| COMPUT METHOD APPL M | 2.015 |
| PSYCHOSOMATICS | 2.015 |
| MAR PETROL GEOL | 2.013 |
| PHYSIOL BIOCHEM ZOOL | 2.011 |
| ULTRASOUND MED BIOL | 2.011 |
| ELECTROCHEM SOLID ST | 2.009 |
| PARASITE IMMUNOL | 2.009 |
| PROG PHOTOVOLTAICS | 2.009 |
| DEV MED CHILD NEUROL | 2.008 |
| PROCESS BIOCHEM | 2.008 |
| AIDS PATIENT CARE ST | 2.007 |
| FORTSCHR PHYS | 2.007 |
| MAR POLLUT BULL | 2.007 |
| PEDIATR NEPHROL | 2.007 |
| INT J COLORECTAL DIS | 2.006 |
| GENE EXPR PATTERNS | 2.005 |
| MED MYCOL | 2.005 |
| ORG PROCESS RES DEV | 2.004 |
| PEDIATR TRANSPLANT | 2.004 |
| CEREBROVASC DIS | 2.003 |
| IEEE J SOLID-ST CIRC | 2.002 |
| J OPT SOC AM A | 2.002 |
| J OPT SOC AM B | 2.002 |
| BIOL LETT-UK | 2 |
| COMP IMMUNOL MICROB | 2 |
| DIGEST LIVER DIS | 2 |
| ECOTOX ENVIRON SAFE | 2 |
| EUR J SOIL SCI | 2 |
| GENET RES | 2 |
| HOLOCENE | 2 |
| J COMPUT BIOL | 2 |
| J NEUROPSYCH CLIN N | 2 |
| J RECEPT SIG TRANSD | 2 |
| MATCH-COMMUN MATH CO | 2 |
| NEURAL NETWORKS | 2 |
| NEUROTOX RES | 2 |
| RECEPTOR CHANNEL | 2 |
| HORM METAB RES | 1.997 |
| CURR OPIN PEDIATR | 1.994 |
| VET IMMUNOL IMMUNOP | 1.994 |
| CYTOGENET GENOME RES | 1.993 |
| EUR J CANCER PREV | 1.993 |
| CURR HYPERTENS REP | 1.992 |
| ENVIRON MODELL SOFTW | 1.992 |
| CLIN CHEST MED | 1.991 |
| COMP BIOCHEM PHYS C | 1.991 |
| ALZ DIS ASSOC DIS | 1.99 |
| NUKLEARMED-NUCL MED | 1.99 |
| SCAND J MED SCI SPOR | 1.989 |
| CLIN DIAGN LAB IMMUN | 1.988 |
| EUR PHYS J D | 1.988 |
| J TOXICOL-CLIN TOXIC | 1.988 |
| QSAR COMB SCI | 1.987 |
| CLIN EXP METASTAS | 1.986 |
| CHEM PHYS | 1.984 |
| J ANIM SCI | 1.983 |
| ENVIRON SCI POLLUT R | 1.98 |
| EUR J CARDIOV PREV R | 1.979 |
| AM MINERAL | 1.977 |
| CAN J ANAESTH | 1.976 |
| GAIT POSTURE | 1.976 |
| ROFO-FORTSCHR RONTG | 1.976 |
| BMC STRUCT BIOL | 1.975 |
| AUTON AGENT MULTI-AG | 1.974 |
| ANAT REC PART A | 1.973 |
| MAR MICROPALEONTOL | 1.973 |
| GENOME | 1.972 |
| J GERIATR PSYCH NEUR | 1.97 |
| AQUAT GEOCHEM | 1.969 |
| SURG ENDOSC | 1.969 |
| PEDIATR PULM | 1.965 |
| ANNU REP NMR SPECTRO | 1.964 |
| ANTON LEEUW INT J G | 1.964 |
| J BIOCHEM | 1.963 |
| HEAD NECK-J SCI SPEC | 1.961 |
| ADV APPL MICROBIOL | 1.96 |
| ECOL ENTOMOL | 1.96 |
| ULTRASON SONOCHEM | 1.96 |
| EXP BRAIN RES | 1.959 |
| BEST PRACT RES CL RH | 1.958 |
| J MED SCREEN | 1.957 |
| J NERV MENT DIS | 1.957 |
| PLASMID | 1.956 |
| YEAST | 1.955 |
| AM J ORTHOPSYCHIAT | 1.954 |
| NEUROSCI RES | 1.953 |
| PROSTAG OTH LIPID M | 1.951 |
| J MED ENTOMOL | 1.95 |
| HIGH ALT MED BIOL | 1.949 |
| J MICROSC-OXFORD | 1.947 |
| MATURITAS | 1.947 |
| DEV PSYCHOBIOL | 1.946 |
| J AEROSOL MED | 1.945 |
| INTERMETALLICS | 1.943 |
| J HERED | 1.942 |
| J OCCUP ENVIRON MED | 1.942 |
| PALLIATIVE MED | 1.939 |
| BRIT J GEN PRACT | 1.938 |
| IEEE T INFORM THEORY | 1.938 |
| RISK ANAL | 1.938 |
| MICROB DRUG RESIST | 1.936 |
| AM J HEALTH-SYST PH | 1.935 |
| DIAM RELAT MATER | 1.935 |
| IEEE INTERNET COMPUT | 1.935 |
| LIPIDS | 1.935 |
| MANUAL THER | 1.931 |
| ANN NY ACAD SCI | 1.93 |
| INT J GERIATR PSYCH | 1.93 |
| APPL SOIL ECOL | 1.929 |
| J GASTROENTEROL | 1.927 |
| MON WEATHER REV | 1.927 |
| ANIM CONSERV | 1.926 |
| CHAOS | 1.926 |
| J NEUROSURG ANESTH | 1.926 |
| J PHYS SOC JPN | 1.926 |
| LEARN BEHAV | 1.926 |
| EXTREMOPHILES | 1.921 |
| J FOOD PROTECT | 1.921 |
| PURE APPL CHEM | 1.92 |
| THYROID | 1.92 |
| AGE AGEING | 1.919 |
| ANN OCCUP HYG | 1.919 |
| J EXP MAR BIOL ECOL | 1.919 |
| CARDIOVASC PATHOL | 1.917 |
| FISHERIES | 1.917 |
| TRANSGENIC RES | 1.915 |
| NEW ASTRON REV | 1.914 |
| AMYLOID | 1.91 |
| DYES PIGMENTS | 1.909 |
| IEEE T NANOTECHNOL | 1.909 |
| J PHOTOCH PHOTOBIO B | 1.909 |
| APIDOLOGIE | 1.906 |
| J QUATERNARY SCI | 1.906 |
| DNA CELL BIOL | 1.905 |
| INT J EARTH SCI | 1.905 |
| SUPPORT CARE CANCER | 1.905 |
| CLIN LAB MED | 1.904 |
| ARTIF ORGANS | 1.903 |
| ANN STAT | 1.902 |
| AUST NZ J PSYCHIAT | 1.9 |
| EUR J IMMUNOGENET | 1.9 |
| J URBAN HEALTH | 1.9 |
| PHARMACOTHERAPY | 1.9 |
| VET PARASITOL | 1.9 |
| BMC INFECT DIS | 1.898 |
| J GEOL | 1.898 |
| THERIOGENOLOGY | 1.898 |
| ENZYME MICROB TECH | 1.897 |
| Z KRISTALLOGR | 1.897 |
| J CHEM ECOL | 1.896 |
| AUST J CHEM | 1.895 |
| EUR J GASTROEN HEPAT | 1.895 |
| KIDNEY BLOOD PRESS R | 1.895 |
| WATER RESOUR RES | 1.894 |
| BIOMETALS | 1.893 |
| POSTHARVEST BIOL TEC | 1.892 |
| WORLD J UROL | 1.89 |
| J OROFAC PAIN | 1.889 |
| ECOL MODEL | 1.888 |
| INFORM SYST | 1.887 |
| SOL PHYS | 1.887 |
| GEOMICROBIOL J | 1.886 |
| CORROS SCI | 1.885 |
| J STUD ALCOHOL | 1.884 |
| AM J HEMATOL | 1.882 |
| CAN J FISH AQUAT SCI | 1.882 |
| CONTRACEPTION | 1.882 |
| PEDIATR BLOOD CANCER | 1.882 |
| BRIT MED BULL | 1.881 |
| BIOELECTROCHEMISTRY | 1.88 |
| SURF SCI | 1.88 |
| VIB SPECTROSC | 1.88 |
| APPL SPECTROSC | 1.879 |
| CATAL COMMUN | 1.878 |
| APMIS | 1.875 |
| COMPOS PART A-APPL S | 1.875 |
| HEMATOL ONCOL | 1.875 |
| AAPS J | 1.874 |
| EJSO-EUR J SURG ONC | 1.873 |
| CONCEPT MAGN RESON A | 1.872 |
| MOL CELLS | 1.872 |
| COMMUNITY DENT ORAL | 1.87 |
| SCAND J GASTROENTERO | 1.869 |
| SOIL SCI SOC AM J | 1.869 |
| INT REV IMMUNOL | 1.868 |
| IMMUNOBIOLOGY | 1.867 |
| NUTR METAB CARDIOVAS | 1.867 |
| PROTEIN EXPRES PURIF | 1.867 |
| APPL GEOCHEM | 1.866 |
| INT J HYPERTHER | 1.866 |
| REV ENDOCR METAB DIS | 1.866 |
| PLAST RECONSTR SURG | 1.864 |
| ACTA ANAESTH SCAND | 1.863 |
| EUR J HAEMATOL | 1.863 |
| MOL CELL BIOCHEM | 1.862 |
| SUPRAMOL CHEM | 1.861 |
| MYCOL RES | 1.86 |
| EAR HEARING | 1.858 |
| GEOCHEM T | 1.857 |
| PROG EXP TUMOR RES | 1.857 |
| ACTA ONCOL | 1.856 |
| J HAZARD MATER | 1.855 |
| DERMATOLOGY | 1.854 |
| INT J MOL MED | 1.854 |
| ARCH BRONCONEUMOL | 1.851 |
| ARCH VIROL | 1.85 |
| COMPOS PART B-ENG | 1.85 |
| HASTINGS CENT REP | 1.848 |
| J NEURO-ONCOL | 1.848 |
| J OCCUP HEALTH | 1.848 |
| PLANT PHYSIOL BIOCH | 1.847 |
| CRIT CARE CLIN | 1.845 |
| INJURY PREV | 1.844 |
| J AM ASSOC GYN LAP | 1.843 |
| POLYHEDRON | 1.843 |
| IEEE T NEUR SYS REH | 1.842 |
| J CHEM THERMODYN | 1.842 |
| CELLS TISSUES ORGANS | 1.841 |
| MEAT SCI | 1.84 |
| FOREST ECOL MANAG | 1.839 |
| INT J EAT DISORDER | 1.839 |
| J PHYS OCEANOGR | 1.838 |
| ACTA DERM-VENEREOL | 1.837 |
| DIABETES RES CLIN PR | 1.837 |
| REGUL TOXICOL PHARM | 1.836 |
| ACTA NEUROL SCAND | 1.833 |
| PAEDIATR PERINAT EP | 1.833 |
| AGR ECOSYST ENVIRON | 1.832 |
| FISH OCEANOGR | 1.832 |
| J BIOMED BIOTECHNOL | 1.829 |
| B SEISMOL SOC AM | 1.828 |
| COMBUST FLAME | 1.828 |
| INT UROGYNECOL J | 1.828 |
| ARCH PHYS MED REHAB | 1.826 |
| DIGESTION | 1.826 |
| J ZOOL SYST EVOL RES | 1.826 |
| EUR BIOPHYS J BIOPHY | 1.825 |
| CHEM ERDE-GEOCHEM | 1.824 |
| EUR SPINE J | 1.824 |
| SIAM J SCI COMPUT | 1.824 |
| PALAEOGEOGR PALAEOCL | 1.822 |
| PATTERN RECOGN | 1.822 |
| ARCH MICROBIOL | 1.82 |
| ENVIRON EXP BOT | 1.82 |
| UROL CLIN N AM | 1.819 |
| J MANAGE INFORM SYST | 1.818 |
| REPROD NUTR DEV | 1.817 |
| IEEE J SEL AREA COMM | 1.816 |
| PSYCHIATRY | 1.816 |
| MYCORRHIZA | 1.813 |
| BOREAS | 1.812 |
| J LAB CLIN MED | 1.812 |
| J TOXICOL ENV HEALTH | 1.811 |
| NURS ECON | 1.81 |
| PROSTATE CANCER P D | 1.81 |
| AVIAN PATHOL | 1.809 |
| EPIDEMIOL INFECT | 1.809 |
| J CRYST GROWTH | 1.809 |
| J ARTHROPLASTY | 1.806 |
| ENDOCRINE | 1.805 |
| MATH MOD METH APPL S | 1.805 |
| IEEE T FUZZY SYST | 1.803 |
| J PEPT SCI | 1.801 |
| CHEM-BIOL INTERACT | 1.8 |
| COMPUT LINGUIST | 1.8 |
| LETHAIA | 1.8 |
| J GLAUCOMA | 1.799 |
| SIAM J MATRIX ANAL A | 1.798 |
| J SPORT SCI | 1.797 |
| CARDIOLOGY | 1.795 |
| J ARTIF INTELL RES | 1.795 |
| PLANT DIS | 1.795 |
| IEEE T VIS COMPUT GR | 1.794 |
| MED MICROBIOL IMMUN | 1.793 |
| J AM ACAD ORTHOP SUR | 1.792 |
| J NEURAL TRANSM-SUPP | 1.792 |
| J BIOMOL NMR | 1.791 |
| J FORAMIN RES | 1.791 |
| SPINAL CORD | 1.791 |
| J BONE JOINT SURG BR | 1.79 |
| COLLOID SURFACE B | 1.789 |
| IEEE ACM T NETWORK | 1.789 |
| BASIC CLIN PHARMACOL | 1.788 |
| ARCH TOXICOL | 1.787 |
| INORG CHEM COMMUN | 1.787 |
| PARASITOLOGY | 1.786 |
| EVOL ECOL RES | 1.785 |
| J GASTROEN HEPATOL | 1.785 |
| BIOPHYS CHEM | 1.784 |
| BIOPHYS CHEM | 1.784 |
| CARBOHYD POLYM | 1.784 |
| EARTH SURF PROC LAND | 1.784 |
| ACAD RADIOL | 1.781 |
| J PHYS G NUCL PARTIC | 1.781 |
| CLIN EXP PHARMACOL P | 1.78 |
| FOOD ADDIT CONTAM | 1.78 |
| NEUROIMMUNOMODULAT | 1.779 |
| GENET SEL EVOL | 1.778 |
| J BIOMED MATER RES B | 1.778 |
| PATIENT EDUC COUNS | 1.778 |
| XENOTRANSPLANTATION | 1.777 |
| ONCOLOGY-NY | 1.774 |
| CATAL LETT | 1.772 |
| AUSTRAL ECOL | 1.771 |
| FUND CLIN PHARMACOL | 1.771 |
| ARTIF LIFE | 1.769 |
| MINI-REV ORG CHEM | 1.768 |
| J MATH IMAGING VIS | 1.767 |
| J SEA RES | 1.765 |
| WORLD J SURG | 1.765 |
| CANCER BIOTHER RADIO | 1.763 |
| IEEE T DEPEND SECURE | 1.762 |
| BMC GASTROENTEROL | 1.761 |
| TRANSPORT RES B-METH | 1.761 |
| AUDIOL NEURO-OTOL | 1.758 |
| DIAGN MOL PATHOL | 1.757 |
| TWIN RES | 1.757 |
| MAR BIOL | 1.756 |
| AMYOTROPH LATERAL SC | 1.755 |
| RENEW SUST ENERG REV | 1.754 |
| IEEE T GEOSCI REMOTE | 1.752 |
| SOLID STATE SCI | 1.752 |
| J COMP PHYSIOL A | 1.751 |
| ADDICT BIOL | 1.75 |
| ADV GEOPHYS | 1.75 |
| HEALTH POLICY PLANN | 1.75 |
| EUR J ORAL SCI | 1.747 |
| PHYS MED REHAB KUROR | 1.746 |
| PLANTA MED | 1.746 |
| SEDIMENTOLOGY | 1.746 |
| INT PSYCHOGERIATR | 1.745 |
| INFORM RETRIEVAL | 1.744 |
| J BURN CARE REHABIL | 1.744 |
| AM J REPROD IMMUNOL | 1.743 |
| IEEE T CIRC SYST VID | 1.743 |
| DIABETES METAB | 1.742 |
| ACAD EMERG MED | 1.741 |
| ANN CLIN BIOCHEM | 1.741 |
| J COMP PHYSIOL B | 1.74 |
| APPL PHYS A-MATER | 1.739 |
| J CARDIOVASC MAGN R | 1.739 |
| EARLY HUM DEV | 1.738 |
| ASIAN J ANDROL | 1.737 |
| STAT MED | 1.737 |
| J APPL METEOROL CLIM | 1.736 |
| LARYNGOSCOPE | 1.736 |
| MED DECIS MAKING | 1.736 |
| BIOL CONTROL | 1.735 |
| SCAND J WORK ENV HEA | 1.735 |
| ARCH OTOLARYNGOL | 1.734 |
| CHEM LETT | 1.734 |
| ESTUAR COAST SHELF S | 1.733 |
| EXPERT OPIN PHARMACO | 1.733 |
| INT J HYG ENVIR HEAL | 1.733 |
| EQUINE VET J | 1.73 |
| EUR J PROTISTOL | 1.729 |
| IEEE T ULTRASON FERR | 1.729 |
| APPETITE | 1.727 |
| PLANT CELL REP | 1.727 |
| INT J MED INFORM | 1.726 |
| CLIN CHEM LAB MED | 1.725 |
| J ELECTROMYOGR KINES | 1.725 |
| INT REV NEUROBIOL | 1.724 |
| ONKOLOGIE | 1.724 |
| MULTISCALE MODEL SIM | 1.723 |
| NEUROPSYCHIATRIE | 1.722 |
| STRUCT HEALTH MONIT | 1.721 |
| TERRA NOVA | 1.721 |
| B MATH BIOL | 1.72 |
| J GERONTOL B-PSYCHOL | 1.72 |
| MATERN CHILD NUTR | 1.72 |
| VASC PHARMACOL | 1.718 |
| APPL OPTICS | 1.717 |
| BIOSCIENCE REP | 1.717 |
| BIOSCIENCE REP | 1.717 |
| J CONTAM HYDROL | 1.717 |
| USP KHIM+ | 1.717 |
| J PROCESS CONTR | 1.716 |
| J FISH DIS | 1.715 |
| DOC OPHTHALMOL | 1.712 |
| PROG THEOR PHYS | 1.712 |
| J WOMENS HEALTH | 1.711 |
| CELL IMMUNOL | 1.709 |
| J RADIAT RES | 1.709 |
| OPT MATER | 1.709 |
| CORNEA | 1.708 |
| ULTRAMICROSCOPY | 1.706 |
| ILAR J | 1.705 |
| INT J ORAL MAX IMPL | 1.705 |
| WEED RES | 1.705 |
| EXP DIABESITY RES | 1.704 |
| HIV CLIN TRIALS | 1.704 |
| MELANOMA RES | 1.704 |
| CARBOHYD RES | 1.703 |
| J PERIODONTOL | 1.703 |
| SIAM J APPL DYN SYST | 1.703 |
| J DENT | 1.702 |
| JAVMA-J AM VET MED A | 1.701 |
| J ATHL TRAINING | 1.699 |
| J DRUG TARGET | 1.699 |
| CARDIOVASC DRUG REV | 1.698 |
| GEOMORPHOLOGY | 1.698 |
| PHYS FLUIDS | 1.697 |
| J FOOD ENG | 1.696 |
| J NEUROCYTOL | 1.695 |
| CELL BIOCHEM BIOPHYS | 1.693 |
| J AM SOC ECHOCARDIOG | 1.69 |
| MOL PHYS | 1.69 |
| ECOL COMPLEX | 1.688 |
| ACTA CRYSTALLOGR D | 1.687 |
| MANAGE SCI | 1.687 |
| AM J CRIT CARE | 1.685 |
| J MOL HISTOL | 1.685 |
| J VOLCANOL GEOTH RES | 1.685 |
| SYNTHETIC MET | 1.685 |
| BRAIN RES BULL | 1.684 |
| METHOD INFORM MED | 1.684 |
| J VET INTERN MED | 1.683 |
| SYST CONTROL LETT | 1.683 |
| BIOL NEONATE | 1.681 |
| FLUID PHASE EQUILIBR | 1.68 |
| MICROSC RES TECHNIQ | 1.68 |
| PANMINERVA MED | 1.68 |
| ADV ATOM MOL OPT PHY | 1.679 |
| CHEM VAPOR DEPOS | 1.679 |
| INT J WILDLAND FIRE | 1.679 |
| PLATELETS | 1.679 |
| IEEE COMMUN MAG | 1.678 |
| BREAST | 1.677 |
| CLIN REV ALLERG IMMU | 1.677 |
| PEDIATR ANESTH | 1.677 |
| ACTA CRYSTALLOGR A | 1.676 |
| ACTA DIABETOL | 1.676 |
| TECTONOPHYSICS | 1.675 |
| INORG CHIM ACTA | 1.674 |
| PHYSICA D | 1.674 |
| BIOETHICS | 1.672 |
| CLIN J SPORT MED | 1.672 |
| J INVEST MED | 1.671 |
| J ORTHOP TRAUMA | 1.67 |
| MOL BRAIN RES | 1.67 |
| AM J HUM BIOL | 1.669 |
| J ECONOMETRICS | 1.669 |
| J BIOMED SCI | 1.668 |
| EVOL ECOL | 1.667 |
| INT J COAL GEOL | 1.667 |
| INTERFACE SCI | 1.667 |
| J COMPUT NEUROSCI | 1.667 |
| THIN SOLID FILMS | 1.666 |
| CLIN RADIOL | 1.665 |
| J MATH BIOL | 1.664 |
| INT J APPL CERAM TEC | 1.663 |
| NEUROLOGIST | 1.662 |
| INT J PROSTHODONT | 1.66 |
| INVENT MATH | 1.659 |
| MATER CHEM PHYS | 1.657 |
| METROLOGIA | 1.657 |
| CRIT REV ANAL CHEM | 1.656 |
| MINER DEPOSITA | 1.656 |
| POULTRY SCI | 1.656 |
| SURG CLIN N AM | 1.656 |
| ARCH ORAL BIOL | 1.655 |
| J FOOD COMPOS ANAL | 1.655 |
| RHEOL ACTA | 1.653 |
| APPL CLAY SCI | 1.652 |
| FOOD RES INT | 1.652 |
| EUR PHYS J B | 1.651 |
| INT J MOD PHYS D | 1.651 |
| ARCH RATION MECH AN | 1.65 |
| BIOL BULL-US | 1.649 |
| RESPIRATION | 1.649 |
| ADV WATER RESOUR | 1.648 |
| RIVER RES APPL | 1.645 |
| J MICROBIOL | 1.644 |
| PATHOLOGY | 1.643 |
| AQUACULT NUTR | 1.642 |
| INFECT DIS CLIN N AM | 1.642 |
| J CHEM ENG DATA | 1.642 |
| HYDROL PROCESS | 1.64 |
| METHOD ENZYMOL | 1.64 |
| OPHTHAL EPIDEMIOL | 1.64 |
| ACM T SOFTW ENG METH | 1.636 |
| J ENZYM INHIB MED CH | 1.636 |
| ARCH IMMUNOL THER EX | 1.635 |
| ARTIF INTELL MED | 1.634 |
| CURR OPIN OBSTET GYN | 1.634 |
| FIELD CROP RES | 1.634 |
| J PSYCHOPHYSIOL | 1.634 |
| TRANSFUSION MED | 1.634 |
| TRANSPORT RES A-POL | 1.634 |
| FRONT HORM RES | 1.632 |
| PLANT SCI | 1.631 |
| SAR QSAR ENVIRON RES | 1.63 |
| CHEM ENG SCI | 1.629 |
| SYST BOT | 1.629 |
| J APPL TOXICOL | 1.625 |
| J CARDIOVASC PHARM | 1.625 |
| J ETHNOPHARMACOL | 1.625 |
| NEURORADIOLOGY | 1.625 |
| CANCER DETECT PREV | 1.622 |
| INT J PLANT SCI | 1.622 |
| J POLYM SCI POL PHYS | 1.622 |
| APPL IMMUNOHISTO M M | 1.621 |
| EXP CLIN PSYCHOPHARM | 1.621 |
| INT J OBSTET ANESTH | 1.621 |
| INT BIODETER BIODEGR | 1.619 |
| SOIL TILL RES | 1.619 |
| J PLANKTON RES | 1.617 |
| AM FAM PHYSICIAN | 1.616 |
| ANN NUTR METAB | 1.616 |
| CHEM BIODIVERS | 1.616 |
| MRS INTERNET J N S R | 1.615 |
| EUR J MED GENET | 1.614 |
| XENOBIOTICA | 1.613 |
| RESTOR ECOL | 1.612 |
| BIOMED CHROMATOGR | 1.611 |
| COLLOID SURFACE A | 1.611 |
| FLUORIDE | 1.611 |
| MAGN RESON CHEM | 1.61 |
| SPACE WEATHER | 1.61 |
| GRAEF ARCH CLIN EXP | 1.609 |
| BIOCHEM ENG J | 1.608 |
| CHEM SENSES | 1.608 |
| J BIOMAT SCI-POLYM E | 1.607 |
| QUATERN INT | 1.607 |
| SEMIN MUSCULOSKEL R | 1.607 |
| ULTRASONIC IMAGING | 1.606 |
| ARCH PATHOL LAB MED | 1.605 |
| EUR J EPIDEMIOL | 1.605 |
| CONDOR | 1.604 |
| J OPT A-PURE APPL OP | 1.604 |
| NURS RES | 1.604 |
| BMC PUBLIC HEALTH | 1.603 |
| EUR J APPL PHYSIOL | 1.601 |
| CLIN DERMATOL | 1.6 |
| SEP PURIF REV | 1.6 |
| J QUANT SPECTROSC RA | 1.599 |
| BRAIN DEV-JPN | 1.598 |
| DEV BRAIN RES | 1.598 |
| J VAC SCI TECHNOL B | 1.597 |
| COMPUT PHYS COMMUN | 1.595 |
| IBIS | 1.595 |
| MED SCI MONITOR | 1.595 |
| SURG ONCOL | 1.595 |
| CHEM ENG J | 1.594 |
| J PHYS ORG CHEM | 1.593 |
| LETT APPL MICROBIOL | 1.593 |
| REDOX REP | 1.593 |
| J PHARM PHARM SCI | 1.592 |
| INT J ROBOT RES | 1.591 |
| PROG ORG COAT | 1.591 |
| J CLIN EXP NEUROPSYC | 1.59 |
| ORIGINS LIFE EVOL B | 1.59 |
| AMBUL PEDIATR | 1.589 |
| ANAL SCI | 1.589 |
| VET J | 1.589 |
| J PROD INNOVAT MANAG | 1.588 |
| PUBL ASTRON SOC AUST | 1.588 |
| SEMICOND SCI TECH | 1.586 |
| PERCEPTION | 1.585 |
| WAVE RANDOM COMPLEX | 1.585 |
| HEARING RES | 1.584 |
| J MINER PETROL SCI | 1.583 |
| ENVIRON TOXICOL | 1.582 |
| J CUTAN PATHOL | 1.582 |
| METHOD CELL BIOL | 1.582 |
| MAGN RESON IMAGING | 1.58 |
| BIODEGRADATION | 1.579 |
| FOOD CONTROL | 1.579 |
| AUTON ROBOT | 1.578 |
| BRAIN RES PROTOC | 1.578 |
| J PHYS A-MATH GEN | 1.577 |
| CAN J GASTROENTEROL | 1.576 |
| J EUR CERAM SOC | 1.576 |
| J PHYSIOL-PARIS | 1.575 |
| ARTHROSCOPY | 1.574 |
| CLIN EXP MED | 1.574 |
| J INHERIT METAB DIS | 1.574 |
| MYCOLOGIA | 1.574 |
| ANTARCT SCI | 1.573 |
| NEUROL RES | 1.573 |
| MAMMAL REV | 1.571 |
| TRANSPORTMETRICA | 1.571 |
| IEEE T SIGNAL PROCES | 1.57 |
| CATHETER CARDIO INTE | 1.569 |
| INT J BIOMETEOROL | 1.568 |
| CAN J APPL PHYSIOL | 1.567 |
| J SEDIMENT RES | 1.567 |
| ONCOL REP | 1.567 |
| THEOR APPL CLIMATOL | 1.566 |
| ACTA HAEMATOL-BASEL | 1.564 |
| MOD PHYS LETT A | 1.564 |
| MOTOR CONTROL | 1.564 |
| AQUAT SCI | 1.563 |
| ESTUARIES | 1.563 |
| ELEMENTS | 1.562 |
| J MATER SCI-MATER M | 1.562 |
| REACT FUNCT POLYM | 1.561 |
| SCAND J INFECT DIS | 1.56 |
| SCI AM | 1.56 |
| LEUKEMIA LYMPHOMA | 1.559 |
| SURF COAT TECH | 1.559 |
| FAM PRACT | 1.558 |
| MICROCHEM J | 1.558 |
| INVERTEBR BIOL | 1.556 |
| J ASIAN EARTH SCI | 1.556 |
| SOLID STATE COMMUN | 1.556 |
| J AM SOC INF SCI TEC | 1.555 |
| AAPG BULL | 1.553 |
| COMP BIOCHEM PHYS A | 1.553 |
| J MORPHOL | 1.553 |
| J COMP PSYCHOL | 1.552 |
| HELV CHIM ACTA | 1.55 |
| CAN J FOREST RES | 1.549 |
| J MAMMAL | 1.549 |
| VADOSE ZONE J | 1.549 |
| COMPUT VIS IMAGE UND | 1.548 |
| J R STAT SOC A STAT | 1.547 |
| INFORM PROCESS MANAG | 1.546 |
| DEV GROWTH DIFFER | 1.545 |
| J GEODYN | 1.545 |
| NEUROCASE | 1.545 |
| CANCER GENET CYTOGEN | 1.544 |
| IEEE T INF TECHNOL B | 1.542 |
| J SOLID STATE ELECTR | 1.542 |
| PEDIATR NEUROL | 1.542 |
| REV SCI INSTRUM | 1.541 |
| SCAND J PRIM HEALTH | 1.541 |
| CELLULOSE | 1.539 |
| PHIL MAG LETT | 1.539 |
| IEEE T SYST MAN CY B | 1.538 |
| J WILDLIFE MANAGE | 1.538 |
| J ENDOUROL | 1.536 |
| ASAIO J | 1.534 |
| POPUL ECOL | 1.534 |
| J PHARM PHARMACOL | 1.533 |
| PREV VET MED | 1.533 |
| COMP BIOCHEM PHYS B | 1.532 |
| J EUR ACAD DERMATOL | 1.532 |
| SOLID STATE NUCL MAG | 1.532 |
| GEN RELAT GRAVIT | 1.531 |
| J WATER RES PL-ASCE | 1.531 |
| STAT SCI | 1.531 |
| J COMPUT ASSIST TOMO | 1.53 |
| J ORAL PATHOL MED | 1.53 |
| INT J SOLIDS STRUCT | 1.529 |
| DIGEST DIS | 1.528 |
| J PUBLIC HEALTH | 1.527 |
| BIOMED PHARMACOTHER | 1.526 |
| J DIABETES COMPLICAT | 1.526 |
| J DATABASE MANAGE | 1.525 |
| J ORTHOP SPORT PHYS | 1.525 |
| J ENVIRON MONITOR | 1.523 |
| PUBLIC HEALTH REP | 1.523 |
| BIOL PHARM BULL | 1.522 |
| J PLANT PHYSIOL | 1.521 |
| ANIM GENET | 1.52 |
| INT ARCH OCC ENV HEA | 1.52 |
| CLIM RES | 1.519 |
| ENERG FUEL | 1.519 |
| AM J EMERG MED | 1.518 |
| IND ENG CHEM RES | 1.518 |
| J AM BOARD FAM MED | 1.518 |
| RESPIROLOGY | 1.518 |
| PHYS CHEM MINER | 1.517 |
| J ENG EDUC | 1.515 |
| J FLUORINE CHEM | 1.515 |
| BIOELECTROMAGNETICS | 1.514 |
| MAGN RESON MATER PHY | 1.514 |
| PRENATAL DIAG | 1.514 |
| PALAIOS | 1.512 |
| REV FISH BIOL FISHER | 1.512 |
| CHEMOTHERAPY | 1.511 |
| FOLIA PARASIT | 1.511 |
| IEEE T MULTIMEDIA | 1.511 |
| PHYS THER | 1.51 |
| SMART MATER STRUCT | 1.51 |
| STRUCT CHEM | 1.51 |
| AUST SYST BOT | 1.509 |
| COMMUN ACM | 1.509 |
| DIS AQUAT ORGAN | 1.509 |
| J OPT B-QUANTUM S O | 1.509 |
| PLANET SPACE SCI | 1.509 |
| CORONARY ARTERY DIS | 1.507 |
| CLIN NEUROL NEUROSUR | 1.506 |
| EUR HEART J SUPPL | 1.506 |
| B CHEM SOC JPN | 1.505 |
| BEST PRACT RES CL OB | 1.504 |
| J ELECTRON MATER | 1.504 |
| DRUGS TODAY | 1.503 |
| REPROD DOMEST ANIM | 1.503 |
| MICROBIOL IMMUNOL | 1.502 |
| POLAR BIOL | 1.502 |
| CLIN REHABIL | 1.5 |
| CURR ANAL CHEM | 1.5 |
| ENDOCR PATHOL | 1.5 |
| J NONLINEAR SCI | 1.5 |
| PARASITOL INT | 1.5 |
| MACROMOL MATER ENG | 1.498 |
| CHINESE PHYS | 1.497 |
| IEEE T NUCL SCI | 1.497 |
| INT J NUMER METH ENG | 1.497 |
| LANGENBECK ARCH SURG | 1.496 |
| J MOL STRUCT | 1.495 |
| PLANT SOIL | 1.495 |
| BLOOD PURIFICAT | 1.493 |
| GENETICA | 1.492 |
| AUST J PHYSIOTHER | 1.49 |
| MAT SCI ENG A-STRUCT | 1.49 |
| BIOMETRICS | 1.489 |
| EXPERT OPIN THER PAT | 1.488 |
| J EUR MATH SOC | 1.486 |
| INFLAMM RES | 1.485 |
| SEX PLANT REPROD | 1.485 |
| CR BIOL | 1.484 |
| MALACOLOGIA | 1.484 |
| VISUAL NEUROSCI | 1.484 |
| ASIA PAC J CLIN NUTR | 1.483 |
| BIOMASS BIOENERG | 1.483 |
| IBM J RES DEV | 1.483 |
| KOREAN J RADIOL | 1.483 |
| OPHTHAL PHYSL OPT | 1.483 |
| INT J HEAT MASS TRAN | 1.482 |
| PERCEPT PSYCHOPHYS | 1.482 |
| EUR J PUBLIC HEALTH | 1.481 |
| INSECT SOC | 1.481 |
| TWIN RES HUM GENET | 1.481 |
| IEEE T ANTENN PROPAG | 1.48 |
| OPT COMMUN | 1.48 |
| SKIN PHARMACOL PHYS | 1.48 |
| ANTICANCER RES | 1.479 |
| ECOL FRESHW FISH | 1.479 |
| BEHAV PROCESS | 1.478 |
| J NEUROSURG-SPINE | 1.478 |
| EUROPACE | 1.477 |
| J ENVIRON MANAGE | 1.477 |
| J ASTHMA | 1.476 |
| WEED SCI | 1.476 |
| ONCOL NURS FORUM | 1.475 |
| ONCOL RES | 1.475 |
| POLYM INT | 1.475 |
| ARCH INSECT BIOCHEM | 1.474 |
| BIOL CYBERN | 1.474 |
| PHYS REV SPEC TOP-AC | 1.474 |
| AGR FOREST ENTOMOL | 1.473 |
| ZOOLOGY | 1.473 |
| CLIN ONCOL-UK | 1.471 |
| ICES J MAR SCI | 1.469 |
| INT J GYNECOL CANCER | 1.469 |
| J ENDOCRINOL INVEST | 1.469 |
| COMPUT FLUIDS | 1.468 |
| HEMATOL ONCOL CLIN N | 1.468 |
| J BONE MINER METAB | 1.468 |
| PHYS LETT A | 1.468 |
| PROG CRYST GROWTH CH | 1.467 |
| J BIOCHEM MOL BIOL | 1.465 |
| BMC MUSCULOSKEL DIS | 1.464 |
| ORAL DIS | 1.464 |
| EUR PSYCHIAT | 1.463 |
| NEUROSURG REV | 1.462 |
| TREES-STRUCT FUNCT | 1.461 |
| CLIN RHEUMATOL | 1.459 |
| EUR PHYS J A | 1.459 |
| ACTA OPHTHALMOL SCAN | 1.458 |
| FOREST SCI | 1.457 |
| J SPORT EXERCISE PSY | 1.457 |
| MODEL SIMUL MATER SC | 1.457 |
| BMC GENET | 1.456 |
| SIGMOD REC | 1.455 |
| SURV GEOPHYS | 1.452 |
| J MOTOR BEHAV | 1.45 |
| J NON-NEWTON FLUID | 1.449 |
| OPER DENT | 1.449 |
| UROL RES | 1.449 |
| DIGEST DIS SCI | 1.448 |
| INTERVIROLOGY | 1.448 |
| J ATMOS SOL-TERR PHY | 1.448 |
| J NEPHROL | 1.448 |
| J MARINE SYST | 1.447 |
| COMPUT AIDED DESIGN | 1.446 |
| J GLACIOL | 1.446 |
| CLIN BIOMECH | 1.445 |
| INT J QUAL HEALTH C | 1.444 |
| IEEE T ADV PACKAGING | 1.443 |
| J AIR WASTE MANAGE | 1.441 |
| J LUMIN | 1.441 |
| SUPERCOND SCI TECH | 1.44 |
| GERONTOLOGY | 1.439 |
| MAR FRESHWATER RES | 1.439 |
| EUR J MASS SPECTROM | 1.438 |
| J THERM ANAL CALORIM | 1.438 |
| PHYSIOL MEAS | 1.438 |
| BIOCATAL BIOTRANSFOR | 1.437 |
| J STAT PHYS | 1.437 |
| APPL SURF SCI | 1.436 |
| IEEE T INTELL TRANSP | 1.434 |
| SENSOR ACTUAT A-PHYS | 1.434 |
| AM J IND MED | 1.433 |
| AMBIO | 1.433 |
| CARDIOL CLIN | 1.433 |
| J ACOUST SOC AM | 1.433 |
| ADAPT BEHAV | 1.432 |
| CALPHAD | 1.432 |
| ANN PHYS-BERLIN | 1.431 |
| SOL ENERGY | 1.431 |
| J CLIN NURS | 1.43 |
| ADV ANAT EMBRYOL CEL | 1.429 |
| ALTERN THER HEALTH M | 1.429 |
| AM J PRIMATOL | 1.429 |
| CONSERV GENET | 1.429 |
| IDRUGS | 1.429 |
| IEEE COMPUT GRAPH | 1.429 |
| INT ENDOD J | 1.429 |
| INT J ELECTRON COMM | 1.429 |
| PEST MANAG SCI | 1.428 |
| ADV CHRONIC KIDNEY D | 1.427 |
| EXP LUNG RES | 1.427 |
| SURF INTERFACE ANAL | 1.427 |
| IEEE T COMPUT | 1.426 |
| SOC STUD SCI | 1.426 |
| SIAM J APPL MATH | 1.425 |
| BLOOD PRESS MONIT | 1.424 |
| DRUG DELIV | 1.424 |
| IEEE MICROW WIREL CO | 1.424 |
| ARCTIC | 1.423 |
| BIODIVERS CONSERV | 1.423 |
| CLAY CLAY MINER | 1.423 |
| J COMPLEXITY | 1.422 |
| INT J LIFE CYCLE ASS | 1.42 |
| ARCH ENVIRON CON TOX | 1.419 |
| J INORG ORGANOMET P | 1.419 |
| NURS OUTLOOK | 1.419 |
| SARCOIDOSIS VASC DIF | 1.419 |
| CLIN NEPHROL | 1.418 |
| J BIOCHEM MOL TOXIC | 1.418 |
| J VERTEBR PALEONTOL | 1.418 |
| SKIN RES TECHNOL | 1.418 |
| CMC-COMPUT MATER CON | 1.417 |
| FORSCH KOMP KLAS NAT | 1.417 |
| LIQ CRYST | 1.417 |
| THERMOCHIM ACTA | 1.417 |
| J IND MICROBIOL BIOT | 1.416 |
| BRAIN TOPOGR | 1.415 |
| COMPUT INTELL | 1.415 |
| POLYM ENG SCI | 1.414 |
| J ZOOL | 1.413 |
| J ANAL APPL PYROL | 1.412 |
| J QUAL TECHNOL | 1.411 |
| ACM T COMPUT SYST | 1.409 |
| DUKE MATH J | 1.409 |
| J APPL ELECTROCHEM | 1.409 |
| J DAIRY RES | 1.407 |
| J VET PHARMACOL THER | 1.406 |
| POLYM ADVAN TECHNOL | 1.406 |
| BIOL FERT SOILS | 1.405 |
| CLIN PERINATOL | 1.405 |
| J PUBLIC HEALTH POL | 1.405 |
| PATHOBIOLOGY | 1.405 |
| COMPUT CHEM ENG | 1.404 |
| FISH B-NOAA | 1.403 |
| J BIOCHEM BIOPH METH | 1.403 |
| PHYTOMEDICINE | 1.403 |
| RETINA-J RET VIT DIS | 1.403 |
| ADV ENG MATER | 1.402 |
| INTERN MED J | 1.402 |
| J FELINE MED SURG | 1.402 |
| CELL BIOL TOXICOL | 1.4 |
| ECOTOXICOLOGY | 1.4 |
| NEPHRON EXP NEPHROL | 1.4 |
| ASTRON NACHR | 1.399 |
| JOINT BONE SPINE | 1.398 |
| MICROELECTRON ENG | 1.398 |
| VET DERMATOL | 1.398 |
| ACTA PHARMACOL SIN | 1.397 |
| DIGEST SURG | 1.397 |
| FORENSIC SCI INT | 1.397 |
| CARDIOVASC DRUG THER | 1.396 |
| J AM CERAM SOC | 1.396 |
| J VAC SCI TECHNOL A | 1.394 |
| PSYCHOL SPORT EXERC | 1.394 |
| CAN J ZOOL | 1.393 |
| J FISH BIOL | 1.393 |
| ARCH HISTOL CYTOL | 1.392 |
| ENTOMOL EXP APPL | 1.391 |
| INT J HEAT FLUID FL | 1.391 |
| ENG FRACT MECH | 1.39 |
| J HUM NUTR DIET | 1.388 |
| J RENAL NUTR | 1.387 |
| T AM FISH SOC | 1.386 |
| ANNU REV INFORM SCI | 1.385 |
| HORM RES | 1.385 |
| J MOL MODEL | 1.384 |
| SEIZURE-EUR J EPILEP | 1.384 |
| MATER RES BULL | 1.383 |
| PLANT ECOL | 1.383 |
| GEMS GEMOL | 1.381 |
| ISPRS J PHOTOGRAMM | 1.381 |
| J FUSION ENERG | 1.381 |
| CAN J PHYSIOL PHARM | 1.38 |
| ANN APPL BIOL | 1.379 |
| AGR SYST | 1.378 |
| EXP MOL PATHOL | 1.377 |
| STAT METHODS MED RES | 1.377 |
| X-RAY SPECTROM | 1.377 |
| GEOL MAG | 1.376 |
| JPN J CLIN ONCOL | 1.376 |
| SUBST USE MISUSE | 1.376 |
| J NEUROGENET | 1.375 |
| J CHEMOTHERAPY | 1.374 |
| IEEE T DEVICE MAT RE | 1.373 |
| SENSORS-BASEL | 1.373 |
| FISHERIES MANAG ECOL | 1.371 |
| OPTOMETRY VISION SCI | 1.371 |
| ANNU REP MED CHEM | 1.37 |
| BLOOD COAGUL FIBRIN | 1.37 |
| AVIAN DIS | 1.369 |
| BIOCHEMISTRY-MOSCOW+ | 1.368 |
| DATA KNOWL ENG | 1.367 |
| IEEE CONTR SYST MAG | 1.366 |
| METALL MATER TRANS A | 1.366 |
| NEUROPEDIATRICS | 1.366 |
| FOOD QUAL PREFER | 1.365 |
| EUR J PAEDIATR NEURO | 1.364 |
| ACTA BIOCHIM POL | 1.363 |
| CELL BIOL INT | 1.363 |
| SCIENTOMETRICS | 1.363 |
| ARCH HYDROBIOL | 1.362 |
| ENERG POLICY | 1.362 |
| J NON-CRYST SOLIDS | 1.362 |
| J PHYSIOL BIOCHEM | 1.362 |
| INT J CLIN PHARM TH | 1.361 |
| SIAM J COMPUT | 1.361 |
| INT J GEOGR INF SCI | 1.36 |
| DEEP-SEA RES PT II | 1.358 |
| FUEL | 1.358 |
| IEEE MICROW MAG | 1.357 |
| EXP CLIN ENDOCR DIAB | 1.356 |
| J VET MED B | 1.356 |
| AM J MED SCI | 1.355 |
| PERMAFROST PERIGLAC | 1.355 |
| PHYSIOL ENTOMOL | 1.355 |
| ANN NONINVAS ELECTRO | 1.354 |
| J EXP ZOOL PART A | 1.354 |
| PHILOS MAG | 1.354 |
| MATER LETT | 1.353 |
| PUBL MATH-PARIS | 1.353 |
| J AOAC INT | 1.352 |
| VET CLIN N AM-FOOD A | 1.352 |
| AQUAT CONSERV | 1.35 |
| ETHNIC HEALTH | 1.35 |
| J CHILD NEUROL | 1.35 |
| NUTR NEUROSCI | 1.349 |
| PEDOBIOLOGIA | 1.347 |
| SWISS MED WKLY | 1.346 |
| CURR CONTR TRIALS C | 1.345 |
| ECON GEOL | 1.345 |
| ENVIRON ENTOMOL | 1.344 |
| J ADV NURS | 1.342 |
| J CHEMOMETR | 1.342 |
| COMP FUNCT GENOM | 1.341 |
| INT GEOL REV | 1.341 |
| OTOL NEUROTOL | 1.339 |
| AQUAT BOT | 1.338 |
| OTOLARYNG HEAD NECK | 1.338 |
| P ROY SOC A-MATH PHY | 1.338 |
| RES NURS HEALTH | 1.337 |
| ABDOM IMAGING | 1.336 |
| J STRENGTH COND RES | 1.336 |
| SIAM J NUMER ANAL | 1.335 |
| ACTA MATH-DJURSHOLM | 1.333 |
| ADV INSECT PHYSIOL | 1.333 |
| ARCH DERMATOL RES | 1.333 |
| CONTEMP CLIN TRIALS | 1.333 |
| HYDROL EARTH SYST SC | 1.333 |
| INT J IMMUNOGENET | 1.333 |
| J CLIN APHERESIS | 1.333 |
| J STORED PROD RES | 1.333 |
| J TRAVEL MED | 1.333 |
| PROTOPLASMA | 1.333 |
| EUR J RADIOL | 1.332 |
| ECOL ENG | 1.331 |
| INT J PRIMATOL | 1.331 |
| MAT SCI ENG B-SOLID | 1.331 |
| ANN MO BOT GARD | 1.328 |
| J KOREAN PHYS SOC | 1.328 |
| J THORAC IMAG | 1.328 |
| ACTA OBSTET GYN SCAN | 1.327 |
| MED CLIN-BARCELONA | 1.327 |
| ENERG CONVERS MANAGE | 1.325 |
| EVOL COMPUT | 1.325 |
| MAT SCI ENG C-BIO S | 1.325 |
| FUEL PROCESS TECHNOL | 1.323 |
| INT J BIOL MACROMOL | 1.323 |
| J ARCHAEOL SCI | 1.322 |
| J ATMOS CHEM | 1.322 |
| ULTRASONICS | 1.322 |
| ACTA OECOL | 1.32 |
| INVERSE PROBL | 1.319 |
| NEUES JAHRB GEOL P-A | 1.319 |
| IEEE MULTIMEDIA | 1.317 |
| ANN ZOOL FENN | 1.316 |
| COAST ENG | 1.315 |
| J ADHES DENT | 1.313 |
| SEDIMENT GEOL | 1.313 |
| INT J RADIAT BIOL | 1.312 |
| NONLINEAR PROC GEOPH | 1.312 |
| POLYM TEST | 1.312 |
| REV FISH SCI | 1.312 |
| PHYSICA A | 1.311 |
| J BIOMATER APPL | 1.31 |
| J BIOMECH ENG-T ASME | 1.309 |
| USER MODEL USER-ADAP | 1.308 |
| J APPL POLYM SCI | 1.306 |
| ACTA ORTHOP | 1.305 |
| NEPHRON CLIN PRACT | 1.305 |
| STAT COMPUT | 1.305 |
| ATMOS RES | 1.304 |
| AUTON NEUROSCI-BASIC | 1.304 |
| J DIGIT IMAGING | 1.304 |
| EUR J DERMATOL | 1.303 |
| ANN PROBAB | 1.301 |
| AM J PHYS MED REHAB | 1.3 |
| J PARASITOL | 1.3 |
| AM SURGEON | 1.299 |
| J BIOMOL STRUCT DYN | 1.299 |
| J CUTAN MED SURG | 1.299 |
| LWT-FOOD SCI TECHNOL | 1.299 |
| MED HYPOTHESES | 1.299 |
| ACM T MATH SOFTWARE | 1.298 |
| J ATMOS OCEAN TECH | 1.298 |
| J NEUROIMAGING | 1.298 |
| NAT CLIN PRACT UROL | 1.298 |
| ACTA PAEDIATR | 1.297 |
| CONNECT SCI | 1.297 |
| PSYCHOPATHOLOGY | 1.296 |
| ADV ENG INFORM | 1.295 |
| CLIN EXP DERMATOL | 1.295 |
| CLIN MED | 1.295 |
| INT J HEMATOL | 1.295 |
| ANN GEOPHYS-GERMANY | 1.293 |
| EUR J PHYCOL | 1.293 |
| Z GASTROENTEROL | 1.293 |
| ANN I H POINCARE-AN | 1.292 |
| IEEE T ROBOT | 1.292 |
| ANIM FEED SCI TECH | 1.29 |
| ANN FOREST SCI | 1.29 |
| ARCHAEOMETRY | 1.29 |
| ANN ENTOMOL SOC AM | 1.289 |
| COMPUTER | 1.289 |
| FAM MED | 1.289 |
| HUM MOVEMENT SCI | 1.288 |
| HYDROGEOL J | 1.288 |
| NONLINEARITY | 1.288 |
| PHYSIOL MOL PLANT P | 1.288 |
| CLIN AUTON RES | 1.286 |
| J HAND SURG-AM | 1.286 |
| J TOXICOL-TOXIN REV | 1.286 |
| CATENA | 1.285 |
| PHOTOGRAMM ENG REM S | 1.284 |
| NUCL MED COMMUN | 1.283 |
| J SCI COMPUT | 1.281 |
| INVERTEBR SYST | 1.28 |
| BRIT J RADIOL | 1.279 |
| CLIN NEUROPSYCHOL | 1.279 |
| COMPLEMENT THER MED | 1.279 |
| J FAM PRACTICE | 1.278 |
| J THERM SPRAY TECHN | 1.278 |
| MATH MED BIOL | 1.278 |
| PROG PHYS GEOG | 1.278 |
| ANAT EMBRYOL | 1.277 |
| ENFERM INFEC MICR CL | 1.277 |
| J TROP ECOL | 1.277 |
| IMMUNOL INVEST | 1.276 |
| J CHEM TECHNOL BIOT | 1.276 |
| J INTEL MAT SYST STR | 1.276 |
| ARCH MED RES | 1.275 |
| CAN J MICROBIOL | 1.275 |
| J ECON ENTOMOL | 1.275 |
| GEOM TOPOL | 1.274 |
| INT J MULTIPHAS FLOW | 1.274 |
| INT J STD AIDS | 1.274 |
| EUR J OBSTET GYN R B | 1.273 |
| IN VIVO | 1.273 |
| AGRON J | 1.272 |
| ADV NURS SCI | 1.271 |
| SPECTROCHIM ACTA A | 1.27 |
| TRANSPORT SCI | 1.27 |
| FOUND COMPUT MATH | 1.269 |
| HEREDITAS | 1.269 |
| J MED FOOD | 1.269 |
| FINANC STOCH | 1.267 |
| J EVAL CLIN PRACT | 1.263 |
| SIAM J CONTROL OPTIM | 1.263 |
| CHEM PHARM BULL | 1.262 |
| INT J APPROX REASON | 1.262 |
| J ANTIBIOT | 1.262 |
| J NUCL MATER | 1.261 |
| ADV PHYSIOL EDUC | 1.26 |
| J MOL SPECTROSC | 1.26 |
| IEEE J OCEANIC ENG | 1.259 |
| NEUROPATHOLOGY | 1.259 |
| SUPERLATTICE MICROST | 1.259 |
| RES VET SCI | 1.258 |
| CHILD NERV SYST | 1.257 |
| BIOSCI BIOTECH BIOCH | 1.256 |
| BIOSCI BIOTECH BIOCH | 1.256 |
| MED ONCOL | 1.256 |
| CLIN EEG NEUROSCI | 1.255 |
| HEPATOL RES | 1.255 |
| J NATL MED ASSOC | 1.255 |
| PROPELL EXPLOS PYROT | 1.255 |
| CEREAL CHEM | 1.254 |
| CR PHYS | 1.254 |
| INT J ARTIF ORGANS | 1.253 |
| IEEE SOFTWARE | 1.252 |
| J COMPUT SYST SCI | 1.252 |
| J MECH DESIGN | 1.252 |
| J ORAL MAXIL SURG | 1.252 |
| J INCL PHENOM MACRO | 1.251 |
| JETP LETT+ | 1.251 |
| GEOFLUIDS | 1.25 |
| GONDWANA RES | 1.25 |
| INT J ADHES ADHES | 1.25 |
| J ALLOY COMPD | 1.25 |
| J IRRIG DRAIN E-ASCE | 1.25 |
| J NURS SCHOLARSHIP | 1.25 |
| STRUCT SAF | 1.25 |
| VET THER | 1.25 |
| COLLOID POLYM SCI | 1.249 |
| AQUAT LIVING RESOUR | 1.247 |
| CLIN EXP OPHTHALMOL | 1.247 |
| NEOPLASMA | 1.247 |
| CELL BIOCHEM FUNCT | 1.246 |
| IEEE T PARALL DISTR | 1.246 |
| CATAL SURV ASIA | 1.245 |
| J MICROLITH MICROFAB | 1.243 |
| J POLYM ENVIRON | 1.243 |
| ACTA PHYS SIN-CH ED | 1.242 |
| CLIN HEMORHEOL MICRO | 1.242 |
| J ANAL TOXICOL | 1.242 |
| AM J VET RES | 1.241 |
| PATHOL ONCOL RES | 1.241 |
| Z ANORG ALLG CHEM | 1.241 |
| INT J SPORTS MED | 1.24 |
| J EPIDEMIOL | 1.24 |
| PHARMACOLOGY | 1.24 |
| WESTERN J NURS RES | 1.24 |
| ZOOL SCI | 1.24 |
| DRUG CHEM TOXICOL | 1.239 |
| J ENG MATER-T ASME | 1.239 |
| J INF TECHNOL | 1.239 |
| PLANT SYST EVOL | 1.239 |
| CELL MOL BIOL LETT | 1.238 |
| J ARID ENVIRON | 1.238 |
| MICROCHIM ACTA | 1.237 |
| IEEE T BROADCAST | 1.235 |
| J INVERTEBR PATHOL | 1.235 |
| MAR MAMMAL SCI | 1.235 |
| OPER RES | 1.234 |
| APPL ORGANOMET CHEM | 1.233 |
| FLORA | 1.232 |
| POWDER TECHNOL | 1.232 |
| INT J OCCUP ENV HEAL | 1.231 |
| ECLOGAE GEOL HELV | 1.23 |
| SAMJ S AFR MED J | 1.23 |
| GEOPHYSICS | 1.228 |
| HIGH PRESSURE RES | 1.228 |
| MEAS SCI TECHNOL | 1.228 |
| PHYTOCHEM ANALYSIS | 1.228 |
| ANN CLIN LAB SCI | 1.227 |
| ANN VASC SURG | 1.227 |
| HYDROMETALLURGY | 1.227 |
| APPL COMPUT HARMON A | 1.226 |
| OPT FIBER TECHNOL | 1.226 |
| OXID MET | 1.226 |
| J PLANT RES | 1.225 |
| LASER PHYS LETT | 1.225 |
| SEMIN RESP CRIT CARE | 1.225 |
| AM J CLIN ONCOL-CANC | 1.224 |
| INDIAN J MED RES | 1.224 |
| OR SPECTRUM | 1.224 |
| ECOL ECON | 1.223 |
| WASTE MANAGE | 1.223 |
| ADV BOT RES | 1.222 |
| J MED ETHICS | 1.222 |
| JPN J APPL PHYS | 1.222 |
| POL J PHARMACOL | 1.222 |
| J EXP ANAL BEHAV | 1.221 |
| ORAL SURG ORAL MED O | 1.221 |
| PHOTODERMATOL PHOTO | 1.221 |
| PHYS STATUS SOLIDI A | 1.221 |
| AM J RHINOL | 1.22 |
| IEEE CIRCUITS DEVICE | 1.22 |
| J APPL SPORT PSYCHOL | 1.22 |
| MOL ECOL NOTES | 1.22 |
| EUR J MINERAL | 1.219 |
| J AGING PHYS ACTIV | 1.218 |
| ADAPT PHYS ACT Q | 1.217 |
| EUR J PLANT PATHOL | 1.217 |
| EUR CYTOKINE NETW | 1.216 |
| FISH RES | 1.216 |
| KNEE SURG SPORT TR A | 1.216 |
| SCAND J CLIN LAB INV | 1.216 |
| APPL VEG SCI | 1.214 |
| BEHAV MED | 1.214 |
| INT J ORAL MAX SURG | 1.212 |
| ACTA NEUROCHIR | 1.212 |
| EVAL HEALTH PROF | 1.212 |
| J MAGN MAGN MATER | 1.212 |
| J SCI MED SPORT | 1.212 |
| ANN APPL PROBAB | 1.211 |
| IEEE SECUR PRIV | 1.211 |
| IEEE T CONTR SYST T | 1.211 |
| SIAM J OPTIMIZ | 1.211 |
| ZOOMORPHOLOGY | 1.211 |
| J GEODESY | 1.21 |
| COMPUT AIDED GEOM D | 1.208 |
| CURR EYE RES | 1.208 |
| IEEE T COMMUN | 1.208 |
| MEM I OSWALDO CRUZ | 1.208 |
| VET QUART | 1.208 |
| ACTA NEUROBIOL EXP | 1.207 |
| REV MATH PHYS | 1.207 |
| LECT NOTES MATH | 1.206 |
| INT J NONLINEAR MECH | 1.205 |
| WATER AIR SOIL POLL | 1.205 |
| EUR J AGRON | 1.203 |
| EPILEPTIC DISORD | 1.202 |
| HEALTH POLICY | 1.201 |
| HYDROLOG SCI J | 1.201 |
| MICRON | 1.2 |
| CROP PROT | 1.199 |
| OPHTHAL SURG LAS IM | 1.199 |
| BIOL PLANTARUM | 1.198 |
| BMC HEALTH SERV RES | 1.198 |
| AGING MENT HEALTH | 1.197 |
| AM J AGR ECON | 1.196 |
| FOLIA GEOBOT | 1.196 |
| PHYCOLOGIA | 1.196 |
| INT J IMPACT ENG | 1.195 |
| STEREOT FUNCT NEUROS | 1.195 |
| NONLINEAR ANAL-REAL | 1.194 |
| SOLDER SURF MT TECH | 1.194 |
| ASTRON LETT+ | 1.193 |
| CAN J BOT | 1.193 |
| ANN TROP MED PARASIT | 1.191 |
| EUR J HISTOCHEM | 1.191 |
| J MOD OPTIC | 1.189 |
| J ULTRAS MED | 1.189 |
| PESTIC BIOCHEM PHYS | 1.189 |
| BOREAL ENVIRON RES | 1.188 |
| INT J CLIN PRACT | 1.188 |
| J FOREST | 1.188 |
| VET PATHOL | 1.188 |
| LASER MED SCI | 1.186 |
| CEMENT CONCRETE RES | 1.185 |
| NUCL INSTRUM METH A | 1.185 |
| CURR APPL PHYS | 1.184 |
| EUR J LIPID SCI TECH | 1.184 |
| IEEE T WIREL COMMUN | 1.184 |
| INT J MACH TOOL MANU | 1.184 |
| INT J PROD ECON | 1.183 |
| ANIM BIOTECHNOL | 1.182 |
| BRAIN INJURY | 1.182 |
| BRIT J PLAST SURG | 1.182 |
| INT J QUANTUM CHEM | 1.182 |
| J HEPATO-BILIARY-PAN | 1.182 |
| FUZZY SET SYST | 1.181 |
| CAN J NEUROL SCI | 1.18 |
| MECH SYST SIGNAL PR | 1.18 |
| PROBAB THEORY REL | 1.18 |
| WEAR | 1.18 |
| CLEV CLIN J MED | 1.179 |
| DERMATOL CLIN | 1.179 |
| MED ENG PHYS | 1.179 |
| WAVE MOTION | 1.178 |
| APPL ANIM BEHAV SCI | 1.177 |
| BIOL RES | 1.177 |
| THER APHER DIAL | 1.177 |
| WORLD POULTRY SCI J | 1.177 |
| HELGOLAND MAR RES | 1.176 |
| J PHOTOPOLYM SCI TEC | 1.176 |
| SKELETAL RADIOL | 1.176 |
| CELEST MECH DYN ASTR | 1.175 |
| ECOSCIENCE | 1.174 |
| ISR J CHEM | 1.174 |
| J ELECTRON SPECTROSC | 1.172 |
| CHROMATOGRAPHIA | 1.171 |
| IMAGE VISION COMPUT | 1.171 |
| J CRANIO MAXILL SURG | 1.171 |
| PURE APPL GEOPHYS | 1.171 |
| J PEDIAT HEMATOL ONC | 1.17 |
| REV PALAEOBOT PALYNO | 1.17 |
| EUR J ANAESTH | 1.169 |
| IND CROP PROD | 1.169 |
| MIDWIFERY | 1.169 |
| VET REC | 1.168 |
| ACTA HISTOCHEM | 1.167 |
| GEOTEXT GEOMEMBRANES | 1.167 |
| RANDOM STRUCT ALGOR | 1.167 |
| J DIFFER EQUATIONS | 1.166 |
| MACROMOL RES | 1.166 |
| BEHAVIOUR | 1.165 |
| OCEAN DYNAM | 1.165 |
| COMPUT GRAPH FORUM | 1.164 |
| DISABIL REHABIL | 1.164 |
| J PHYS CHEM SOLIDS | 1.164 |
| J NEUROLINGUIST | 1.163 |
| POLYM COMPOSITE | 1.163 |
| ACTA PROTOZOOL | 1.162 |
| J AM DENT ASSOC | 1.162 |
| NETH J MED | 1.162 |
| SOLVENT EXTR ION EXC | 1.162 |
| J MATH PURE APPL | 1.161 |
| PHYS SCRIPTA | 1.161 |
| DECIS SUPPORT SYST | 1.16 |
| IRRIGATION SCI | 1.16 |
| ETRI J | 1.159 |
| IMA J NUMER ANAL | 1.159 |
| SOLID STATE ELECTRON | 1.159 |
| J ELECTROCERAM | 1.157 |
| Z KARDIOL | 1.157 |
| GENE EXPRESSION | 1.156 |
| J THROMB THROMBOLYS | 1.155 |
| MATH COMPUT | 1.155 |
| CAN J CHEM | 1.153 |
| CROP SCI | 1.153 |
| J PERINAT NEONAT NUR | 1.153 |
| JPC-J PLANAR CHROMAT | 1.153 |
| BIOPHARM DRUG DISPOS | 1.152 |
| BIOPHARM DRUG DISPOS | 1.152 |
| CR PALEVOL | 1.152 |
| J PEDIATR ORTHOPED | 1.152 |
| INT J TECHNOL ASSESS | 1.151 |
| J HEALTH POLIT POLIC | 1.151 |
| SOFT MATER | 1.15 |
| CARDIOVASC INTER RAD | 1.149 |
| J REPROD DEVELOP | 1.149 |
| CONTRIB NEPHROL | 1.148 |
| CLIN EXP HYPERTENS | 1.147 |
| GERIATRICS | 1.147 |
| REV GEOL CHILE | 1.147 |
| POLYM J | 1.146 |
| CR CHIM | 1.145 |
| J VET DIAGN INVEST | 1.145 |
| IEEE T PLASMA SCI | 1.144 |
| PHYTOTHER RES | 1.144 |
| ADV MATH | 1.143 |
| COMPUT IND | 1.141 |
| ECOL INDIC | 1.14 |
| ENDOCR J | 1.14 |
| PARASITOL RES | 1.14 |
| BURNS | 1.139 |
| IEEE T CIRCUITS-I | 1.139 |
| CRYOLETTERS | 1.138 |
| KOVOVE MATER | 1.138 |
| EUR J PEDIATR | 1.137 |
| POLIMERY-W | 1.137 |
| ARCH GERONTOL GERIAT | 1.136 |
| J BIOSCI BIOENG | 1.136 |
| STARCH-STARKE | 1.136 |
| BRIT POULTRY SCI | 1.135 |
| CHINESE PHYS LETT | 1.135 |
| ORYX | 1.135 |
| SEMIN ULTRASOUND CT | 1.135 |
| CAN J CARDIOL | 1.134 |
| SIAM J MATH ANAL | 1.134 |
| AUST J AGR RES | 1.133 |
| EXP MECH | 1.133 |
| J HUM LACT | 1.133 |
| PATHOPHYSIOL HAEMO T | 1.133 |
| RESOUR GEOL | 1.133 |
| HUM BIOL | 1.132 |
| PSYCHIAT CLIN NEUROS | 1.132 |
| TRIBOL INT | 1.132 |
| Z PHYS CHEM | 1.132 |
| LIVEST PROD SCI | 1.131 |
| PROTEIN PEPTIDE LETT | 1.13 |
| CHEM ENG PROCESS | 1.129 |
| CLIN GERIATR MED | 1.129 |
| CERAM INT | 1.128 |
| ATOM SPECTROSC | 1.127 |
| ORG DIVERS EVOL | 1.127 |
| MATH BIOSCI | 1.126 |
| COMPUT COMPLEX | 1.125 |
| COMPUT MUSIC J | 1.125 |
| J MAR RES | 1.125 |
| BLOOD PRESSURE | 1.124 |
| SCI TECHNOL ADV MAT | 1.124 |
| CONNECT TISSUE RES | 1.123 |
| J PSYCHOSOM OBST GYN | 1.123 |
| AGR WATER MANAGE | 1.122 |
| HUM EXP TOXICOL | 1.122 |
| ACTA GEOL SIN-ENGL | 1.121 |
| VET SURG | 1.121 |
| CURR PHARM ANAL | 1.12 |
| EARTHQ SPECTRA | 1.12 |
| J CHEM SCI | 1.12 |
| T ROY SOC EDIN-EARTH | 1.12 |
| ENVIRON TOXICOL PHAR | 1.119 |
| INT J CARDIOVAS IMAG | 1.119 |
| J ALGORITHM | 1.119 |
| GENET TEST | 1.118 |
| J HEART VALVE DIS | 1.118 |
| J MED PRIMATOL | 1.118 |
| AUST NZ J PUBL HEAL | 1.117 |
| GROUND WATER | 1.117 |
| IEEE SENS J | 1.117 |
| J CLIN LAB ANAL | 1.117 |
| J NEURO-OPHTHALMOL | 1.117 |
| MATH PROGRAM | 1.117 |
| NUMER MATH | 1.116 |
| GEOM FUNCT ANAL | 1.115 |
| J PORPHYR PHTHALOCYA | 1.115 |
| CONCEPT MAGN RESON B | 1.113 |
| CONTRIB PLASM PHYS | 1.113 |
| EXP FLUIDS | 1.112 |
| J SPINAL DISORD TECH | 1.11 |
| ACTA CHROMATOGR | 1.109 |
| ANN AGR ENV MED | 1.109 |
| J ENVIRON PATHOL TOX | 1.109 |
| J PEDIATR SURG | 1.109 |
| SIGNAL PROCESS-IMAGE | 1.109 |
| WETLANDS | 1.109 |
| Z PSYCHOSOM MED PSYC | 1.109 |
| EXP PARASITOL | 1.108 |
| FOOD REV INT | 1.108 |
| INT J ROBUST NONLIN | 1.108 |
| PATHOL INT | 1.108 |
| AM MUS NOVIT | 1.107 |
| INFORM COMPUT | 1.107 |
| J INVEST SURG | 1.107 |
| INT J PHYTOREMEDIAT | 1.106 |
| J MOL LIQ | 1.106 |
| J OPTOELECTRON ADV M | 1.106 |
| COMP MATER SCI | 1.104 |
| J ALTERN COMPLEM MED | 1.104 |
| REQUIR ENG | 1.103 |
| ACM T PROGR LANG SYS | 1.102 |
| APPL BIOCHEM BIOTECH | 1.102 |
| MATH FINANC | 1.102 |
| MATH STRUCT COMP SCI | 1.102 |
| VIRUS GENES | 1.102 |
| AM J DERMATOPATH | 1.1 |
| DRY TECHNOL | 1.1 |
| NEUROL CLIN | 1.1 |
| SOFTW TEST VERIF REL | 1.1 |
| KNEE | 1.099 |
| CLIN OTOLARYNGOL ALL | 1.098 |
| DISTRIB COMPUT | 1.097 |
| ENVIRON MANAGE | 1.097 |
| ANN OTO RHINOL LARYN | 1.096 |
| RHINOLOGY | 1.096 |
| BIOFACTORS | 1.095 |
| J NEW MAT ELECTR SYS | 1.095 |
| NEPHROLOGY | 1.095 |
| PACE | 1.095 |
| COMMUN PART DIFF EQ | 1.094 |
| CONSTR APPROX | 1.094 |
| INT J HUM-COMPUT ST | 1.094 |
| TISSUE CELL | 1.094 |
| B MAR SCI | 1.093 |
| POSTGRAD MED J | 1.093 |
| BIOPROC BIOSYST ENG | 1.092 |
| BIOPROC BIOSYST ENG | 1.092 |
| CLIN TOXICOL | 1.091 |
| INTERFACE FREE BOUND | 1.091 |
| PALAEONTOLOGY | 1.091 |
| J NURS ADMIN | 1.09 |
| RADIAT ENVIRON BIOPH | 1.09 |
| TRANSFUS APHER SCI | 1.09 |
| TRIBOL LETT | 1.09 |
| SCAND J UROL NEPHROL | 1.089 |
| COMPUT MECH | 1.087 |
| DISCRETE CONT DYN S | 1.087 |
| PEDIATR DEVEL PATHOL | 1.087 |
| AFR J MAR SCI | 1.086 |
| COMPUT EDUC | 1.085 |
| RESOUR CONSERV RECY | 1.085 |
| EUR FOOD RES TECHNOL | 1.084 |
| J INTERV CARD ELECTR | 1.084 |
| MOL SIMULAT | 1.084 |
| PHYSICA E | 1.084 |
| RADIO SCI | 1.084 |
| PALAEONTOGR ABT A | 1.083 |
| CURR OPIN PSYCHIATR | 1.081 |
| INT J TOXICOL | 1.081 |
| JPN J PHYSIOL | 1.081 |
| SPORT EDUC SOC | 1.081 |
| BIOSYSTEMS | 1.08 |
| BIOSYSTEMS | 1.08 |
| CLIN PLAST SURG | 1.08 |
| J NONDESTRUCT EVAL | 1.08 |
| INT J GYNECOL OBSTET | 1.078 |
| HETEROCYCLES | 1.077 |
| J AM SOC BREW CHEM | 1.077 |
| MEM AM MATH SOC | 1.077 |
| ACTA PALAEONTOL POL | 1.076 |
| ARCH PHARM | 1.076 |
| JPN HEART J | 1.076 |
| PEDIATR RADIOL | 1.076 |
| BRAZ J MED BIOL RES | 1.075 |
| COMPUT SECUR | 1.075 |
| J ANIM PHYSIOL AN N | 1.075 |
| J CARDIOTHOR VASC AN | 1.075 |
| NURS SCI QUART | 1.074 |
| PHOTOMED LASER SURG | 1.074 |
| POLAR RES | 1.074 |
| B SOC MATH FR | 1.073 |
| DYNAM SYST | 1.073 |
| INT J NURS STUD | 1.073 |
| J ENVIRON RADIOACTIV | 1.073 |
| MACROMOL THEOR SIMUL | 1.073 |
| ARCH ITAL BIOL | 1.072 |
| AUST J SOIL RES | 1.072 |
| J R STAT SOC C-APPL | 1.072 |
| ANN SCI ECOLE NORM S | 1.071 |
| ENVIRONMENT | 1.071 |
| IEEE T VEH TECHNOL | 1.071 |
| J NETW COMPUT APPL | 1.071 |
| RHEUMATOL INT | 1.07 |
| PHYCOL RES | 1.069 |
| AGING CLIN EXP RES | 1.068 |
| COMPUT BIOL MED | 1.068 |
| J INTELL DISABIL RES | 1.068 |
| RADIOCHIM ACTA | 1.068 |
| INJURY | 1.067 |
| PROBABILIST ENG MECH | 1.067 |
| ADV HEALTH SCI EDUC | 1.065 |
| J APPL GEOPHYS | 1.065 |
| J VET MED EDUC | 1.065 |
| PERSPECT BIOL MED | 1.065 |
| MINERAL MAG | 1.064 |
| ELECTRON LETT | 1.063 |
| MT SINAI J MED | 1.063 |
| INT J ENG SCI | 1.06 |
| J OCEANOGR | 1.06 |
| CLIN INVEST MED | 1.058 |
| J VESTIBUL RES-EQUIL | 1.057 |
| SURG NEUROL | 1.057 |
| HEART VESSELS | 1.056 |
| KLIN PADIATR | 1.055 |
| WEATHER FORECAST | 1.055 |
| J CRIT CARE | 1.054 |
| PRIMATES | 1.053 |
| ENVIRON SCI POLICY | 1.052 |
| AQUAC RES | 1.051 |
| ARCH ANIM NUTR | 1.051 |
| OPHTHALMOLOGICA | 1.051 |
| EARTHQ ENG STRUCT D | 1.05 |
| ECHOCARDIOGR-J CARD | 1.05 |
| NEUROSURG CLIN N AM | 1.05 |
| HYDROBIOLOGIA | 1.049 |
| PEDIATR CLIN N AM | 1.048 |
| J DIFFER EQU APPL | 1.047 |
| AM J MED QUAL | 1.046 |
| EUR J MED RES | 1.046 |
| GEOPHYS PROSPECT | 1.046 |
| J ADHESION | 1.046 |
| J AGRON CROP SCI | 1.046 |
| BOT BULL ACAD SINICA | 1.045 |
| CURR PROB CANCER | 1.045 |
| INT J SURG PATHOL | 1.044 |
| J ORAL REHABIL | 1.044 |
| J AM SOC HORTIC SCI | 1.043 |
| CIN-COMPUT INFORM NU | 1.042 |
| CURR PROB SURG | 1.042 |
| CCAMLR SCI | 1.038 |
| ENERG J | 1.038 |
| EUR J CANCER CARE | 1.038 |
| J RURAL HEALTH | 1.038 |
| MAT SCI SEMICON PROC | 1.038 |
| MINER PETROL | 1.038 |
| CEREAL RES COMMUN | 1.037 |
| IEE P SYST BIOL | 1.037 |
| J LIPOSOME RES | 1.037 |
| SCAND CARDIOVASC J | 1.037 |
| DISCRETE EVENT DYN S | 1.036 |
| J OCUL PHARMACOL TH | 1.035 |
| CLIN NEUROPATHOL | 1.034 |
| OPEN SYST INF DYN | 1.033 |
| COLOR RES APPL | 1.032 |
| WILDLIFE RES | 1.032 |
| EUR NEUROL | 1.031 |
| STUD APPL MATH | 1.031 |
| BIOSYST ENG | 1.03 |
| BIOSYST ENG | 1.03 |
| DRUG EXP CLIN RES | 1.03 |
| EMPIR SOFTW ENG | 1.03 |
| IEEE T POWER ELECTR | 1.029 |
| INDIANA U MATH J | 1.029 |
| J MATER SCI-MATER EL | 1.029 |
| J CLIN ANESTH | 1.028 |
| J INVEST ALLERG CLIN | 1.028 |
| AM J DENT | 1.027 |
| ANN PLAS SURG | 1.027 |
| DIS ESOPHAGUS | 1.027 |
| DISTRIB PARALLEL DAT | 1.027 |
| HEALTH CARE FINANC R | 1.027 |
| AQUACULT ENG | 1.026 |
| J SCI FOOD AGR | 1.026 |
| J SOLUTION CHEM | 1.026 |
| ANDROLOGIA | 1.025 |
| MET MATER-INT | 1.025 |
| FOOD TECHNOL-CHICAGO | 1.024 |
| ENVIRON ECOL STAT | 1.022 |
| J SHOULDER ELB SURG | 1.022 |
| ANIM SCI | 1.021 |
| SCAND J PUBLIC HEALT | 1.021 |
| INT J FATIGUE | 1.02 |
| J CARDIOVASC SURG | 1.02 |
| HERPETOLOGICA | 1.019 |
| INT J SPORT NUTR EXE | 1.019 |
| REV ADV MATER SCI | 1.019 |
| STRUCT MULTIDISCIP O | 1.019 |
| COMPLEXITY | 1.018 |
| FOOD SCI BIOTECHNOL | 1.018 |
| J HYDROL ENG | 1.018 |
| J MATH PHYS | 1.018 |
| MED BIOL ENG COMPUT | 1.018 |
| ACTA ODONTOL SCAND | 1.017 |
| DISPLAYS | 1.017 |
| J MOL STRUC-THEOCHEM | 1.016 |
| BIOL PHILOS | 1.015 |
| BIOMETRIKA | 1.014 |
| HOLZFORSCHUNG | 1.014 |
| J CLUST SCI | 1.014 |
| PEDIATR DERMATOL | 1.014 |
| THEOR COMP FLUID DYN | 1.014 |
| SOZ PRAVENTIV MED | 1.013 |
| AGGRESSIVE BEHAV | 1.012 |
| ECOL RES | 1.012 |
| J I BREWING | 1.012 |
| TECHNOMETRICS | 1.012 |
| TOHOKU J EXP MED | 1.012 |
| BERNOULLI | 1.011 |
| OCEAN COAST MANAGE | 1.011 |
| BRYOLOGIST | 1.01 |
| GEOCHEM J | 1.01 |
| J ORNITHOL | 1.01 |
| OPHTHAL RES | 1.01 |
| AM J ENOL VITICULT | 1.009 |
| BOT MAR | 1.009 |
| J ANIM BREED GENET | 1.009 |
| J SOL-GEL SCI TECHN | 1.009 |
| J THEOR COMPUT CHEM | 1.009 |
| CLIN APPL THROMB-HEM | 1.008 |
| BIOL TRACE ELEM RES | 1.007 |
| CURR MICROBIOL | 1.007 |
| METEOROL Z | 1.007 |
| APPL ENERG | 1.006 |
| IEEE T SPEECH AUDI P | 1.006 |
| J OCCUP ENVIRON HYG | 1.005 |
| J REHABIL RES DEV | 1.005 |
| SCI MAR | 1.005 |
| J FOOD SCI | 1.004 |
| J HYDRAUL ENG-ASCE | 1.004 |
| LETT ORG CHEM | 1.004 |
| INFORM SCIENCES | 1.003 |
| J BRAZIL CHEM SOC | 1.003 |
| COMPOS STRUCT | 1.002 |
| SYNTHETIC COMMUN | 1.001 |
| AI MAG | 1 |
| ANN CARNEGIE MUS | 1 |
| ANN HENRI POINCARE | 1 |
| ATMOS OCEAN | 1 |
| AUST J EARTH SCI | 1 |
| COLD REG SCI TECHNOL | 1 |
| COMPUTAT GEOSCI | 1 |
| DYSPHAGIA | 1 |
| IEEE T ELECTRON PACK | 1 |
| J BIOL REG HOMEOS AG | 1 |
| J BUS ECON STAT | 1 |
| J CARDIOVASC PHARM T | 1 |
| J COMPUT GRAPH STAT | 1 |
| J GREAT LAKES RES | 1 |
| J PERINAT MED | 1 |
| J R SOC NEW ZEAL | 1 |
| J WOOD CHEM TECHNOL | 1 |
| LUNG | 1 |
| METHOD MICROBIOL | 1 |
| NAT CLIN PRACT ENDOC | 1 |
| NAT CLIN PRACT NEPHR | 1 |
| NATL MED J INDIA | 1 |
| NETWORK-COMP NEURAL | 1 |
| NEUROPSYCHOL REHABIL | 1 |
| P GEOLOGIST ASSOC | 1 |
| PRESENCE-TELEOP VIRT | 1 |
| PROG AEROSP SCI | 1 |
| REV CHEM ENG | 1 |
| S AFR J GEOL | 1 |
| SEMIN CUTAN MED SURG | 1 |
Subscribe to Posts [Atom]